2019N398432_01 CONFIDENTIA L
ViiV Healthcare group of companies 212355
1TITLE PA GE
Protocol Title: A Phase 3b multi -center, open label, single arm, 52-week pi[INVESTIGATOR_799] , 
evaluating the feasibility , efficacy  and safet y of a rapid Test and Treat intervention in 
newly  diagnosed HIV- 1 infected adults using a fixed dose combination of dolutegravir 
plus lamivudine (DOVATO )as a first line regimen
Protocol Number : 212355 / 01
Compound Number: [COMPANY_004]1349572+ GR109714 ([COMPANY_004]3515864)
Study Phase: PHASE IIIB
Short Title : Rapid Test and Treat dolutegravir plus lamivudine study  in newly  diagnosed 
HIV-1 infected adults
US IND Sponsor Name [CONTACT_29560] :
ViiV Healthcare Company
Five Moore Drive
P.O. [ZIP_CODE]
Research Triangle Park, NC [ZIP_CODE]- 3398, [LOCATION_003]
Telephone:
This study  is sponsored by [CONTACT_103673].  GlaxoSmithKline is supporting ViiV 
Healthcare in the conduct of this study .  
[COMPANY_003] I nc is operationalizing this study  with GlaxoSmithKline support.
Medical Monitor Name [CONTACT_9352] [CONTACT_842486].
Regulatory Agency Identifying Numbe r(s): US IND: 127475/ EudraCT: 2018 -000177 -
72
Approval Date: 06- JUN -[ADDRESS_1170777] dates of original protocol and all amendments in reverse chronological order.
Document Date DNG Number
Amendment 1 06-Jun-2019 2019N398432_01
Original Protocol 25-MAR -2019 2019N398432_00
Amendment 01 06-June-2019
Overall Rationale for the Amendment:
A global protocol amendment was required to update the primary  objective and endpoint 
based o n FDA feedback.   Additional changes were incorporated as a result of feedback 
and discussion from the Investigator Meeting held in May  2019.  Administrative changes 
for clarit y and corrections to minor errors in the previous version of the protocol were 
made.  Changes were made in the Protocol Summary  sections to reflect text changes in 
other sections of the protocol, as appropriate . 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
4Section # and Name [CONTACT_344380]
1.[ADDRESS_1170778] the 
primary goal of the study which is to provide 
pi[INVESTIGATOR_842435] , efficacy and 
safetyof using DTG + 3TC FDC in a test and 
treat model of care setting
1.[ADDRESS_1170779] 
observed analysis at Week 24, per FDA 
feedbackModified the primary objective to add to the 
evaluation of the “feasibility” of a Test and Treat 
Model of Care from evaluating the “efficacy and 
safety” of DTG + 3TC FDC in this setting
Modified primary endpoint to remove the 
analysis using a modified FDA Snapshot 
Algorithm to an observed analysis based on 
FDA feedback
Secondary endpoint modified to reflect 
an Observed analysis at Week 48, per 
FDA feedbackAs in the primary endpoint the secondary 
endpoint was modified to remove the modified 
FDA Snapshot analysis 
1.1 Synopsis
1.2 Schema
1.3 Schedule of 
Activities (SoA)
2.1 Study Rationale 
2.3.1 Risk Assessment
3 Objectives and 
Endpoint s
4.1 Overall Design
4.2 Scientific Rationale 
for the study
6.3 Measure to 
Minimize Bias
7.2.1 Screening/Day [ADDRESS_1170780]- line DTG + 
3TC Regimen 
Modi fication
10.2 Clinical Screening Visit and Day 1 Visit were 
merged into one visit and text changed to 
“...must be on the same day.”
Modifications were made f or all activit ies 
and references to Screening and Day [ADDRESS_1170781] and treat model of care setting 
where participants are diagnosed and initiate 
HIV-1 treatment on the same day 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
5Section # and Name [CONTACT_842522]
10.6.[ADDRESS_1170782] replaced the 
use of females or women. 
The gender -neutral terms include: 
participants, females at birth, sex at birth, 
current gender, participants of 
childbearing potential (POCBP).Text regarding females or women of 
childbearing potenti al or reproductive potential 
have been modified to gender neutral language 
to make the study protocol more Trans inclusive
2.3.1 Risk Assessment
5.1 Inclusion Criteria
5.2 Exclusion Criteria
7.4 Other Additional 
Intervention Criteria
8.3.5 Pregnancy
9.5.2 Secondary 
Analysis
10.2 Clinical 
Laboratory Tests
10.5.3 Collection of 
Pregnancy InformationPregnancy status at the Screening/Day [ADDRESS_1170783] trimester should 
immediately discontinue DTG + 3TC FDC 
and be started on an alternate regimen 
that doe s not contain DTG.  If the 
pregnancy is after the first trimester, the 
participant can continue study treatment.  The allowance of pregnant participants to 
remain on study intervention if the pregnancy is 
detected after the first trimester as this is more
consistent with the DOVATO label
1.[ADDRESS_1170784] line regimen based 
on Screening/Day 1labs, the Week 12 analysis 
may or may not be conducted. 
1.3 Schedule of 
Activities (SoA)Modified the text in the comment field for 
HIV Diagnostic Test by [CONTACT_842487]-1 diagnosis is new “and confirmed”Restating the need for the confirmation of the 
HIV-1 diagnosis by 2 tests
Added collection of plasma samples at 
the Week 52 visitCorrection from original protocol  2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
6Section # and Name [CONTACT_842523] 3TC Resistance 
and HBV DNA samples for participants 
with confirmed HBV infection from 
Screening/Day 1labs at Weeks 1 and 
Week 4Added the check marks to match the comment 
associated with the collection of these samples 
for participants with HBV infection
1.3 Schedule of 
Activities (SoA)
10.2 Clinical 
Laboratory 
AssessmentsHLA B5701 testing as needed was added Testing for HLA B5701 was added if an 
Investigator is considering using abacavir when 
modifying ART
1.3.1 SoA for ART 
Regimen Modification
4.1 Overall Design
10.2 Clinical 
Laboratory TestsModified the comment s to clarify when 
HBV 3TC Resistance and HBV DNA 
samples should be collected for 
ART modification visit sarenot at the 
Week 1 or at the Week 4 study visit, or if 
an HBV infection is acquired after 
Screening/Day 1”Clarification of sample collection
Modified the header n ote for clarification 
about what assessments need to be 
completed if either of the ART 
Modification Visits occurs at a scheduled 
study visitClarification of visit assessments 
5.2 Exclusion Criteria Exclusion Criteria 2: Created to capture 
changes in pre gnancy status at 
Screening/Day 1Created to exclude participants from the study 
who are in their first trimester of pregnancy
Exclusion 3: Removed restrictions 
regarding known renal impairment and 
HBV infection status, and modified text 
for known HIV -[ADDRESS_1170785] unnecessarily excluded that person
Exclusion 4: Modified the study allowed 
CDC Class 3 stage diseasesModified to include an exemption for cutaneous 
Kaposi’s sarcoma not requiring systemic 
therapy as treatment of this condition does not 
pose an added safety risk for patients who are 
initiating ART, including DTG + 3TC in 
treatment of HIV -1
Exclusion 5 was modified, and Exclusion 
6 was added to create separate criteria 
for known or suspected hepatic 
impairment from known or suspected 
hepatitis B.As hepatic impairment and hepatitis B are 
unique conditions, these were separated into 2 
criteria 
1.1 Synopsis
1.3 Schedule of Events
2.1 Study RationaleAdded text to clarify that Screen ing/Day [ADDRESS_1170786] be 14 days or less from the time of 
the “initial” HIV -1 infection diagnosisText added for clarification 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
7Section # and Name [CONTACT_23688]
4.1 Overall Design
4.2 Scientific Rationale 
for Study Design
Title Page
1.1 Synopsis
4.3 Justification of 
DoseUse of DTG + 3TC FDC has been edited 
to DOVATO, where appropriateAdded to indicate t hat DOVATO is approved in 
the U.S.
2.3 Benefit/Risk 
Assessment
10.3.4 Recording and 
Follow -Up of AE and 
SAE
[IP_ADDRESS] Rash
11 ReferencesAddition of the Tivicay, Epi[INVESTIGATOR_842436]/or 
DOVATO Package inserts as references 
where appropriate.Reference information
2.3.1 Risk Assessment
10.7 Prohibited 
MedicationsRemoved pi[INVESTIGATOR_842437] a theoretical 
serious drug interactionPi[INVESTIGATOR_842438] U.S.
Throughout the 
ProtocolRevised all instances of DTG + 3TC to 
DTG + 3TC FDC when referring to study 
medicationConsistency and for clarity of when the FDC is 
applicable or the individual agents are 
applicable 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
8TABLE OF CONTENTS
PAGE
PROTOCOL AMEND MENT SUMMARY OF CHAN GES TABLE ..................................... 3
1.PROTOCOL SUMMARY ........................................................................................ 11
1.1. Synopsis ..................................................................................................... 11
1.2. Schema ...................................................................................................... 15
1.3. Schedule of Activities (SoA) ........................................................................ 16
1.3.1. SoA for ART Regimen Modifications ............................................ 24
2.INTRODUCTION .................................................................................................... 26
2.1. Study Rationale .......................................................................................... 26
2.2. Background ................................................................................................ 26
2.3. Benefit/Risk Ass essment ............................................................................ 28
2.3.1. Risk Assessment ......................................................................... 29
2.3.2. Benefit Assessment ..................................................................... 33
2.3.3. Overall Benefit: Risk Conclusion .................................................. 33
3.OBJECTIVES AND ENDPO INTS ........................................................................... 33
4.STUDY DESIGN .................................................................................................... 35
4.1. Overall Design ............................................................................................ 35
4.2. Scientific Rationale for Study Design .......................................................... 37
4.3. Justification for Dose .................................................................................. 38
4.4. End of Study Definition ............................................................................... 38
5.STUDY POPULATION ........................................................................................... 39
5.1. Inclusion Criteria ......................................................................................... 39
5.2. Exclusion Criteria ........................................................................................ 42
5.3. Lifestyle Consider ations .............................................................................. 43
5.4. Screen Failures ........................................................................................... 43
6. STUDY INTERVENTION ........................................................................................ 43
6.1. Study Intervention Administered ................................................................ .44
6.2. Preparation/Handling/Storage/Account ability .............................................. 45
6.3. Measures to Minimize Bias: Study Intervention and Blinding ...................... 45
6.4. Study Intervention Compliance ................................................................... 45
6.5. Dose Modification ....................................................................................... 46
6.6. Concomitant Therapy .................................................................................. 46
6.6.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014] .......................... 46
6.7. Treatment after the End of the Study .......................................................... 47
7.STUDY INTERVENTION D ISCONTINUATION C RITERIA .................................... 47
7.1. Discontinuation of Study Intervention .......................................................... 47
7.2. Additional Intervention Criteria .................................................................... 47
7.2.1. Baseline Laboratory Safety Criteria: ............................................. 47
7.2.2. Baseline Resistance Mutation Criteria: ........................................ 48
7.3. Virologic Failure Criteria .............................................................................. 48
7.3.1. Confirmatory testing of virologic non -response: ........................... 49
7.3.2. Management of V irologic Non -Response ..................................... 49
7.4. Other Additional Intervention Criteria: ......................................................... 50 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
97.5. Liver Chemistry Stoppi[INVESTIGATOR_2121] ............................................................... 51
7.5.1. Temporary Discontinuation .......................................................... 51
7.5.2. Study Intervention Restart ........................................................... 51
7.6. Participant Discontinuation/W ithdrawal from the Study ............................... [ADDRESS_1170787] to Follow Up ........................................................................................ 53
8.STUDY ASSESSMENTS AN D PROCEDUR ES..................................................... 53
8.1. Efficacy Assessments ................................................................................. 56
8.1.1. Primary Efficacy Endpoint ............................................................ 57
8.1.2. Secondary Efficacy Endpoints ..................................................... 57
8.2. Safety Assessments ................................................................................... 57
8.2.1. Physical Examinations ................................................................ .57
8.2.2. Vital Signs .................................................................................... 57
8.2.3. Clinical Safety Laboratory Assessments ...................................... 58
8.2.4. Suicidal Ideation and Behaviour R isk Monitoring ......................... 58
8.3. Adverse Events and Serious Adverse Events ............................................. 59
8.3.1. Time Period and Frequency for Collecting AE and SAE 
Information ................................................................................... 59
8.3.2. Method of Detecting AEs and SAEs ............................................. 60
8.3.3. Follow -up of AEs and SAEs ......................................................... 60
8.3.4. Regulatory Reporting Requirements for SAEs ............................. 60
8.3.5. Pregnancy ................................................................................... 61
8.3.6. Cardiova scular and Death Events ................................................ 61
8.3.7. Disease -Related Events and/or Disease- Related 
Outcomes Not Qualifying as SAEs ............................................... [ADDRESS_1170788]-line DTG + 3TC FDC Regimen Modification ....................................... 66
9.4. Data Analysis Considerations ..................................................................... 66
9.4.1. Analysis Populations .................................................................... 66
9.5. Key Elements of the Analysis Plan .............................................................. 66
9.5.1. Efficacy Analysis .......................................................................... 66
9.5.2. Secondary Analyses .................................................................... 67
9.5.3. Safety Analyses ........................................................................... 68
[IP_ADDRESS]. Viral Genotypi[INVESTIGATOR_007]/Phenotypi[INVESTIGATOR_339141] ..................... 69
9.5.4. Other Analyses ............................................................................ 69
9.6. Interim Analyses ......................................................................................... 69
10.SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS ............................................................................................... 71 2020N440514_00
2019N398432_01 CONFIDENTIA L
[PHONE_17526].1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations ............................................................................................ 71
10.1.1. Regulatory and Ethical Considerations ........................................ 71
10.1.2. Financial Disclosure ..................................................................... 71
10.1.3. Informed Consent Process .......................................................... 72
10.1.4. Data Protection ............................................................................ 72
10.1.5. Publication Policy ......................................................................... 72
10.1.6. Dissemination of Clinical Study Data ........................................... 73
10.1.7. Data Quality Assurance ............................................................... 73
10.1.8. Source Documents ...................................................................... 74
10.1.9. Study and Site Closure ................................................................ 74
10.2. Appendix 2: Clinical Laboratory Tests ......................................................... 75
10.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Rep orting ....................................... 77
10.3.1. Definition of AE ............................................................................ 77
10.3.2. Definition of SAE .......................................................................... 78
10.3.3. Definition of Cardiovascular Events ............................................. 79
10.3.4. Recording and Foll ow-Up of AE and SAE .................................... 79
10.3.5. Reporting of SAE and other events to ViiV/[COMPANY_004]/[COMPANY_003] .................. 81
10.4. Appendix 4: Toxicity Management .............................................................. 83
10.4.1. Specific Toxicities/Adverse Event Ma nagement ........................... 84
[IP_ADDRESS]. Liver Chemistry Stoppi[INVESTIGATOR_53051] -up 
Criteria ........................................................................ 85
[IP_ADDRESS]. Restarting Study Intervention ..................................... 85
[IP_ADDRESS]. Decline in Renal Function ........................................... 85
[IP_ADDRESS]. Proteinuria .................................................................. 85
[IP_ADDRESS]. Allergic reaction .......................................................... 86
[IP_ADDRESS]. Rash ........................................................................... 86
[IP_ADDRESS]. Hypertriglyceridemia/Hypercholesterolemia ................ 87
10.5. Appendix 5: Contraceptive Guidance and Collection of Pregnancy 
Information .................................................................................................. 88
10.5.1. Definitions: ................................................................................... 88
10.5.2. Contraception Guidance: ............................................................. 88
10.5.3. Collection of Pregnancy Information: ........................................... 90
10.6. Appendix 6: Liver Safety Required Actions and Follow -up 
Assessments and Study Intervention Rechallenge Guidelines .................... 91
10.6.1. Liver Chemistry Stoppi[INVESTIGATOR_2121]:  Requi red Actions and 
Follow up Assessments ............................................................... 91
10.6.2. Study Intervention Restart after Stoppi[INVESTIGATOR_842439] .......... 94
10.7. Appendix 7: Prohibited Medications ............................................................ 99
10.8. Append ix 8:  Division of AIDS Table for Grading the Severity of 
Adult and Pediatric Adverse Events Version 2.1, March 2017 ................... 101
10.9. Appendix 9:  CDC Classification for HIV -1 Infection (2014) ....................... 131
10.10. Appendix 10: Abbreviations and Trademarks ............................................ 133
10.11. Appendix 11: Protocol Amendment History ............................................... 136
11.REFERENCES ..................................................................................................... 137 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
111. PROTOCOL SUMMA RY
1.1. Synopsis
Protocol Title: A Phase IIIb multi -center, open label, single arm, 52-week pi[INVESTIGATOR_799] , 
evaluating the feasibility , efficacy  and safet y of a rapid test and treat intervention in 
newly  diagnosed HIV- 1 infected adults using a fixed dose combination of dolutegravir 
plus lamivudine (DOVATO )as a first line regimen
Short Title: Rapid Test and Treat with dolutegravir plus lamivudine in newly diagnosed 
HIV-1 infected adults
Rationale:
Study  [ADDRESS_1170789] evaluation of the 
feasibility , effectiv eness and safet yof using a fixed dose combination (FDC) of 
Dolutegravir (DTG) plus L amivudine (3TC) as a first line regimen of arapid Test and 
Treat model of care over 48 weeks.  Participants with a new and confirmed diagnosis of 
HIV-1 infection will in itiate DTG +3TC FDC immediately  (or, for those participants 
referred from another site, within 14 day s of initial diagnosis at the external clinic/testing 
center ) at the Screening/ Day 1 Visit, prior to safety  laboratory  tests and HIV-1 resistance
mutation laboratory results being available for review.   The Screening/Day  1 Visit is 
considered Baseline.  
This study  aims to evaluate the feasibility , efficacy and safet y of using DTG + 3TC FDC 
as a first regimen in a rapid Test and Treat care setting in the U.S , where the prevalence 
of both transmitted M184V/I and co- infection with Hepatitis B virus is low .
Objectives and Endpoints:
Objective Endpoint
Primary
To evaluate the feasibility  and 
efficacy  of a rapid Test and Treat 
model of care in participants with a 
new diagnosis of HIV -1 initiating 
treatment with DTG + 3TC FDC 
immediately  (or, for those 
participants referred from another 
site, within 14 day s of initial 
diagnosis at the external 
clinic/testing center ).Percentage of all participants who 
have plasma HI V-1 RNA <50 c/mL  
at Week 24, regardless of ART 
regimen (observed anal ysis)
Secondary
To demonstrate the antiviral activity  
of DTG +3TC FDC over 48 weeksProportion of participants:
who have plasma HIV -1 RNA <50  2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
12Objective Endpoint
c/mL  at Week 48, regardless of 
ART regim en(observed anal ysis)
with plasma HIV -1 RNA <50 
c/mL  at Week 24 and 48 using the 
FDA Snapshot algorithm 
Time to suppression of HIV -1 RNA 
<50c/mL
To evaluate the barriers (e.g., HIV -1 
resistance mutation results) to 
initiate and maintain DTG + 3TC 
FDC t reatment in a Test and Treat 
Model of CareProportion of participants who 
change first line regimen of DTG + 
3TC FDC due to Baselin e labs or 
HIV-1 resistance mutation results
To assess viral HI V-1 resistance 
mutation in participants meeting 
confirmed viro logic failure criteriaIncidence of treatment -emergent 
genot ypic and phenot ypic resistance 
to DTG and/or 3TC , or any  other 
ART if treatment is modified, in 
participants meeting confirmed 
virologic failure criteria
To evaluate the safet y and 
tolerability  of a rapid test and treat 
model of care using DTG + 3TC 
FDC as first line regimen Incidence and severit y of adverse 
events and laboratory  abnormalities
Proportion of participants who 
discontinue treatment due to AEs 
and drug -related AEs over 48 weeks 
of treatment
To evaluate the immune effects of a 
rapid test and treat model of care 
using DTG + 3TC FDC as first line 
regimenChange from Baseline in CD4+ cell 
counts and CD4+/CD8+ ratio at 
Weeks 24 and 48
Incidence of disease progression 
(stage 3 HIV -associa ted conditions, 
AIDS, and death) through Week 48
To evaluate retention in care Proportion of participants 
owho completed their Week 24 and 
Week 48 Visit ;
owho complete their Week [ADDRESS_1170790] a HIV-1 
RNA <200 c/mL
Exploratory
To evaluat e the effect of participant
demographics and Baseline Proportion of participants with 
plasma HIV -1 RNA <50 c/mL  at  2020N440514_00
2019N398432_01 CONFIDENTIA L
[ADDRESS_1170791] and treat model of 
care using DTG +3TC FDC as first 
line regimenWeeks 24 and 48 b y participant
subgroup(s) by [CONTACT_842488]
To asses change in treatment 
symptom index for participants 
under a rapid test and treat model of 
care using DTG + 3TC FDC as a 
first line regimen Change from Baseline in overall 
symptom bother score from the HIV 
Symptom Distress Module at Weeks 
4, 8, 12, 24, 36, and 48 
To assess change in specific 
symptoms for participants treated 
with DTG +3TC FDCChange from Baseline in 20 item-
specific s ymptoms from the HIV 
Symptom Distress Module at Weeks 
4, 8, 12, 24 , 36, and 48
To assess adherence to study  
treatmentAdherence will be assessed by  
[CONTACT_842489] 7 day s prior to the 
Visit
Overall Design:
This is a Phase III b multi -center, open label, single arm, 52-week pi[INVESTIGATOR_799], evaluating 
the feasibility ,efficacy and safet y ofonce dail y dolutegravir plus lamivudine fixed dose 
combination (FDC) regimen in a rapid test and treat intervention in newly diagnosed 
HIV-1 infected adults.
The study  will enrol participants in the U .S. with a new and confirmed diagnosis of HIV 1 
infection and are willing to initiate anti-retroviral therap y (ART )immediately  (or, for 
those participants referred from another site, within 14 day s of initial diagnosis at the 
external clinic/testing center ).  
Study  212355 will include a Screening /Day 1 Visit, and visits at Weeks 1, 4, 8, 12, 24, 
36, 48, 52 and a potential Follow- up Visit .
The Screening /Day [ADDRESS_1170792] be the same day .  Labs will be drawn prior to initiating 
study  treatment on Day  1. The Screening/Day  1 Visit is considered Baseline.  
Investigators will review safet y labs as they become available and schedule a visit with 
the participant to review (Week 1 Visit).  HIV-1 resistance mutation results will be 
reviewed as they  are made availab le (Week 4 Visit ).  
When all participants complete their Week 12 Visit, an Interim Anal ysis may be 
conducted to review the proportion of participants requiring a modification in treatment.  
The primary  endpoint is the proportion of all participants with plasma HIV -1 RNA 
<50c/mL  at Week 24 , regardless of ART regimen, using a nobserved anal ysis). 2020N440514_00
2019N398432_01 CONFIDENTIA L
[ADDRESS_1170793] to follow -up.
Disclosure Statement : This is a single group , open -label, treatment study  with 1 arm.
Number of Participants:
The study  will recruit approximately  [ADDRESS_1170794] been screened, screening will 
continue until enrolment of approximately  120 individuals is met. 
Intervention Groups and Duration:
A participant’s total time in the study  will be approximately  13months and includes a 
maximum of 14 day sfrom the time of the initial HIV -1 diagnosis to the S creening /Day 1 
Visit and initiation of study  drug, a 52-week treatment period and a 4- week follow -up 
phase.
Study  intervention, 50 mg DTG + 300 mg 3TC will be provided to all participants as a
fixed dose combination (FDC) as first line therap y.  DTG + 3TC FDC will be taken 
orally , once dail y, with or without food.
Participants meeting safety  criteria and HIV-1 resistance mutation criteria ( e.g., M184I, 
M184V, K65R) based on the Screening/Day  1laboratory  data will modify  their current 
DTG + 3TC FDC treatment and will remain in the study.  Criterion for the management 
of virologic non -response criteria are prespecified for study  visits a t and after Week 8 .  
Data Monitoring Committee: No 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
151.2. Schema
Figure 1 Study  Schematic
The study  will enrol participants with a new and confirmed diagnosis of HIV -1 infection 
and are willing to initiate anti-retroviral therap y (ART )immediately  (or, for those 
participants referred from another site, within 14 day s of initial diagnosis at the external 
clinic/testing center ).  If participants HIV -[ADDRESS_1170795] be the same day .  Labs will be drawn prior to 
study  treatment on Day  1. Investigators will review safet y labs as they  become available
and schedule a visit with the participant to review ( Week 1 Visit ).  HIV-1 resistance 
mutation results will be reviewed as they  are made available (Week 4 Visit ).  
When all participants complete their Week 12 Visit, an Interim Anal ysis may be 
conducted to review the proportion of participants requiring a modification in treatment
for an y reaso n (e.g., Screening/Day  1 HIV-1 resistance mutation , Screening/Day 1
abnormal laboratory  results, etc ).  
The primary  endpoint is the proportion of participants with plasma HIV -1 RNA 
<50c/mL at Week 24, regardless of ART Regimen (Observed Analysis).
Additi onal visits will be at Weeks 8, 36, 48 , 52 and a potential Follow- up Visit.  
 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
161.3. Schedule of A ctivities (SoA )
Procedures
Screening / Day 1 
(Baseline) a, b Intervention Period Weeks
Withdrawal
Follow-upi
[CONTACT_72411]
1c4d 8e12f24g36 48g, h52h
a. The Screening /Day 1 Visit is toassess the participant’s appropriateness for the study, confirm the participant has a new diagnosis of HIV -1 infection and is willing to initiate ART on 
the same day. For those participants referred from another site, Screening/Day [ADDRESS_1170796] be 14 days or less from the initial diagnosis at the external clinic/testing center.
b. If the participant meets all study inclusion and exclusion criteria, participant will start study treatment (DTG + 3TC FDC) at the end of Screening/Day [ADDRESS_1170797] been completed . 
c. Participants will attend a Week 1 Visit after notification from the sites once the Screening/Day 1 laboratory results become available.  Investigators should review the safety labs and 
assess whether any additional interventions are required (see Section 7.2Discontinuation and Additional Intervention Criteria).
d. Participants will attend a Week 4 Visit after notification from the sites once the HIV -1 Resistance mutation results become available.  Investigators should review the resistance data 
and assess whether additional interventions are required (see Section 7.2Discontinuation and Additional Intervention Criteria).
e. At Week 8, if the decrease HIV -1 RNA is less than 2.0 log10 c/mL, a retest should be scheduled 2 -4 weeks later, unless plasma HIV -1 RNA is <200 c/mL.
f. At Week 12, participants will require a virologic retest if HIV -1 RNA 1000 c/mL.
g. At Week [ADDRESS_1170798] if HIV- 1 RNA 50c/mL.  At Week 36, participants will require a virologic retest if HIV- 1 RNA 200c/mL.
h. Participants who require a virologic retest at Week 48, must have HIV -[ADDRESS_1170799] on -study visit: All ongoing 
SAEs and non -serious AEs of special interest (as defined in Section 2.3.1 ), regardless of attributability.  However, the investigator, in consultation with the medical monitor, should 
follow -up with the participant until the event is resolved, stabilized, otherwise explained, or the participant is lost to follow -up. 
 
 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
17Procedures
Screening / Day 1 
(Baseline) a, b Intervention Period Weeks
Withdrawal
Follow-upi
[CONTACT_72411]
1c4d 8e12f24g36 48g, h52h
Clinical and Other Assessments
Informed consent X
Inclusion and 
exclusion criteriaXInclusion/exclusion cri teria will be fully assessed at the Screening /Day [ADDRESS_1170800] w ill be collected.
Medical history 
(includes active 
substance usage)XFull medical history will be conducted prior to initiating study intervention 
and include assessments of cardiovascular, metabolic (e.g., Type I or II 
diabetes mellitus), psychiatric (e.g., depression), renal (e.g., 
nephrolithiasis, nephropathy, renal failure), hepatobiliary disorders (e.g., 
history of jaundice, icterus, ascites) and bone disorders.
Current Medical 
ConditionsX
Symptom Directed 
Physical ExamXLimited physical examination to include blood pressure (recorded in 
eCRF) for Framingham score assessment. 
Physical exams should be conducted as part of normal routine clinical care 
but will not be collected systematically in the eCRF.  Abnormalities noted 
during any exam must be recorded in the eCRF (e.g. in the current medical 
conditions or AE logs). 
 
 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
18Procedures
Screening / Day 1 
(Baseline) a, b Intervention Period Weeks
Withdrawal
Follow-upi
[CONTACT_72411]
1c4d 8e12f24g36 48g, h52h
Cardiovascular risk 
assessment XAt Diagnosis Visit, assessment for cardiovascular risk will include height, 
weight, blood pressure, smoking status and history, pertinent medical 
conditions (e.g., hypertension, diabetes mellitus), and family history of 
premature car diovascular disease. Body mass index (BMI) will be 
calculated within the eCRF. 
Vital signs X X X X X X X X X XBlood pressure to be measured after resting in a semi -supi[INVESTIGATOR_42428] 5 minutes.
Body  Weight X X X X X X X X X XBMI will be calculated within the eCRF.  
The same scale should be used at each study visit.
Prior PEP/PREP 
TherapyXParticipants who received HIV post -exposure prophylaxis (PEP) or pre-
exposure prophylaxis (PrEP) in the past are allowed as long as the last 
PEP/PrEP dose w as >[ADDRESS_1170801] in the eCRF (see Section 10.9).
HIV associated 
conditionsX X X X X X X X X 
 
 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
19Procedures
Screening / Day 1 
(Baseline) a, b Intervention Period Weeks
Withdrawal
Follow-upi
[CONTACT_72411]
1c4d 8e12f24g36 48g, h52h
Suicidality 
AssessmentX X X X X X X X X X XInvestigator must assess participant suicidality using their usual clinical 
practice.
HIV Symptom 
Distress ModuleX X X X X X X XQuestionnaire/Surveys are recommended to be administered at the 
beginning of the visit before any oth er assessments are conducted.  See 
Section 8.9for additional information on how this questionnaire should be 
completed.
Laboratory assessments
HIV Diagnostic Test X**Participants must have a new and confirmed diagnosis of HIV- 1 infection 
based on the criterion outlined in Section 5.1(Inclusion Criteria).
HIV Diagnostic test results should be stored in the participant source 
documents. 
Quantitative plasma 
HIV-[ADDRESS_1170802] requires a regimen modification (e.g., based on Baseline labs, a 
Confirmed Virologic Failure, or an AE), see SoA ART Regimen 
Modification Section 1.3.1 .
Whole Blood X X X X**Collect sample only if Withdraw al Visit is replacing the Week 24 or 
Week 48 Vi sit.
Lymphocyte subset X X X X X X X 
 
 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
20Procedures
Screening / Day 1 
(Baseline) a, b Intervention Period Weeks
Withdrawal
Follow-upi
[CONTACT_72411]
1c4d 8e12f24g36 48g, h52h
Plasma for HIV 
genotypi[INVESTIGATOR_842440]-1 resistance mutations (see 
Section 1.3.1 ).
Plasma for storage X X X X X X X X X XPlasma samples for storage will be collected at each visit, including 
unscheduled visits (e.g. for HIV- 1 RNA levels and immunological 
parameters).  Additionally, these samples will be used wh en needed such 
as when samples are lost or arrive at the laboratory unevaluable or as a 
priority need for genotypic and/or phenotypic analyses when participants 
meet Confirmed Virologic Failure criteria.
Clinical Chemistry X X X X X X X X X
Hem atology X X X X X X X X X
Lipid Panel X X X
HBsAg, anti -HBc, 
anti-HBs, and HBV 
DNAXHBV DNA testing will be performed for participants with positive anti -
HBc and negative HBsAg and negative anti -HBs.   
 
 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
21Procedures
Screening / Day 1 
(Baseline) a, b Intervention Period Weeks
Withdrawal
Follow-upi
[CONTACT_72411]
1c4d 8e12f24g36 48g, h52h
HBV 3TC 
Resistance and HBV 
DNA (only for 
participants with 
chronic HBV 
infection)X X* X**Testing for HBV 3TC resistance will be performed using samples from 
Week 1 or Week 4 (depending on when ART modification occurs) as well 
as Baseline samples.  For these participants, HBV DNA w ill also be 
obtained at the Week 1 and/or Week 4 visit.
HCV antibody X
Rapid plasma reagin 
(RPR)X
Urinalysis X X X X X X X A morning specimen is preferred.  Reflex microscopic.
Pregnancy test 
(POCBP only)S/U S S S S S S S S SPregnancy testing will be conducted (participants of childbearing potential 
only) on serum (S) samples .  At Screening/ Day 1 Visit (before start of 
study treatment), a urine (U) test must be used to confirm pregnancy status 
prior to administration of st udy treatment.
Remind participants of childbearing potential at each study visit of the 
need to avoid pregnancy and to adhere tothe study’s contraception 
requirements. 
 
 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
22Procedures
Screening / Day 1 
(Baseline) a, b Intervention Period Weeks
Withdrawal
Follow-upi
[CONTACT_72411]
1c4d 8e12f24g36 48g, h52h
FSH XA high follicle stimulating hormone (FSH) level in the postmenopausal 
range may be used to confirm a postmenopausal state in females at birth
not using hormonal contraception or hormonal replacement therapy 
(HRT).  
HLA B5701 **Testing for HLA B5701 may be required before adding or modifying 
ART therapy and shoul d be discussed with the Medical Monitor. Please 
schedule this test using the Unscheduled Q2 requisition.
Study treatm ent
IWRS X X X XScreening/Day [ADDRESS_1170803] is required.
Dispense 
DTG +3TC FDC 
study treatment X X X XParticipants must return their pi[INVESTIGATOR_598229].  Site should remind 
partici pants of the importance of adherence.
ART may be modified as described in Section 7.  Required ART 
modification assessments are outlined in Section 1.3.[ADDRESS_1170804] be 
recorded. 
 
 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
23Procedures
Screening / Day 1 
(Baseline) a, b Intervention Period Weeks
Withdrawal
Follow-upi
[CONTACT_72411]
1c4d 8e12f24g36 48g, h52h
Adverse Event (AE) 
reviewX==============X=============  X X XOnly AEs related to study related events will be collected betw een 
obtaining i nformed consent and initiation of study treatment on 
Screening/ Day 1.  After Day 1, all AEs and SAEs will be collected 
through the Follow -up Visit.  See additional information in the SAE 
Revie w on Follow -up assessments.
Serious Adverse 
Event (SAE) reviewX============X===============  X X XOnly SAEs related to study participation or to a concomitantly 
administered ViiV Healthcare/[COMPANY_004] product w ill be collected betw een 
obtaining informed consent and administration of study drug at the 
Screening/ Day 1Visit.
Only Participants with ongoing SAEs and non -serious AEs of special 
interest (as defined in Section 2.3.1 ), regardless of attributability, will 
attend a Follow -up Visit approximately four w eeks after their last dose of 
study treatment.  Assessments at the Follow -up Visit should reflect any 
ongoing complaints (e.g. blood draws to follow a laboratory abnormality).  
The investigator, in consultation with the medical monitor, should follow -
up with the participant unt il the event is resolved, stabilized, otherwise 
explained, or the participant is lost to follow -up
Prior and 
Concomitant 
medication reviewX============X===============  X X XPrior medications over the last 4 w eeks will be collected at the 
Screening /Day 1Visit. 
 
 2020N440514_00
2019N398432_01 CONFIDENTIA L
[ADDRESS_1170805]-ART 
Regim en 
ModificationbNote: If the ART Regimen Modification Visit or the Post- ART Regimen 
Modification Visit occurs at a scheduled visit (Section 1.3),assessments should be 
completed at the scheduled visit and only the additional assessments in this table 
should be completed .
a.The ART Regimen Modification visit is used when modifying a participants ART regimen (e.g., b ased on Baseline labs, a Confirmed Virologic Failure, or 
an AE) betw een scheduled visits.  
b.Four w eeks after the ART modification , the participant must return for the Post ART regimen Modification Visit; participants will resume the regular study 
visit sch edule after this visit.  
Clinical and Other Assessments
Vital signs X XBlood pressure to be measured after resting in a semi -supi[INVESTIGATOR_21683] 
5minutes.
Body  Weight X XBMI will be calculated within the eCRF.  
The same scale should be use d at each study visit.
Suicidality Assessment X X Investigator must assess participant suicidality using their usual clinical standards.
HIV associated conditions X X
HIV Symptom Distress 
ModuleX XQuestionnaire/Surveys are recommended to be administe red at the beginning of the 
visit before any other assessments are conducted.  See Section 8.9 for additional 
information on how this questionnaire should be completed.
Laboratory assessments
Quantitative plasma HIV-1 
RNAX* X*If the ART modification is based on Baseline laboratory results, a HIV- [ADDRESS_1170806]-ART 
Regim en 
ModificationbNote: If the ART Regimen Modification Visit or the Post- ART Regimen 
Modification Visit occurs at a scheduled visit (Section 1.3),assessments should be 
completed at the scheduled visit and only the additional assessments in this table 
should be completed .
Plasma for storage X XPlasma samples for storage will be collected (e.g. for HIV- 1 RNA levels and 
immunological parameter s). These samples will be used when needed such as when 
samples are lost or arrive at the laboratory unevaluable or as a priority need for 
genotypic and/or phenotypic analyses when participants meet Confirmed Virologic 
Failure criteria.
Clinical Chemistr y X
Hem atology X
HBV 3TC Resistance and 
HBV DNA (only for 
participants with chronic HBV 
infection)X**A sample should be taken for HBV 3TC resistance and HBV DNA i f the ART 
modification visit is not at the Week [ADDRESS_1170807] ( POCBP only) S SPregnancy testing will be conducted (participants of childbearing potential only) on 
serum (S) samples.
Remind participants of childbearing potential at each study visit of the need to avoid 
pregnancy and to adhere to the study’s contraception requirements.
Study treatm ent
Treatment Adherence X X 7- day participant recall.  All study treatment stop and start dates must be recorded.
Adverse Event (AE) review X X
Serious Adverse Event (SAE) 
reviewX X
Concomitant medication 
reviewX X 
 
 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
262. INTRODUCTION
Early initiation of antiretroviral therap y (ART) reduces morbidity  and mortality  for 
individuals infected with HIV. Supressing viral replication with ART also reduces the 
potential for transmission of HIV. Because of this, ART is recommended for all persons 
with HIV viremia regardless of CD4 count.  Delays between diagnosis and treatme nt 
results in many  individuals not engaging in their care.  Thus, rapid ART initiation (Test 
and Treat) at the time of HIV -1 diagnosis is imperative for increasing the proportion of 
individuals starting ART earlier and achieving and maintaining viral suppr ession DHHS , 
2018 ].
The goal of rapid Test and Treat is for adults with newly  diagnosed HIV- 1 infection to be 
offered and start ART, as well as counselling as soon as possible [ Saag , 2018; WHO , 
2017].  The I nternational AIDS Society  (IAS) Guideline [ Saag , 2018] and the World 
Health Organization (WHO) [ WHO , 201 7]recommend a rapid start of ART.  T he rapid 
start strategy  has been tested in multiple randomized controlled, pi[INVESTIGATOR_585041] 
[Bacon , 2018; Rosen ,2016; Koenig , 2017 ]. Recent studies have demonstrated the 
efficacy  of immediate ART at entry  into care. Same day  ART improves the rate of viral 
suppression, reduces the time to viral suppression, improves retention in care, and reduce 
the risk of transmission.  The percentage of naïve patients initiating therap y the same day 
as diagnosis has increased almost 50% since 2015 to 19% in 2017.  However, for a 
variet y of reasons, not all ART regimens are suitable for use in a rapid test& treat setting.
2.1. Stud y Rationale
Study  212355 is a 52-week pi[INVESTIGATOR_842441] , efficacy  and 
safet yof using a fixed dose combination (FDC) of Dolutegravir (DTG) plus L amivudine 
(3TC) as a first line regimen in a T est and T reat model of care .  Participants with a new 
diagnosis of HIV -1 infection will in itiate DTG +3TC FDC within 14days of the initial 
diagnosis at the Screening/ Day 1 Visit, prior to safety  laboratory results , Hepatitis B 
serolog ies, and HIV-1 drug resistance genoty pe results being available for review.
There are possible barriers to DTG +3TC FDC use in a rapid Test and Treat model of 
care due to concerns over the potential initiation of therapy  in participant s with 
transmitted M184V, M184I  or K65R mutation or HBV -HIV co infection. This study  
aims to evaluate the feasibility , efficacy  and safety of using DTG + 3TC FDC as a first 
regimen in a rapid Test and Treat care setting in the U.S, where the prevalence of both 
transmitted M184V/I  and co -infection with HBV is low .
2.2. Background
FDCs and once -daily single tablet regimen have greatl y simplified the treatment of 
people living with HIV and may  be of greater importance in people with lifesty les or care 
commitments that may  impair adherence to dosing schedules, including some women and 
those in underserved populations.   In a stud y b
y Paterson et. al. [ Paterson, 2000], a linear 
relationship between levels of adherence and viral load suppression was observed . 
Adherence to therap y is essential to achieve viral suppression and prevent emergence of 
resistance mutations. Among regimens of comparable efficacy , phy sicians and people  2020N440514_00
2019N398432_01 CONFIDENTIA L
[ADDRESS_1170808] 
in class efficacy , and a high barrier to resistance.  These properties and its safet y profile 
make it an optimal core agent for 2- drug regimens. In addition, due to its mechanism of 
metabolism, DTG lacks many  of the frequent DDIs associated with other medications 
commonly  taken b y people living with HIV.  To date, the efficacy , pharmacokinetics 
(PK), safet y and drug interaction potential of DTG has been evaluated in an extensive 
program of Phase I to IIIB clinical trials [ TIVICAY Package Insert, 201 8; DTG IB , 
2018 ].
3TC is a potent cy tidine nucleoside analogue without major side effects and has a well 
proven safety  profile.  Available since 1995 as a single agent (EPI[INVESTIGATOR_122498]) [ EPI[INVESTIGATOR_842442], 2018], it is also available as part of three FDC products (zidovudine (ZDV)/3TC, 
COMBIVIR, abacavir (ABC)/3TC, EPZICOM/KIVEXA, ABC/3TC/DTG, TRI UMEQ).  
3TC monotherapy  is known to select for resistance due to a single point mu tation that 
reduces antiviral activit y.  However, it is predicted that 3TC, when combined with DTG 
with its high barrier to resistance and abilit y to confer a very rapid decline in HIV -[ADDRESS_1170809] for resistance consistent with clin ical studies combining 
DTG, 3TC and ABC [ Walmsley , 2013; Walmsley , 2015; Cahn, 2018].  
A pi[INVESTIGATOR_799]  (PADDLE) evaluated the anti -viral efficacy , safety  and tolerability  of a 2 -
drug regimen with DTG 50 mg and 3TC 300 mg, both dosed once dail y [Cahn, 2017].  
Twenty  treatment naïve participants were enrolled, with a median baseline viral load of 
24,128 c/mL .  A rapid decline in viral load was observed, with a median viral load decay  
from baseline to Week 12 o f 2.74 logs.  At Week 48, 90% (18 of 20) reached a viral load 
of <50 c/mL.  Four subjects were enrolled with baseline HIV- RNA 100,000 c/mL ; all 
achieved HIV -RNA <400 c/mL  at Week 3, and <50 c/mL  at Week 8.  No major 
tolerability  issues were observed.
The AIDS Clinical Trial Group (ACTG) Stud y A5353 evaluated DTG + 3TC in 120 
treatment -naïve HIV -1 infected participants, including with HIV -1 RNA  1000 c/mL  and 
<500,000 c/mL  [Taiwo , 2018 ].  The median viral load was 4.61 log10 at baseline; 37 of 
the 120 participants had viral load 100,000 c/mL. Virologic efficacy  (<50 c/mL ) at 
Week 24 was 108/120 (90%), with comp arable results in the >100,000 c/mL (89%) and 
the  100,000 (90%) strata’s.  One participant discontinued the study  at Week 18 due to 
non-compliance with study  treatment and met confirmed virologic failure criteria at 
Week 24 (off ART) with the M184V plus t he mixture R263R/K mutations detected (no 
mutation seen at baseline).  Two participants experienced Grade 3 possible/probable 
treatment -related AEs; no participants discontinued study  treatment due to AEs.
DTG +3TC FDC provides a novel, well- tolerated two -drug first -line regimen for HIV 
infected treatment- naïve patients that, by  [CONTACT_842490] -retroviral ( ARV ) in the 
regimen may  potentiall y limit the cumulative risk of drug- related toxicities.  GEMINI [ADDRESS_1170810] ed ART -naïve participants with a 
Screening HIV -1 RNA of  500,000 copi[INVESTIGATOR_014]/mL  (c/mL ) and with no drug -resistance 
mutations, DTG +3TC was non-inferior to DTG + TDF/FTC at W eek 48 [Cahn, 2019].  
The proportion of participants with plasma HIV -1 RNA <50 c/mL was similar in each
treatment group.  At least 90% of participants in each treatment group had plasma HIV -1 
RNA <50 c/mL using the Snapshot algorithm.  DTG +3TC was effective across a 
diverse spectrum of ART -naïve partic ipants, including those with high Baseline HIV-1 
RNA (>100,000 c/mL).  Over 48 weeks, the pooled safet y data was consistent with the 
known safet y profile for the individual products.  There was a small number of AEs 
leading to withdrawal of study  drug; few were considered drug -related.  Clinical 
laboratory  assessments demonstrated there were no newly  identified laboratory  signals of 
concern.  DTG +3TC was associated with lower impact on renal and bone biomarkers 
compared with DTG +TDF/FTC FDC.
One of the potential risks of a two -drug regimen, such as DTG + 3TC FDC, is the 
increase in virologic failure associated with the emergence of HIV-1 resistance
mutations.  DTG, with its higher barrier to resistance, may reduce treatment -emergent 
resistance in partici pants taking a two -drug regimen.  The overall efficacy  data from the 
pi[INVESTIGATOR_842443]- naïve participants are extensive, with no 
resistance mutations being identified through 144 weeks of treatment ( SINGL E, 
ING114467) [ Walmsley , 2015].  The absence of treatment- emergent mutations to DTG 
or background agents in ART -naïve individuals, rapid virologic response demonstrated 
for DTG -based regimens, and the in vitro potency and well -tolerated safet y profile of 
both DTG and 3TC all provide a strong rationale for the development of a DTG + 3TC 
single tablet regimen as a treatment option for people living with HIV.  In the Gemini 
studies, there was no emergent INST Ior NRTI resistance observed for partic ipants 
meeting confirmed virologic withdrawal criterion in either the DTG + 3TC or 
DTG +TDF/FTC treatment arms [Cahn, 2019].
2.3. Benefit/Risk A sses sment
More detailed information about the known and expected benefits and risks and 
reasonabl y expected adverse events of DTG , 3TC or DTG + 3TC FDC may be found in 
the most recent version of the Investigator’s Brochure (IB) and an y IB supplement s and 
the product labels [TIVICAY Package Insert, 2018 ; EPI[INVESTIGATOR_842444], 2018; 
DOVATO Package Insert, 2019] .
The following section outlines the risk assessment and mitigation strategy  for DTG and 
3TC in this protocol.  2020N440514_00
2019N398432_01 CONFIDENTIA L
[ADDRESS_1170811] 12 weeks of stud y intervention (Weeks 1, 4, 8 and 12 Visits), with visits every  12 weeks thereafter.
Potential Risk of 
Clinical SignificanceData/Rationale for Risk Mitigation Strategya
Study Intervention [DTG , 3TC]
Refer to DTG IBs and country product labels for additional information
DTG: Hypersensitivity 
reaction (HSR) and rashDTG: HSR has been observed uncommon ly with DTG.  Rash was commonly 
reported in DTG Phase IIb/III clinical trials; epi[INVESTIGATOR_842445]; no epi[INVESTIGATOR_473385], such as Stevens -Johnson 
Syndrome (SJS), Toxic Epi[INVESTIGATOR_19342] (TEN) and erythema multifor me 
were reported. Specific/detailed toxicity management guidance is provided for HSR 
and rash ( Section [IP_ADDRESS] ).
The participant informed consent form (ICF) includes information on 
this risk and the actions pa rticipants should take in the event of a 
HSR or associated signs and symptoms .
DTG: Drug induced liver 
injury (DILI) and other 
clinically significant liver 
chemistry elevations 
3TC: Use in HBV co -infected 
participants and emergence 
of HBV variants resist ant to DTG : Non -clinical data suggested a possible, albeit low, risk for hepatobiliary 
toxicity with DTG.  Drug -related hepatitis is considered an uncommon risk for 
ART containing DTG regardless of dose or treatment population.  For 
participants with hepa titis B virus (HBV) and/or hepatitis C virus (HCV) co -
infection, improvements in immunosuppression as a result of HIV virologic and 
immunologic responses to DTG -containing ART, along with inadequate 
therapy for HBV co -infected participants, likely contributed to significant 
elevations in liver chemistries.  A review of post -marketing data found that the 
number of cases reporting particularly severe liver dysfunction was found to be 
very low in the context of exposure to DTG and DTG/ABC/3TC. The reported 
cases of severe liver dysfunction (including acute hepatic failure) are complex 
with potential confounding factors but in a very small number of cases, drug -
induced liver injury is likely and the role of DTG containing regimens cannot be 
ruled out particular ly in those involving DTG with ABC/3TC or DTG/ABC/3TC.
3TC:   Current treatment guidelines [ DHHS , 2018; EACS , 2017] do not 
recommend monotherapy with 3TC for participants with HBV infection, which 
is what participants randomised to DTG + 3TC FDC, would effectively be 
receiving.  Emergence of HBV variants associated with resistance to 3TC has 
been reported in HIV -1-infected participants who have received 3TC -
containing antiretroviral regimens i n the presence of concurrent infection with Participants will be tested for chronic hepatitis B at Baseline
(Screening/Day 1) .
Participants with chronic hepatitis B infection as shown by [CONTACT_842491] a Tenofovir containing regimen.
Positive for HBsAg; 
Negative for HBsAg and HBsAb, and positive for HBcAb and 
HBV DNA .
For participants with chronic HBV infection, testing for HBV 3TC 
resistance will be performed using samples from Week 1 and Week 
4 (depending on when ART modification occurs) as well as Baseline 
samples.  HBV DNA will also be obtained at the Week 1 or 
Week 4visit.
Liver chemistries will be monitored. Specific/detailed liver stoppi[INVESTIGATOR_842446] 
(Section 10.6). 
 
 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
30Potential Risk of 
Clinical SignificanceData/Rationale for Risk Mitigation Strategya
Study Intervention [DTG , 3TC]
Refer to DTG IBs and country product labels for additional information
HBV.  Additionally, discontinuation of 3TC in HBV co -infected participants can 
result in severe exacerbations of hepatitis B.
DTG: Psychiatric disorders DTG: Psychiatric disorders including suicidal ideation and behaviours are 
common in people living with HIV. Events of suicidal ideation, attempt, 
behaviour and completion were observed in clinical studie s of DTG, primarily 
in participants with a pre -existing history of depression or other psychiatric 
illness. The psychiatric profile for DTG (including suicidality, depression, 
bipolar and hypomania, anxiety and abnormal dreams) was similar to RAL -or 
favou rable compared with EFV -based regimens. Participants who in the investigator’s judgment, pose a significant 
suicidality risk, are excluded from participating.  Because of the 
elevated risk in the HIV -infected population, treatment emergent 
assessment of suicidality will be monitored during this study .  See 
Section 8.2.4for additional information . 
Investigator smust assess participant suicidality using their usual 
clinical practice at every study visit .
Investigators are advis ed to consider mental health consultation or 
referral for participants who experience signs of suicidal ideation or 
behaviour.
The participant informed consent form includes information on this 
risk of depression and suicidal ideation and behaviours.
DTG and 3TC :Increased 
rates of virologic failure/ 
Observed ResistanceDTG: Week 96 and Week 144 analyses for the Phase III/IIIb clinical studies 
supported the efficacy findings from earlier analyses and demonstrated robust 
maintenance of viral suppression wit h no finding of HIV -1 resistance in 
treatment- naïve participants. 
3TC:  M184V, M184I and K65R (associated with resistance on TDF treatment 
failure) single mutation sthat confer resistance to 3TC.  Subjects with evidence of primary viral resistance based on the 
presence of M184I, M184V or K65R or any DTG primary resistance 
associated mutation will have their antiretroviral regimen modifie d 
based on the results of Baseline resistance genotype asthey 
become available ( Week 4 Visit ) (see Section 7.2.2 ). 
Subjects will have HIV -[ADDRESS_1170812] 
a resistance genotype/phenotype performed, and their regimens 
may be modified based on the results of th e resistance test.
DTG: Theoretical serious 
drug interaction with 
dofetilide Co-administration of DTG may increase dofetilide plasma concentration via 
inhibition of organic cation transporter (OCT -2), resulting in potentially life -
threatening toxicity. The co -administration of DTG with dofetilide is prohibited in the 
study (Section 10.7).
DTG and 3TC: Renal 
functionDTG : Mild elevations of creatinine have been observed with DTG which are 
related to a likely ben ign effect on creatinine secretion with inhibition of OCT -2.  
DTG has been shown to have no significant effect on glomerular filtration rate Due to requirements for dose reduction of 3TC in participants with 
renal dysfunction, participants with a creatinine clearance (CrCL) 
<30mL/m in/1.[ADDRESS_1170813] DTG + 3TC FDC discontinued and  
 
 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
31Potential Risk of 
Clinical SignificanceData/Rationale for Risk Mitigation Strategya
Study Intervention [DTG , 3TC]
Refer to DTG IBs and country product labels for additional information
(GFR) or effective renal plasma flow.
3TC:3TC is eliminated by [CONTACT_842492].  3TC is not recommended to treat 
participants with a creatinine clearance <50 mL/min.modify toa new ART regimen .
Creatinine Clearance ( CrCl)will be calculated in all participants and 
renal function (creatinine clearance and serum phosphate) will be 
monitored at all study visits.
DTG: N eural tube defects In one ongoing birth outcome surveillance study in Botswana, early results 
from an unplanned interim analysis show that 4/426 (0.9%) of cis women who 
were taking DTG when they became pregnant had babies with neural tube 
defects compared to a background rate of 0.1%.1. A participant who is female at birth is eligible to participate if not 
pregnant , if pregnant and pa st the first trimester , or of 
childbearing potential andagrees to follow one of the options 
listed in the Modified List of Hi ghly Effective Methods for 
Avoiding Pregnancy in Participants of Childbearing Potential 
(Section 10.5.2 ) for at least [ADDRESS_1170814] dose of study 
medication.
2.Participants of childbearing potential who plan to become 
pregnant during the study are excluded;
3.Participants who become pregnant and are in the first trimester 
should immediately discontinue DTG + 3TC FDC and an 
alternate ART regimen that does not contain DTG should be 
started, unless no suitable al ternative is available, in 
consultation with the Medical Monitor.  If the pregnancy is post 
first trimester, the participant can continue study treatment.  
Any participant who becomes pregnant during the study can 
remain in the study, including those who n eeded to modify the 
ART Regimen.
4.Participants who desire to be pregnant while in the study, or 
who state they no longer are willing to comply with the 
approved pregnancy avoidance methods, will have DTG + 3TC
FDC discontinued and switched to a new ART regi men.
5.Participants of childbearing potential are reminded re: 
pregnancy avoidance and adherence to contraception 
requirements at every study visit. 
 
 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
32Potential Risk of 
Clinical SignificanceData/Rationale for Risk Mitigation Strategya
Study Intervention [DTG , 3TC]
Refer to DTG IBs and country product labels for additional information
6.Pregnancy status is monitored at every study visit.
a. Careful monitoring of events will be conducted using ser ious adverse event (SAE) reports and alerts for Grade 3 or 4 laboratory toxicities (per Division of Acquired Immune 
Deficiency Syndrome [DAIDS] toxicity gradings for HIV- infected participant s). Serious/severe events will be managed appropriately including , but not limited to, withdrawal of 
study drug, and will be followed to resolution as per Sponsor’s standard medical monitoring practices.  
b. Clinical Safety Data will be routinely reviewed in GlaxoSmithKline ([COMPANY_004] ) /ViiV Safety Review Team meetings. This w ill include in -stream review of data from this clinical trial on a 
routine basis, review of aggregate data on a protocol and program basis when available, and review of competitor data from th e literature. 
 
 2020N440514_00
2019N398432 _01 CONFIDENTIA L
[ADDRESS_1170815] to meals, 
without need for a PK booster, and with limited safety implications resulting from 
theoretical or actual DDIs compared to other ART agents (including EFV and those 
requiring a PK booster).  In additi on, the high barrier to HIV-[ADDRESS_1170816] the development of resistance to both 
components of the DTG + 3TCFDC regimen.  Individually , DTG and 3TC in 
combination with other ARVs have demonstrated durab le virologic and immunologic 
response. 
In general, ART immediately  after diagnosis may increase participants’ engagement to 
care and increase adherence to ART. Study  participants also may  benefit from the 
medical tests and procedures performed as part of this study .
2.3.3. Overall Benefit: Risk Conclusion
Taking into account the measures taken to minimize risk to participants participating in 
this study , the potential risks identified in association with DTG +3TC FDC are justified 
by [CONTACT_842493][INVESTIGATOR_842447] 2 -drug regimen.
3. OBJECTIVES A ND ENDPO INTS
Objectives Endpoints
Primary
To evaluate the feasibility and efficacy  
of a rapid Test and Treat model of care 
in participants with a new diagnosis of 
HIV-1 initiating treatment with DTG + 
3TC FDC immediately  (or, for those 
participants referred from another site, 
within 14 day s of initial diagnosis at 
the external clinic/testing center )Percentage of all participants who have  
plasma HIV -1 RNA <50 c/mL  at 
Week 24, regardless of ART regimen
(observed anal ysis)
Secondary
To demonstrate the antiviral activity  of 
DTG +3TC FDC over 48 weeksProportion of all participants:
who have plasma HIV -1 RNA <50 
c/mL  at Week 48, regardless of ART 
regimen (observed anal ysis)
with plasma HIV -1 RNA <50 c/mL  
at Week 24 and 48 using the FDA 
Snapshot algorithm 
Time to suppression of HIV -1 RNA  2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
34Objectives Endpoints
<50c/mL
To evaluate the barriers (e.g., HIV -1 
resistance mutation results) to initiate 
and maintain DTG + 3TC FDC 
treatment i n a Test and Treat Model of 
CareProportion of participants who change 
first line regimen of DTG + 3TC FDC 
due to Baseline laboratory  results or 
HIV-1 resistance mutation results .  
To assess viral resistance in 
participants meeting confirmed 
virologic fa ilure criteriaIncidence of treatment -emergent 
genot ypic and phenot ypic resistance to 
DTG and/or 3TC , or any  other ART if 
treatment is modified, in participants 
meeting confirmed virologic failure 
criteria
To evaluate the safet y and tolerability  
of a rapi d test and treat model of care 
using DTG + 3TC FDC as first line 
regimen Incidence and severit y of adverse 
events (A Es) and laboratory  
abnormalities
Proportion of participants who 
discontinue treatment due to AE s and 
drug-related AE s over 48 weeks of 
treatment
To evaluate the immune effects of a 
rapid test and treat model of care using 
DTG + 3TC FDC as first line regimenChange from Baseline in CD4+ cell 
counts and CD4+/CD8+ ratio at 
Weeks 24 and 48
Incidence of disease progression 
(stage 3 HIV -associate d conditions, 
AIDS, and death) through Week 48
To evaluate retention in care Proportion of participants 
owho completed their Week 24 and 
Week 48 Visit ;
owho complete their Week [ADDRESS_1170817] a HIV-1 RNA
<200 c/mL
Exploratory
To evaluate the effect of participant
demographics and Screening/Day  [ADDRESS_1170818] and treat model of 
care using DTG +3TC FDC as first 
line regimenProportion of participants with plasma 
HIV-1 RNA <50 c/mL by  [CONTACT_328548] 24 
and 48 by  [CONTACT_842494](s) by 
[CONTACT_842495]
To asses change in treatment sy mptom Change from Baseline in overall  2020N440514_00
2019N398432 _01 CONFIDENTIA L
[ADDRESS_1170819] 
and treat model of care using DTG + 
3TC FDC as a first line regimen symptom bother score from the HIV 
Symptom Distress Module at Weeks 4, 
8, 12, 24, 36, and 48 
To assess change in specific sy mptoms 
for participants treated with 
DTG +3TC FDCChange from Baseline in 20 item-
specific s ymptoms from the HIV 
Symptom Distress Module at Weeks 4, 
8, 12, 24, 36, and 48
To assess adherence to study  treatment Adherence will be assessed by  
[CONTACT_842489] 7 day s prior to the 
visit
4. STUDY DESIGN
4.1. Overall Design
Study  212355 is a Phase IIIb, multicentre, 52- week, open label, single arm, pi[INVESTIGATOR_842448] a new diagnosis of HIV- 1, who are willing to start study  treatment 
(DTG +3TC FDC ) immediatel y.  Eligible participants will be enrolled and started on 
DTG +3TC FDC, without waiting for Screening /Day  1laborat ory results. The 
Screening/Day  1 Visit is considered Baseline.
The study  will be conducted in the U.S., with approximately  120 participants with a new 
HIV-1 diagnosis who are willing to start DTG + 3TC FDC within 14days of diagnosis.  
A participant’s to tal time in the study  will be approximately  13months and includes a 
maximum of 14 day s between the initial diagnosis of HIV- 1 infection and initiation of 
study  drug at the Screening/Day  1 Visit, a 52- week treatment period and a 4- week 
follow -up phase if required.
This study  will comprise:
The Screening /Day  1 Visit is the date the site assesses the participant’s 
appropriateness for the study  and consents for and initiate sstudy  treatment.  
Diagnosis may  have occurred at an external clinic/ testing center pri or to participant 
visiting the site.
Participants are considered HIV -[ADDRESS_1170820] positive results from 
2 different HI V Rapid tests (different assay  or manufacturer) , or they  are positive 
with an FDA -approved antigen/antibod y combination immun oassay  (4th
generation assay ) or an FDA approved HIV antibody  immunoassay  that detects 
HIV-1 and HIV -2 antibodies (3rdgeneration assay) confirmed b y an FDA -
approved antibod y immunoassay that differentiates HIV -1 antibodies from 
HIV-2 antibodies or an HIV western blot or an HIV -1 RNA. 2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
36For participants who are referred to the stud y site with a single positive 
Rapid HIV test, a second and different Rapid HIV test (different assay  or 
manufacturer) should be conducted. If the second Rapid HIV test is 
nonreacti ve, the participant is presumed to be HIV -negative. If both tests are 
reactive, the participant is confirmed HIV -infected.
Screening/Day  1labs should be taken prior to the administration of study  
treatment.
Investigator should review the Baseline laborato ry findings as they  become available 
and schedule a study  visit (Week 1 )
, see Section 7.2for additional information.  If  
results for HBV surface antigen (HB sAg) or HBV core antibod y (anti -HBc) and 
HBV DNA are no t available, this review should be completed at the Week 4 V isit 
when the HI V-1 resistance mutation results are available. 
Note: For participants with chronic HBV infection, testing for HBV 3TC resistance 
will be performed using samples from Week 1 orWeek 4 (depending on when ART 
modification occurs) as well as B aseline samples.  In these participants, HBV DNA 
will also be obtained at the Week 1 or Week 4 visit.
A visit should be scheduled when the central laboratory  data from Baseline genot ype
for HIV-1drug resistance mutations are available (Week 4 Visit ) and additional 
intervention should be performed if required (see Section 7.2.2 for more details).  If 
the HBV surface antigen (HB sAg) or HBV core antibody  (anti -HBc) and HBV DNA 
data w erenot available at the time of the Week 1 V isit, these results should be 
review edat Week 4.  The investigator should also review the tolerance to 
DTG +3TC FDC, A Es, assess adherence to study treatment and enforce the 
importance of adherence.   
Virologic non -response criteria for Week 8, Week 12, and on or after Week 24 are 
defined in Section 7.3.
Additional study  visits are scheduled at Weeks 12, 24, 36 , 48, 52, and a potential 
Follow -up Visit .  At Week 36, s tudy participants will be provided DTG + 3TC FDC 
to ensure that they  have enough study  intervention until Week 52.  
When the I nvestigator is modify ing a participants ART regimen between scheduled 
visits , the study  assessments shown in the SoA in Section 1.3.1 should be followed .  
During t he ART Regimen Modification Visit ,the date of the modification and the 
new 
ART regimen will be captured .  Four weeks after the ART modification (Post ART 
Regimen Modification Visit) , the participant must return for another visit to determine 
adherence, safet y of and virologic response to the new regimen.  The participants will 
resume regular study  visit schedule after this visit. If the ART Regimen Modification 
Visit or the Post -ART Reg imen Modification Visit occurs at a scheduled visit (Section 
1.3), assessments should be completed at the scheduled visit and only  the additional 
assessments at the ART Modification visit should be completed .
When all participan ts complete the Week [ADDRESS_1170821] participant has had their 
Week 24 viral load assessed , including an y retests .  
All participants who remain in the study  will complete the Week 52 Visit (which can 
occur an ytime within 2 -4 week of the Week 48 V isit), where study  intervention stop date 
will be captured, and collect and follow -up on A Es and SAEs.  Participants who require a 
virologic retest must have HIV -1 RNA level re -assessed by  a second measurement 
performed 2 -4 weeks later, which will be captured under the Week 52 Visit.  
4.2. Scientific Rationale for Study  Design
Individuals who receive a diagnosis of HIV -1 infection should be started on ART as soon 
as possible after di agnosis.  Recently  diagnosed individuals are often referred to HIV care 
providers for evaluation, follow -up and management, resulting in a delay  between 
initiation and time ART is prescribed.  This delay  between diagnosis and treatment 
results in many  individuals not engaging in their care.  Thus, rapid ART initiation (Test 
and Treat) , ideall yon the same day  of HIV -1 diagnosis may  increase the proportion of 
individuals who start ART earlier and achieve and maintain viral suppression [DHHS ,
2018 ; Saag , 2018 ].
When ARTs are started before HIV-1resistance mutation results are available, the DHHS 
Guidelines recommend either DRV/r or DRV/c plus Tenofovir/FTC or DTG plus 
Tenofovir/FTC DHHS , 2018] .  No specific ty pe of tenofovir is favoured.  They  do not 
recommend NNRTIs or the use of ABC.  Transmitted mutations conferring NNRTI 
resistance are more likely  than mutations associated with PI  [INVESTIGATOR_842449]. HLA -
B*[ADDRESS_1170822] generation INSTI s are not 
recommended because of lower barriers to resistance.  BI C/TAF/FTC is not 
recommended because of lack of data.   
The IAS Guidelines also recommend a rapid ART initiation for all HI V infected 
individuals willing to start ART [Saag , 2018]. Current IAS guidelines recommend DTG 
plus TAF (or tenofovir disoproxil fumarate [TDF]), emtricitabine (or lamivudine)) or 
bictegravir/TAF/emtricitabine or boosted darunavir TAF (or TDF), emtricitabine (or 
lamivudine) as initial rapid therapy .  Because of concerns about transmitted drug 
resistance ( e.g., K103N mutation), immediate ART should not be nonnucleosi de reverse 
transcriptase inhibitor (NNRTI) –based.  Participants requiring abacavir should not begin 
until the result of testing for the HLAB* 5701 allele is available [ Saag , 2018].
Phase 3 Studies GEMINI 1 and GEMINI 2 demonstrated that a 2 -drug regimen of 
DTG +3TC was non -inferior to DTG + TDF /FTC in HI V-1 infected ART naïve 
participants, with comparable safety results observed between the 2 treatment groups
[Cahn, 2019]. In both studies, Kaplan- Meier estimates of the time to viral suppression 
(<50 c/mL) through Week 48 indicated that participants reached viral suppression at a 
similar time point, irrespective of whether they  received DTG + 3TC or a standard of care 
triple drug regimen in both tr eatment groups, with a median time to viral suppression of  2020N440514_00
2019N398432 _01 CONFIDENTIA L
[PHONE_17527].0 day s.  The proportion of participants with HIV -1 RNA <50 c/mL b y visit in the 
DTG + 3TC group in GEMI NI 1/GEMINI 2 was 73%/71% at Week 4, 85%/ 89% at 
Week 8, 87%/90% at Week 12 and 92%/94% at Week 24.  No statistically  significant 
evidence of heterogeneity  between the Baseline HIV -1 RNA subgroups ( or >100,000 
c/mL ) was observed for the difference in the proportion of participant s with HIV -1 RNA 
<50 c/mL  at Week 48 between arms .  2% of partici pants in both groups had baseline viral 
loads of 500,000 c/ mL or more , Week 48 e fficacy  outcomes in these participants were 
similar in the two -drug regimen group (11 [85%] of 13) and three- drug regimen group 
(12 [80%] of 15).   At Week 12, the median (IQR) log 10 c/mL change from baseline was 
-2.840 (-3.290, -2.450) in GEMINI 1 and -2.800 (-3.250, -2.360) in GEMINI 2.  
However, there are possible barriers to DTG + 3TC use in a rapid Test and Treat model 
of care due to concerns over transmitted M184V, M184I  and K65R resistance mutations 
and/or HBV -HIV co infection.  Study  212355 is a pi[INVESTIGATOR_842450] , effectiveness, safet y and ease of use of DTG + 3TC FDC as a first line 
therap y in a rapid Test and Treat model of care. 
Study 212355 is a multi -center, open -label, one arm pi[INVESTIGATOR_842451] y diagnosed adult 
HIV-1 participants.  P articipants will start study  treatment at the time of or within 14 days 
of the initial diagnosis and prior to the availability  of Screening/Day  1 labs.  The 
Screening /Day 1 Visit is to review participant inclusion/exclusion criteria and initiate 
study  intervention .  The Screening /Day  1Visit will be no more than [ADDRESS_1170823] a review of central labs and resistance genoty pic data as they  
become available from Baseline Visit labs to confirm that DTG +3TC FDC is an 
appropriate therap y (see also Section 7.2.1 and Section 7.2.2 ).  Study visits will also 
occur at Week 8, Week 12 and then every  12-weeks through Week 48 to ensure 
compliance with study  treatment, and to assess the efficacy and safet y and tolerabil ity of 
DTG +3TC FDC .  
4.3. Justification for Dose
The efficacy , PK, safet y, and drug interaction potential of DTG and 3TC as individual 
agents and in combination (DTG + 3TC) have been evaluated in extensive clinical 
development programmes.  DTG + 3TC FDC is approved in the US and marketed as 
DOVATO.  In addition, DTG and 3TC are approved and marketed as TIVICAY [ADDRESS_1170824] dose 
of study  medication only for participants with ongoing AE s of intere stor SAEs 
regardless of attributability (as defined in Section 2.3.1 ) at the last on -study visit.  
Assessments at the Follow -up Visit should reflect any  ongoing complaints (e.g., blood 
draws to follow a laborator y abnormalit y). Theinvestigator, in consultation with the 
medical monitor, should follow -up with the participant until the event is resolved, 
stabilized, otherwise explained, or the participant is lost to follow -up.
5. STUDY POPULA TION
Specific information regarding warnin gs, precautions, contraindications, adverse events, 
and other pertinent information on the investigational product or other study  interventions 
that may  impact participant eligibility  is provided in the Product Insert(s) for DTG and 
3TC.
Deviations from inclusion and exclusion criteria are not allowed because they  can 
potentially  jeopardize the scientific integrity  of the study , regulatory  acceptability  or 
participant safety.  Therefore, adherence to the criteria as specified in the protocol is 
essential. Prospective approval of protocol deviations to recruitment and enrolment 
criteria, also known as protocol waivers or exemptions, is not permitted.
The following are stud y specific eligibility  criteria unless stated otherwise.  In addition to 
these criteria , Investigators must exercise clinical discretion regarding selection of 
appropriate stud y participants, taking into consideration an y local treatment practices or 
guidelines and good clinical practice (GCP).
5.1. Inclusion Criteria
Eligible participants must:
be able to understand and comply  with protocol requirements, instructions, and 
restrictions;
be likely  to complete the study  as planned;
be considered appropriate candidates for participation in an investigative clinical 
trial with oral medication (e.g. no active problematic substance abuse, acute major 
organ disease, or potential long -term work assignments out of the country ).  
Participants are eligible to be included in the study onl y if all of the following criteria 
apply :
Age
1. Participant must be 18atthe time of signing the informed consent.
Type of Participant and Disease Characteristics
2. P articipants must have a new confirmed diagnosis of HIV -1 infection based on the 
criterion below , and are willing to initiate ART immediately  (or, for those  2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
40participants referred from another site, within 14 day s of initial diagnosis at the 
external clinic/testing center );as documented in source documents.
Participant must have an initial positive rapid HI V test
NOTE: This includes participants whose firstrapid test was positive either at the 
study  site or those who are referred to the study  site with a single positive rapid 
HIV test. The stud y site must have viewable documentation of the positive rapid 
test available and placed into the study  source documents.
AND
Participant has a second positive confirmatory  rapid HIV test, using a test kit from 
a different manufacturer than the firsttest 
NOTE: If the second Rapid HIV test is nonreactive, the participant is presumed to 
be HIV -negative.  If both tests are reactive, the participant is confirmed HIV -
infected.
OR
Participant has been identified as HIV -1 infected using an FDA- approved 4th
generation assay  antigen/antib ody combination immunoassay  or 3rdgeneration 
immunoassay  that detects and differentiates HIV- 1 and HIV-2 antibodies 
AND
has a confirmatory  HIV western blot OR an HIV -1 RNA   
OR
Participant has a positive FDA -approved 4thgeneration assay  and a positive 3rd
generation immunoassay  that detects and differentiates HIV- [ADDRESS_1170825] -exposure proph ylaxis 
(PEP) or pre -exposure prophy laxis (PrEP) in the past are allowed as long as the last 
PEP/PrEP dose was > 6months from HIV diagnosis or there is documented HIV 
seronegativit y at least 2month s after the last prophy lactic dose and prior to the date 
of HIV diagnosis.  The study site must have viewable documentation of the 
seronegative test available and placed into the study source documents.
Sex
4.Male and/or female
Participants who are female at birth : 
Participants who are female at birth are eligible to participate if at least one of the 
following conditions applies:
Not pregnant, as confirmed by a negative urine human chorionic gonadotropin 
(hCG) test at Screening/Day  1 2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
41Pregnant and post the first trimester (the physician and patient should decide 
whether enrolling in this study  is in the participants best interest during the 
consent process)
Not a participant of childbearing potential (P OCBP ) (see Section 10.5.1 ).
OR
A POCBP who agrees to follow the contraceptive guidance asdefined in 
Section 10.5.[ADDRESS_1170826] dose of study  medication.  
Participants who are f emale at birth and who are in the following categories are not 
considered P OCBP
a)Premenarchal
b)Premenopausal with ONE of the following: 
Documented h ysterectomy
Documented bilateral salpi[INVESTIGATOR_1656]
Documented bilateral oophor ectom y
Note: Documentation can come from the site personnel’s: review of participant’s
medical records, medical examination, or medical history  interview.
c)Postmenopausal :
A postmenopausal state is defined as no menses for 12 months without an 
alternative m edical cause.
A high follicle stimulating hormone (FSH) level in the postmenopausal 
range may  be used to confirm a postmenopausal state in participants who 
are female at birth and not using hormonal contraception or hormo nal 
replacement therap y (HRT). 
Participants who are f emale at birth on HRT and whose menopausal status 
is in doubt will be required to use one of the non -hormonal highl y 
effective contraception methods if they  wish to continue their HRT during 
the study . 
The investigator is responsible fo r ensuring that participants understand how to properl y 
use these methods of contraception.
All participants in the study  should be counselled on safer sexual practices including the 
use and benefit/risk of effective barrier methods (e.g., male condom) and on the risk of 
HIV transmission to an uninfected partner.
The investigator is responsible for review of medical history , menstrual history , and 
recent sexual activity  to decrease the risk for inclusion of a participants who are female at 
birth with an ear ly undetected pregnancy . 2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
42Informed Consent
5. Capable of giving signed informed consent as described in Section 10.1 which 
includes compliance with the requirements and restrictions listed in the informed 
consent form (ICF) and in this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions
1.Participants who are breastfeeding , plan to become pregnant or breastfeed during the 
study
2.Participants who are in their first trimester of pregnancy ;
3.HIV-[ADDRESS_1170827] results are known prior to Screening/ Day 1;  
4.Any evidence of an active Centers for Disease Control and Prevention (CDC) Stage 3 
disease [CDC , 2014], except fo resophageal candidiasis and cutaneous Kaposi’s 
sarcoma not requiring systemic therap y;
5. Participants with known or suspected Hepatitis B infection;
6.Known or suspected severe hepatic impairment or unstable liver disease (as defined 
by [CONTACT_31816] , encephalopath y, coagulopathy, h ypoalbuminaemia, 
oesophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary  
abnormalities (with the exception of Gilbert’ s syndrome or as ymptomatic gallstones );
7.Know n moderate to severe renal impairment (creatinine clearance 
<30ml/min/1.73m2);
8.Ongoing malignancy  other than basal cell carcinoma, or resected, non -invasive 
cutaneous squamous cell carcinoma, or cervical, anal or penile intraepi[INVESTIGATOR_26507]; other localised malignancies require agreeme nt between the investigator 
and the Study  Medical Monitor for inclusion of the participant ;
9.Participants who in the investigator’s judgment, poses a significant suicidality  risk. 
10.Any pre-existing phy sical or mental condition which, in the opi[INVESTIGATOR_684], may  interfere with the participant’s ability  to compl y with the dosing 
schedule and/or protocol evaluations or which may compromise the safety  of the 
participant. 
11. Participants with substance abuse disorders or social restraints that the Inves tigator 
considers to be possible deterrents to successful initiation of ART. 
12.History  or presence of allergy  or intolerance to the study  drugs or their components 2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
43Exclusionary Treatments Prior to Initiation of DTG + 3TC FDC
13.Treatment with an y of the follow ing agents within [ADDRESS_1170828] dose of study  
treatment
radiation therap y,
cytotoxic chemotherapeutic agents,
any systemic immune suppressant.
14.Participants receiving any  prohibited medication (see Section 10.7) and who are 
unwilling or unable to switch to an alternate medication .
15.Exposure to an experimental drug or experimental vaccine within either [ADDRESS_1170829] one of the exclusion criteria . A 
minimal set of screen failure information is required to ensure transparent reporting of 
screen failure participants to meet the Consolidated Standards of Reporting Trials 
(CONSORT ) publishing requirements and to respond to queries from regulatory  
authorities. Minimal information includes demography , screen failure details, eligibility  
criteria, and an y serious adverse events (SAEs).
Participants are not allowed to re -screen for this study .  
Source documentation to verify  entry  criteria must be reviewed by  [CONTACT_9532] [INVESTIGATOR_842452] .  If a participant is referred to 
the site for treatment, evidence of HIV -[ADDRESS_1170830] be confirmed and documented in 
source documents prior to starting stud y treatment.
6. STUDY INTERVENTION
Study  intervention is defined as an y investigational intervention(s), marketed product(s), 
placebo, or medical device (s)intended to be administered to a study  partic ipant according 
to the study  protocol.
In this stud y, study intervention refer stoDTG + 3TC FDC .  All study  interventions will 
be administered at the approved dosages.   The study  intervention DTG + 3TC FDC will 
be supplied by  [CONTACT_103673]/[COMPANY_004] as the fixed dose combination tablet. For subjects 
requiring ART modification as part of this trial, provisions will be in place, as needed and  2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
44after discussion with the study  team, to provide financial assistance for patients in 
obtaining their additional ART dur ing the stud y.
DTG + 3TC FDC must be stored in a secure area under the appropriate phy sical 
conditions for the product.  Access to and dispensing of the DTG+ 3TC FDC will be
limited to the investigator and authorized site staff.  Study  intervention must be dispensed 
or administered onl y to participants enrolled in the study and in accordance with the 
protocol.  For further details on storage, access and administration of study interventions, 
refer to the SRM.
Study  intervention , 50mg DTG + [ADDRESS_1170831] line therap y.  DTG + 3TC FDC will be taken orall y, once daily, with or without 
food.
6.1. Stud y Intervention Administered
Table 1 Study  Intervention
ARM Name [CONTACT_473390] + 3TC FDC
Intervention 
NameDolutegravir + Lamivudine = [COMPANY_004]3515864
Type Drug
Dose 
FormulationTablet
Unit Dose 
Strength(s)50mg DTG, 300mg 3TC
Dosage Level(s) Take one tablet daily
Route of 
Administrationoral
IMP Yes
Sourcing Provided centrally by [CONTACT_1034].
Packaging and
LabelingWhite oval film -coated tablets, debossed with ‘SV 137’ on one side and plain 
on the other, are packed in high density polyethylene (HDPE) bottles with 
induction seals and child -resistant closures.  Each 60mL bottle contains 30 
tablets and a 2 -gram silica gel desiccant.  Each bottle will be labelled as 
required per country requirement. 2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
456.2. Preparation/Handling/Storage/A ccountability
No special preparation of study  intervention is required.
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  intervention received and any  
discrepancies are reported and resolved before use of the study  intervention.
2. Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply  or administer study  intervention. All study 
interventions must be stored in a secure, environmentally  controlled, and monitored 
(manual or automated) area in accordance with the labeled storage conditions with 
access limite d to the investigator and authorized site staff.
3. The investigator, institution, or the head of the medical institution (where 
applicable) is responsible for study  intervention accountability  and record 
maintenance ( i.e., receipt and final disposition recor ds).
4. Further guidance and information for the final disposition of unused study  
intervention are provided in the Study  Reference Manual (SRM) . 
Under normal conditions of handling and administration, study  intervention is not 
expected to pose significant s afety risks to site staff .  
A Material Safety  Data Sheet (MSDS)/equivalent document describing occupational 
hazards and recommended handling precautions either will be provided to the 
investigator, where this is required b y local laws, or is available upo n request from 
ViiV/ [COMPANY_004].
DTG + 3TC FDC accountability will not be evaluated using pi[INVESTIGATOR_10685].  Adherence 
will be assessed by [CONTACT_842496] 7 days 
prior to the visit.
6.3. Measures to Minimize Bias: Stud y Intervention andBlinding
This is an open -label, single arm study .  The site will contact [CONTACT_941] I WRS prior to the 
initiation of DTG + 3TC FDC at the Screening/Day  1Visit and record the intervention 
assignment on the applicable CRF.
6.4. Stud y Intervention Compliance
Compliance with DTG +3TC FDC willbe assessed through query ing the participant 
during the site visits and documented in the source documents and CRF.  Participants will 
be asked about an y missed doses in the previous [ADDRESS_1170832] of the number of 
DTG +3TC FDC tablets dispensed to each participant must be maintained with study  
intervention and compliance records.   Intervention start and stop dates, including dates 
for intervention delay s and/or dose reductions will also be recorded in the CRF. 2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
466.5. Dose Modification
No dose modifications are allowed for DTG + 3TC FDC .  Section 7details 
discontinuation and additional ART interventions allowed in this study .
6.6. Concomitant Therapy
Any medication or vaccine (including over -the-counter or prescrip tion medicines, 
vitamins, and/or herbal supplements) that the participant is receiving at the time of 
enrolment or receives during the stud y must be recorded along with:
reason for use
dates of administration including start and end dates
dosage informatio n including dose and frequency
Refer to Section 10.[ADDRESS_1170833] current version 
of the U.S. or local prescribing information for DTG and 3TC, especially  if any  new 
concomitant medications are reported by [CONTACT_4317].  All concomitant medications 
(including oral contra ception, implants or oral or topi[INVESTIGATOR_842453] y) 
taken during the stud y will be recorded in the eCRF.  
Concomitant medications (prescription and non- prescription) should be prescribed b y the 
relevant health care provider/investigator and administered only  as medically  necessary  
during the Randomized and Continuation phases of the study  (except prohibited 
medications described in Section 10.7).  Chemoprophy laxis for HIV-associated 
conditions is encouraged, if appr opriate, at the discretion of the participant and their 
physician. All concomitant medications, blood products, and vaccines taken during the 
study  will be recorded in the eCRF with dates of administration.
6.6.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_842454]- HIV vaccines may  cause a temporary  increase in the level of HIV -[ADDRESS_1170834] been drawn and only  
when sc heduled visits are ≥4 weeks apart.  This approach will minimize the risk of non -
specific increases in the level of HIV -1 plasma RNA at the next scheduled assessment.
DTG + 3TC FDC should be administered 2 hours before or 6 hours after taking antacid 
or lax ative products containing pol yvalent cations (e.g. aluminium and magnesium) ,
sucralfate , or calcium supplements.  Proton pump inhibitors and H2 -antagonists may  be 
used in place of antacids with no scheduling restrictions.  Concurrent administration with 
multivitamins is acceptable.  Iron supplements can be taken with study  treatment 2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
47provided that all are taken together with a meal. Under fasted conditions, DTG +3TC 
FDC should be given 2 hours prior to OR 6 hours after iron supplements.
Metformin concentrations may  be increased by  [CONTACT_473390].  A dose adjustment of metformin 
should be considered when starting and stoppi[INVESTIGATOR_50674]- administration of dolutegravir with 
metformin, to maintain gly caemic control.
Clinical monitoring is recommended for participants taking methadone, as methadone 
maintenance therap y may need to be adjusted in some participant s.
Non-protocol defined treatments or medical interventions (e.g., ph ysical therap y, 
radiotherap y, surgical procedures) are permitted during the stud y for appropriate medical 
management of the participant.
6.7. Treatment after the End of the Study
The investigator is responsible for ensuring that consideration has been given to the 
poststudy  care of the subject’s medical condition, whether or not ViiV Healthcare/[COMPANY_004] is 
providing specific post -study  treatment.
7. STUDY INTERVENTIO NDISCONTINUA TION CRITERIA
7.1. Discontinuation of Study  Intervention
It may  be necessary  for a participant to permanently  discontinue study  intervention. If 
study  intervention is permanently  discontinued, the parti cipant will remain in the study . 
7.2. Additional Intervention Criteria
7.2.1. Baseline Laboratory  Safety  Criteria:
Participants meeting an y of the below safet y criteria based on the Baseline
(Screening/Day  1) laboratory  results as they  become available ( Week 1 Visit ) will be 
evaluated for potential modification in their current DTG + 3TC FDC treatment and will 
remain in the study .  See Section 1.3.1 for the assessment srequired when ART is 
modified.
Creatinine clearance of < 30 mL /min/1.73 m2 via the Chronic Kidney  Disease 
Epi[INVESTIGATOR_10444] (CKD -EPI) method.
Evidence of active chronic HBV infection (Investigator should consider either adding 
tenofovir or modify ingto a tenofovir -based regimen ):
oParticipants positive f or HBsAg .
oParticipants negative for HBsAg and anti-HBs, positive for anti -HBc and 
positive for HBV DNA.   2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
48NOTE: If these results are not available for the Week [ADDRESS_1170835] samples from the ART Modification Visit and Baseline Visit sent 
for HBV 3TC -resistance testing.
Any Grade 3 or Grade 4 laboratory  abnormality  from the Baseline Visit, which, in the 
opi[INVESTIGATOR_2511] I nvestigator, would end the participant’s participation in this study .
7.2.2. Baseline Resistance Mutation Criteria:
Participants meeting an y of the HI V-1 resistance mutation criteria based on Baseline 
laboratory  assessments will be evaluated for additional ART interventions as the data are
made available (Week 4).   See Section 1.3.1 for the assessment srequired when ART is 
modified.
Participants with Baseline mutations that confer resistance to 3TC (e.g. M184V/I , K65R, 
etc.) or with DTG primary  resistance associated mutation will discontinue study  
treatment but remain in the study .  Investigators should modify the participants regimen 
based on the Baseline genoty pe results, in consultation with the medical monitor.  A 
plasma sample will be obtained at Week 4 and will be sent for genot ypic and phenoty pic 
resistance testing and the result made known to the study  investigator when available.  
7.3. Virologic Failure Criteria
For the purposes of clinical management in this study , the criteria detailed below w ill 
apply :
Suspected Virologic Failure : A single HIV -1 RNA value as defined by  [CONTACT_842497]-
response or Virologic Rebound
Confirmed Virologic Failure :  Any  of the below conditions are met once the 
Investigator has confirmed participant compliance: 
Virologic Non -Response Criteria:
oA decrease in Baseline plasma HIV -1 RNA of less than 2.0 log10 c/mL at Week 8, 
with subsequent confirmation, unless plasma HIV -1 RNA is <200 c/mL.  
oConfirmed plasma HIV -1 RNA  1000 c/mL  at Week 12.
oConfirmed plasma HIV -1 RNA  200c/mL  on or after Week 24. 
Virologic Rebound Criteria: 
oConfirmed rebound in plasma HIV -1 RNA to  200c/mL  after prior suppression to 
<200 c/mL . 2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
497.3.1. Confirmatory testing of virologic non- response:
The participant must have received full doses of study  treatm ent for at least two weeks at 
the time confirmatory  plasma HIV -1 RNA is conducted, if at all possible. DTG + 3TC 
FDC (or current ART regimen) should continue to be administered and no additional 
ART should be added during re -testing.
Upon notification tha t a participant ’s HIV -1 RNA plasma level initially  meets one of the 
above criteria, the investigator should query  the participant regarding intercurrent illness, 
recent immunization, interruption of therap y or inadequate adherence .
All cases meeting “virologic management” criterion must be confirmed by a second 
measurement performed at least two weeks but not more than 4 weeks apart from 
the date of the original sample , unless delay is necessary to meet the requirements of 
confirmatory HIV -1 RNA testing as outlined below.  
The following guidelines should be followed for scheduling confirmatory HIV -1 RNA 
testing in an effort to avoid false- positive results :
Confirmatory  testing should be scheduled 2- 4 weeks following resolution of any  
intercurrent illness, d uring which time the participant should receive full dose of al l 
antiretrovirals in the regimen .
Confirmatory  testing should be scheduled at least 4 weeks following any  
immunization , during which time the participant should receive full dose of all 
antiret rovirals in the regimen.
If therap y is interrupted due to toxicity  management, non -compliance, or other 
reason s, confirmatory  testing should be scheduled 2- 4 weeks following resumption of 
full dose of all antiretrovirals in the regimen.
The participant sho uld have received full doses of study  interventions for at least 
2weeks at the time confirmatory  plasma HIV -[ADDRESS_1170836] the Medical Monitor to discuss individual participant s, whenever 
necessary .
7.3.2. Management of Virologic Non- Respo nse
Once a participant has been determined as meeting a protocol defined virologic failure 
criterion, a plasma sample from the Suspected Virologic Failure time point, will be sent 
for genot ypic and phenotypic HI V-1 resistance testing and the result made kn own to the 
study  investigator when available to advise on a new ARV- regimen.   Plasma samples 
from storage will also be obtained at unscheduled visits including the time of C onfirmed 
Virologic Failure criteria .
Plasma HIV -1 RNA values determined b y the cent ral laboratory  only will be used to 
assess virologic management criteria.  Upon notification that a participant’s HIV -1 RNA 
plasma level qualifies him/her as meeting a virologic failure criterion, the Investigator  2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
50should query  the participant regarding intercurrent illness, recent immunisation, 
adherence, or interruption of therap y.  
Participants may  continue to receive study  intervention at the discretion of the 
investigator until results of HIV-1 resistance testing are available .  Based on the results of
the resistance testing, the ART regimen may be modified (see Section 7.2.2 ). 
When the I nvestigator is modify ing a participants ART regimen between scheduled 
visits , the study  assessments shown in the SoA in Section 1.3.1 should be followed .  
A participant who meets virologic failure criterion (Section 7.3) can remain in the study .  
Selection of ART regimen for participants meeting confirmed virologic failure criteria 
will b e recorded in the eCRF.  
The protease (PRO)/reverse transcriptase (RT)/integrase assay s used in this study  are not 
validated for plasma HIV -1 RNA levels <500 c/mL.  Nevertheless, for all participants 
who meet confirmed virologic failure criteria, plasma s amples will be anal ysed in an 
attempt to obtain genot ype/phenotype data on samples with HI V-1 RNA ≥200 c/mL , as 
possible.  Participants with confirmed HIV -1 RNA levels between 200 c/mL  and 
<500 c/mL  should be transitioned off study  intervention within 30 d ays even if no HI V-1 
resistance mutation results become available, as genoty pe/phenot ype data may  not be 
reliably  generated from plasma samples collected from these participants.   
Participants who meet a suspected or confirmed virologic failure can remain in the study .  
For participants meeting confirmed virologic failure, “Meeting Confirmed Virologic 
Failure” will be recorded in the eCRF as reason for the modification to a new ARV -
regimen. 
If a participant is prematurely  discontinued from participation i n the study , the 
Investigator must make every  effort to perform the evaluations outlined in the Schedule 
of Activities.  These data will be recorded, as they comprise an essential evaluation that 
needs to be done before discharging an y participant from the study .
7.4. Other A dditional Intervention Criteria:
Participants that meet any  of the following criteria should discontinue DTG + 3TC FDC 
and willremain in the study .  The Investigator and Medical Monitor should consult on 
how to medically  manage these partic ipants.
A pregnancy  (intrauterine) detected in the first trimester ,should have DTG + 3TC 
FDC immediately  discontinued and an alternative regimen that does not contain DTG 
should be started unless no suitable alternative is available [ DHHS , 2018 ].
Pregnancies detected after the first trimester may  continue DTG + 3TC FDC .  All 
participants will remain in the study  and will be followed until completion of 
pregnancy .  As a reminder, participants of childbearing potential ( POCBP) who 
change th eir minds and desire to be pregnant, or who state they  are no longer willing 
to comply  with the approved pregnancy  avoidance methods, should have DTG + 3TC 
FDC discontinued and start an alternate ART regimen .  2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
51Liver toxicity  where stoppi[INVESTIGATOR_842455], these participants will discontinue study  treatment and will continue in the 
study (see Section 10.6). 
Renal toxicity  criteria are met, and no compelling alternat e cause is identified (see 
Section [IP_ADDRESS] );
Grade 4 clinical AE considered causall y related to study drug;
Allergic reaction or rash criteria are met, and no compelling alternate cause is 
identified.
The parti cipant requires concurrent prohibited medications during the course of the 
study .  The participant will discontinue study  treatment and may  remain in the study .
7.5. Liver Chemistry  Stoppi[INVESTIGATOR_534447] (in alignment with the FDA 
premarketing clinical liver safety  guidance). 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf
Discontinuation of study  intervention for abnormal liver tests is required when:
oa participant meets conditions outlined in Section 10.6.
owhen in the presence of abnormal liver chemistries not meeting protocol -specified 
stoppi[INVESTIGATOR_37660], the investigator believes study  intervention discontinuation is in 
the best interest of the participant.
Liver Safet y Required Actions and Follow up Assessments can be found in Section 10.6.
7.5.1. Temporary  Disconti nuation
Participant s may  have a temporary  inter ruption to their study intervention for 
management of toxicities.  Such interruption of study  intervention does not require 
withdrawal from the study.  However, consultation with the Medical Monitor is require d.  
Start and stop dates o fstudy  treatment and reason for temporary  interruption will be 
recorded in the eCRF.
7.5.2. Study Intervention Restart 
If participant meets liver chemistry  stoppi[INVESTIGATOR_842456] :
ViiV Healthcare Safet y and L abelling Committee (VSL C) approval is granted , 2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
52Ethics and/or I RB approval is obtained, if required, and
Separate consent for treatment restart is signed b y the participant.
Refer to Section 10.6.2 for full guidance.
If [COMPANY_004] /ViiV Medical Governance approval to restart/re- challenge participant with study
intervention is not granted , then participant must discontinue study  intervention and may  
continue in the study with alternate ART interventions. 
7.6. Participant Discontinuation/Withdrawal from the Study
Participants may be discontinued from the study for any of the following reasons:
Participant or Investigator non -compliance;
A participant may  withdraw from the study  at an y time at his/her own request or may  
be withdrawn at an y time at the discretion of the investigator for safet y, behavioural , 
compliance or administrative reasons. This is expected to be uncommon.
At the time of discontinuing from the stud y, if possible, an earl y Withdrawal Visit should 
beconducted, as shown in the SoA (Section 1.3). TheSoA has the data to be collected at 
the time of study  discontinuation and follow -up and for an y further evaluations that need 
to be completed.
The participant may be permanentl ydiscontinued both from the study  intervention and 
from the study  at that time.
If the participant withdraws consent for disclosure of future information, the sponsor 
may retain and continue to use any  data collected before such a withdrawal of 
consent.
Ifa participant withdraws from the study , he/she may  request destruction of any  samples 
taken and not tested, and the investigator must document this in the site study  records.
At the request of, [COMPANY_004] or ViiV Healthcare;
The participant requires concurrent p rohibited medications during the course of the 
study (Section 10.7).  The participant may  remain in the study  if in the opi[INVESTIGATOR_518137], such medication will not interfere with the 
conduct or i nterpretation of the study  or compromise the safet y of the participant .  
Alternativel y, the participant can have study intervention discontinued and remain in 
the study  with additional ART interventions.
Refer to the SoA (Section 1.3) for data to be collected at the time of stud y discontinuation 
and follow -up and for any further evaluations that need to be completed.
All data from the Withdrawal V isit will be recorded, as they  comprise an essential 
evaluation that should be done p rior to discharging an y participant from the study.  Anin-
clinic Follow -Up Visit will be conducted [ADDRESS_1170837] dose of study  medication 
for participants with ongoing SAEs regardless of attributability , and any  laboratory  
abnormalities that are considered to be AEs or potentially  harmful to the participant (as 
defined in Section 2.3.1 ), at the last on -study  visit.   Theinvestigator, in consultation with  2020N440514_00
2019N398432 _01 CONFIDENTIA L
[ADDRESS_1170838] be documented by  [CONTACT_833649]/Wit hdrawal 
section of the electronic case report form (eCRF).  Every  effort should be made by  [CONTACT_842498] -up participants who withdraw from the study . 
7.7. Lost to Follow Up
A participant will be considered lost to follow -up if he or she repeatedl yfails to return for 
scheduled visits and is unable to be contact[INVESTIGATOR_530] b y the study  site. 
The following actions must be taken if a participant fails to return to the clinic for a 
required stud y visit:
The site must attempt to contact [CONTACT_521296]/or 
should continue in the study .
Before a participant is deemed lost to follow up, the investigator or designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent metho ds). These contact [CONTACT_14316]’s medical record.
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study.
8. STUDY A SSESSMENTS A ND PROCEDURES
Study  procedures and thei r timing are summarized in the SoA in Section 1.3. 
Protocol waivers or exemptions are not allowed 
Immediate safety  concerns should be discussed with the sponsor immediately  upon 
occurrence or awareness to determine if the parti cipant should continue or 
discontinue study  intervention .
Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study conduct.
All screening evaluations must be completed and reviewed to confirm tha t potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log 
to record details of all participants screened and to confirm eligibility  or record 
reasons for screening failure, as applicable. 
Procedures conducted as part of the participant’s routine clinical management ( e.g., 
blood count) and obtained before signing of ICF may  be utilized for Screening/Day  1
purposes provided the procedure met the protocol -specified criteria and was 
performed within the time frame defined in the SoA. 2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
54Screening/ Day [ADDRESS_1170839] be assessed carefull y at the Screening /Day 1 Visit(Section 5.1
and Section 5.2).  Phy sical examinations should be conducted as part of normal routine 
clinical care but will not be collected s ystematically  in the eCRF.  Cardiovascular 
medical history /risk factors, including vita l signs (as detailed in the eCRF) wil l be 
assessed and assessments will include height, weight, blood pressure, smoking status and 
history , pertinent medical conditions (e.g., h ypertension, diabetes mellitus), and family  
history  of premature cardiovascular disease.  Background information to be collected 
includes demograph y (year of birth, sex at birth and current reported gender , race and 
ethnicity ), prior PEP/PrEP history , medical history and current medical conditions, 
menopause history , concomitant medi cations, and an assessment of CDC HIV -[ADDRESS_1170840] positive results from 2 
different HI V Rapid tests (different assay  or manufacturer) , orthey are positive with an 
FDA -approved antigen/antibody  combination immunoassay  (4thgeneration assay ) or an 
FDA approved HIV antibody  immunoassay  that detects HIV- 1 and HIV -2 antibodies (3rd
generation assay ) confirmed by  [CONTACT_13247] -approved antibody  immunoa ssay that 
differentiates HIV -1 antibodies from HIV- 2 antibodies or an HIV western blot or an 
HIV-1 RNA.  See Inclusion Criteria for additional information (Section 5.1).
For participants who are referred to the st udy site with a single positive Rapid 
HIV test, a second and different Rapid HIV test should be conducted.  If the 
second Rapid HIV test is nonreactive, the participant is presumed to be HIV -
negative. If both tests are reactive, the participant is confirme d HIV -infected.
Medical records/Source documents from external testing centers or medical 
facilities must be received, reviewed and included in the site source documentation 
to confirm participant has a new diagnosis of HIV -1 infection.
Other Screening/Da y 1information to be collected prior to the first dose of study  
intervention includes assessment of HIV risk factors and mode of transmission, general 
medical history and current medical conditions.  Laboratory  and health outcomes 
assessments will also be collected.  Questionnaire/survey s are recommended to be 
administered at the beginning of the visit before any  other assessments are conducted.  
Refer to the SoA Section 1.3for a summary  of all procedures at the Screening/ Day 1 
Visit. 2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
55Week 1 Review of Baseline lab oratory results
The Investigator should review the Screening/Day 1 laboratory  findings as they  become 
available and schedule a study  visit (Week 1 Visit).   
A review of creatinine clearance and HBV surface antigen (H BsAg) or HBV core 
antibody  (anti -HBc), and HBV DNA if available , (if not available at Week 1, review at 
Week 4 )and grade 3 or 4 laboratory abnormalities should be completed to determine if 
the participant should stop study  intervention and initiate an alternate ART regimen (s ee 
Section 7.2.1 ). 
Subjects Co- infected with Hepatitis B Virus (HBV) 
Investigators should consult current treatment guidelines [ Saag , 2018 ]) and Section 
7.2.1 when considering choice of ART regimen for subjects with chronic HBV 
infection (H BsAg positive OR anti- HBc positive with HBV DNA present).  
In addition, clinical trial and marketed use of 3TC, FTC and TDF have shown that 
some subjects with chronic HBV disease may  experience clinical or laboratory  
evidence of recurrent hepatitis upon discontinuation of 3TC, FTC or TDF, which may  
have more severe consequences in subjects with decompensated liver disease.  
Subjects with HBV co -infection should be advised against self -discontinuation of any  
medications with anti -HBV activity .  If 3TC, FTC, TDF or TAF is discontinued in 
subjects co -infected with HBV, periodic monitoring of both liver chemistry  tests and 
markers of HBV replication should be performed. 
Entecavir and telbivudine are permitted, in appropriate clinical situations, for 
treatment of hepatitis B (e.g. prior intolerance or viral resistance to TDF or TAF, viral 
resistance to 3TC/FTC) after discussion and agreement between t he investigator and 
the medical monitor.  
Subjects Co- infected with Hepatitis C Virus (HCV) 
Investigators should consult current treatment guidelines when considering choice of 
therap y for subjects with chronic HCV infection.  
For participants with arequirement for HCV therapy  during the conduct of the study , 
the Investigator must consult with the medical monitor.  HCV treatment based on 
interferon or an y other medications that have a potential for adverse drug -drug 
interactions with study treatment, is prohibited during the conduct of the study .  
Review of Resistance Mutation Data when available (Week 4)
A visit should be scheduled when the central laboratory  data from Screening/Day  1
genot ypi[INVESTIGATOR_842457]-1 drug resistance mutation data are available (Week 4) and additional 
intervention should be performed if required (see Section 7.2.2 ).  The investigator should 
also review the tolerance to DTG + 3TC FDC, A Es, assess adherence to study treatment 
and enforce the impor tance of adherence.   2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
56At Week 8, if the decrease HIV -1 RNA is less than 2.0 log10 c/mL, a plasma HIV -[ADDRESS_1170841] should be scheduled 2 -4 weeks later, unless plasma HIV -1 RNA is <200 
c/mL ; after the retest the Investigator in consultation with the Medical Monitor should 
determine if a modification in ART intervention is warranted.
If a subject requires a regimen modification (e.g., based on Baseline labs or a Confirmed 
Virologic Failure), a plasma HIV-[ADDRESS_1170842] should be scheduled 4 weeks after the 
regim en modification (Section 1.3.1 ).  Post the retest, the participant should continue the 
regular stud y visit schedule.
Participants who have an ART modification due to Baseline laboratory  or HIV-1 
resistance data as described in S ection 7.2.1 and Section 7.2.2 , respectivel y, and require 
subsequent modification (s) will remain in the study .  
8.1. Efficacy  Assessments
Plasma HIV -1 RNA
Plasma for quantita tive HIV -1 RNA will be collected according to the Schedule of 
Activities (Section 1.3).  Methods to be used may  include but are not limited to the 
Abbott Realtime HIV -1 Assay  lower limit of quantitation 40 c/mL .  In some cases, ( e.g., 
where the plasma HIV -1 RNA is below the lower limit of detection for a given assay ) 
additional exploratory  methods may  be used to further characterize plasma HIV -1 RNA 
levels.
See Section 7.3(Virologic Failure Criteria) fo r HIV -[ADDRESS_1170843] criterion.
Lymphocyte Subsets
Lym phocy te subsets will be collected for assessment by  [CONTACT_4133]  (total 
lymphocy te counts, percentage, and absolute CD4+ and CD8+ l ymphocy te counts, 
CD4+/CD8+ ratio) according to the Schedule of Activi ties (Section 1.3).
CDC HIV -1 Classification and HIV Associated Conditions
HIV-associated conditions will be recorded as per the Schedule of Activities 
(Section 1.3).  HIV associated conditions will be assessed according to the 2014 CDC 
Revised Classification Sy stem for HIV Infection in Adults (see Section 10.9).  When 
assessing CDC stage at Screening /Day 1, consider only  the latest available CD4+ T- cell 
count , except when the participant had an active Stage 3 event. Indicators of clinical 
disease progression are defined as:
CDC Stage 1 at enrolment → Stage 3 event;
CDC Stage 2 at enrolment → Stage 3 event;
CDC Stage 3 at enrolment → New Stage 3 Event;
CDC Stag e 1, 2 or 3 at enrolment → Death. 2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
578.1.1. Primary  Efficacy  Endpoint
The primary  endpoint will be the proportion of participants with plasma HIV -1 RNA 
<50c/mL  at Week 24, regardless of ART Regimen (Observed Anal ysis)(see 
Section 9.5).
8.1.2. Secondary  Efficacy Endpoints
 Proportion of participants with plasma HIV -1 RNA <50 c/mL at Week 48 , 
regardless of ART Regimen (Observed Anal ysis).
 Proportion of participants with plasma HIV-1 RNA <50 c/mL at Weeks 24 and 48
using the FDA Snapshot algorithm.
 Time to suppression of HIV -1 RNA <50 c/mL .
 Proportion of participants who modify first line regimen of DTG + 3TC FDC due to 
Baseline lab or HIV-1 resistance mutation data (see Section 7.2).
 Change from Baseline in CD4+ cell coun ts and CD4+/CD8+ ratio at Week 24 and 
Week 48.
 Incidence of disease progression (HIV -associated conditions, AI DS and death).
8.2. Safet y Assessments
Incidence and severit y of AEs and laboratory  abnormalities.
Proportion of participants who discontinue treatment due to AEs and drug- related 
AEs over 48 weeks of treatment
Planned time points for all safety  assessments are provided in the SoA (Section 1.3).
8.2.1. Physical Examinations
A brief ph ysical examination at the Screening /Day 1 Visit will include, at a minimum, 
assessments of the [ e.g., skin, lungs, cardiovascular s ystem].   Investigators should pay  
special attention to clinical signs related to previous serious illnesses.
Physical exams should be conducted as part of normal routine clinic al care but will not be 
collected s ystematicall y in the eCRF.  Abnormalities noted during any exam must be 
recorded in the eCRF (e.g. in the current medical conditions or AE logs).
8.2.2. Vital Signs
At the Screening /Day  [ADDRESS_1170844] and will include height, weight, systolic and diastolic blood 
pressure and Bod y Mass Index (BMI). Vital signs and body  weight willalso be 
assessed at each visit according to the Schedule of Activities (SoA) (Secti on 1.3). 2020N440514_00
2019N398432 _01 CONFIDENTIA L
[ADDRESS_1170845] of clinical laboratory tests to be performed and to the 
SoA (Section 1.3)for the timing and frequency . 
All protocol required laboratory  assessments must be performed by  [CONTACT_842499].  Laboratory  assessments must be conducted in accordance with 
the Laboratory Manual, and SoA (Section 1.3).Laboratory  requisition forms must 
be completed, and samples must be clearly labelled with the participant number, 
protocol number, site/centre number, and visit date. Details for the preparation and 
shipment of samples will be provided b y Q2Solutions and are detailed in the 
laboratory  manual.  Reference ranges for all safety  parameters will be provided to 
the site by  Q2Solutions.
If additional non -protocol specified laboratory  assessments are performed at the 
institution’s local laboratory  and result in a change in participant management or are 
considered clinically  significant by  [CONTACT_093] (e.g. SAE or AE or dose 
modification) the results must be recorded in the eCRF.
Labs will be graded automatically  by [CONTACT_842500] (See Section 10.8 “Division of AIDS Table for Grading the Severity  
of Adult and Pediatric Adverse Events”).
The investigator must review the laboratory  report, document this review, and record 
any clinically  relevant ch anges occurring during the study in the AE section of the 
CRF. The laboratory  reports must be filed with the source documents. Clinically  
significant abnormal laboratory  findings are those which are not associated with the 
underly ing disease, unless judg ed by [CONTACT_19988]’ s condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within [ADDRESS_1170846] dose of study  interventi on 
should be repeated until the values return to normal or B aseline or are no longer 
considered significantly  abnormal by  [CONTACT_10982]. 
If such values do not return to normal/B aseline within a period of time judged 
reasonable b y the investigator, the etiology  should be identified and the sponsor 
notified.
Refer to the SRM for appropriate processing and handling of samples to avoid 
duplicate and/or additional blood draws.
Haematology , clinical chemistry , urinal ysis and additional pa rameters to be tested 
are listed in Section 10.2. 
8.2.4. Suicidal Ideation and Behaviour Risk Monitoring
Participants with HIV infection may occasionally  present with s ymptoms of depression 
and/or suicidality  (suicidal ideation or beha viour).  I n addition, there have been some 
reports of depression, suicidal ideation and behaviour (particularl y in people with a 
pre-existing history  of depression or ps ychiatric illness) in some people being treated 
with I NIs, including DTG.  Therefore, i t is appropriate to monitor and closely  observe  2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
59participants prospectively before and during treatment for suicidal ideation and/or 
behaviour , or any  other unusual changes in behaviour .  
Participants should be monitored appropriately  and observed closely  for suicidal ideation 
and behaviour or an y other unusual changes in behaviour. Investigator must assess 
participant suicidality  using their usual clinical practice.   It is recommended that the 
investigator consider mental health consultation or referral f or participants who 
experience signs of suicidal ideation or behaviour. Participants presenting with new 
onset/treatment emergent depression should be advised to contact [CONTACT_809291] (including suicid al 
ideation/attempts) develop, because medical intervention and discontinuation of the study  
medication may  be required.
The investigator will collect information using the Possible Suicidality -Related AE 
(PSRAE) eCRF form in addition to the AE (non -serious or SAE) eCRF form on any  
participant that experiences a possible suicidality -related AE while participating in this 
study .  This may  include, but is not limited to, an event that involves suicidal ideation, a 
preparatory  act toward imminent suicidal beha viour, a suicide attempt, or a completed 
suicide.  The investigator will exercise his or her medical and scientific judgment in 
deciding whether an event is possibly  suicide -related. PSRAE forms should be 
completed and reported to ViiV/[COMPANY_004] within [ADDRESS_1170847] for managing 
possible risks for suicide related events.
8.3. Adverse Ev ents and Serious A dverse Events
The definitions of an AE or SAE can be found inSectio n 10.3.1 and Section 10.3.2 , 
respectivel y.
The investigator and an y qualified designees are responsible for detecting, documenting, 
and reporting events that meet the definition of an AE or SAE and rema in responsible for 
following up AE sthat are serious, considered related to the study  intervention or the 
study , or that caused the participant to discontinue the study  intervention (see Section 7.2
and Section 7.4).
8.3.1. Time Period and Frequency  for Collecting A E and SA E 
Information
The time period and frequency  for collecting AE and SAE information is as follows:
All SAE swill be collected from the start of intervention until the Follow -up V isitat 
the time points specified in the SoA (Section 1.3).  However, an y SAEs assessed as 
related to stud y participation (e.g., stud y intervention , protocol -mandated procedures, 
invasive tests, or change in exi sting therap y) or related to a ViiV/ [COMPANY_004] product will 
be recorded from the time a participant consents to participate in the study .
All AEs will be collected from the start of stud y intervention until the Follow -up 
Visit,at the time points specified in th e SoA (Section 1.3). 2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
60Medical occurrences that begin before the start of study  intervention but after 
obtaining informed consent will be recorded on the Medical History /Current Medical 
Conditions section of the case report form (CRF) not the AE section.
All SAE swill be recorded and reported to the sponsor or designee immediately  and 
under no circumstance should this exceed 24 hours, as indicated in Section 10.3. 
The investigator will sub mit any  updated SAE data to the sponsor within 24 hours of 
it being available.
Investigators are not obligated to activel y seek AEs or SAEs after the conclusion of 
the study  particip ation. However, if the investigator learns of an y SAE, including a 
death, at an y time after a participant has been discharged from the study, and he/she 
considers the event to be reasonabl y related to the study  intervention or study  
participation, the investigator must promptly  notify  the sponsor.
8.3.2. Method of Detecting A Es and SA Es
The method of recording, evaluating, and assessing causality  of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Section 10.3.
Care will be taken not to introduce bias when detecting AE and/or SAE. Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrence . 
8.3.3. Follow -up of A Es and SA Es
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All SAEs, and non-serious AEs of special 
interest (as defined in Section 2.3.1), will be followed until the event is resolved, 
stabilized, otherwise explained, or the participant is lost to follow -up (as defined in 
Section 7.7). Further information on follow -up procedures is given in Section 10.3.
8.3.4. Regulatory  Reporting Requirements for SA Es
Prompt notifica tion by  [CONTACT_11012] a SAE is essential so that 
legal obligations and ethical responsibilities towards the safet y of participants and 
the safet y of a study intervention under clinical investigation are met. 
The sponsor has a legal re sponsibility  to notify  both the local regulatory  authority  
and other regulatory  agencies about the safet y of a study intervention under clinical 
investigation. The sponsor will comply  with country -specific regulatory  
requirements relating to safet y report ing to the regulatory  authority , Institutional 
Review Boards (IRB ) and investigators.
Investigator safety reports must be prepared for suspected unexpected serious 
adverse reactions ( S[LOCATION_003]R) according to local regulatory  requirements and sponsor 
policy  and forwarded to investigators as necessary.
An investigator who receives an investigator safety report describing a SAE or other 
specific safet y information e.g. , summary  or listing of SAE s) from the sponsor will 
review and then file it along with the Investi gator’s Brochure and will notify  the 
IRB, if appropriate according to local requirements. 2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
618.3.5. Pregnancy
Details of all pregnancies in participants will be collected after the start of study  
intervention and ending at the final Follow -up Visit.  If a pregnancy  is reported, the 
investigator should inform ViiV/[COMPANY_004]/[COMPANY_003] within [ADDRESS_1170848] trimester s hould immediatel y discontinue DTG + 3TC FDC 
and an alternate ART regimen that does not contain DTG should be started, unless no 
suitable alternative is available, in consultation with the Medical Monitor.  If the 
pregnancy  is after the first trimester, the participant can continue stud y treatment.  Any 
participant who becomes pregnant during the study  can remain in the study, including 
those who needed to modify  the ART Regimen.  
Any pregnancy  that occurs during study participation must be reported using a clinical 
trial pregnancy  form. The pregnancy  must be followed up to determine outcome 
(including premature termination) and status of mother and child(ren). Pregnancy  
complications and elective terminations for medical reasons must be reported as an AE or 
SAE.  Abnormal pregnancy  outcomes (e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy ) are considered SAE s and must be reported .
Any SAE occurring in association with a pregnancy  brought to the investigator’s 
attention after the participant has completed the study  and considered by  [CONTACT_842501]/[COMPANY_004] (or 
designee).
[COMPANY_004]’s central safet y department will forward this information to the ART Pregnancy  
Registry .  The international registry  is jointly  sponsored b y manufacturers or 
licensees of ARV products.  Additional information and a list of participating 
manufacturers/licensees are available from http://www.apregistry .com/.  
8.3.6. Cardiovasc ular and Death Events
For an y cardiovascular events detailed in Section 10.3.3 and all deaths, whether or not 
they are considered SAEs, specific Cardiovascular (CV) and Death sections of the eCRF 
will be required to be completed. These sections include questions regarding 
cardiovascular (including sudden cardiac death) and non- cardiovascular death. 
The CV eCRFs are presented as queries in response to reporting of certain CV MedDRA 
terms. The CV information should be recorded in the specific cardiovascular section of 
the e CRF within one week of receipt of a CV Event data query  prompting its completion. 
The Death eCRF is provided immediately  after the occurrence or outcome of death is 
reported. Initial and follow- up reports rega rding death must be completed within one 
week of when the death is reported. 2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
628.3.7. Disease -Related Events and/or Disease -Related Outcomes Not 
Qualify ing as SA Es
The events or outcomes listed in the CDC Classification Sy stem for HIV- 1 Infections 
(Section 10.9)will be recorded on the HIV -Associated Conditions eCRF page if they  
occur. However, these individual events or outcomes, as well as any  sign, sy mptom, 
diagnosis, illness, and/or clinical laboratory  abnormality  that can be linked to any  of these 
events or outcomes are not reported to ViiV/[COMPANY_004] as AEs and SAEs even though such 
event or outcome may  meet the definition of an AE or SAE, unless the following 
conditions apply :
The investigator determines that the event or outcome qualifi es as an SAE under part 
‘f’ of the SAE definition ( see Section 10.3),or
The event or outcome is in the investigator’s opi[INVESTIGATOR_103650] , frequency  
or duration than expected for the individual participant, or
Death occ urring for an y reason during a stud y, including death due to a 
disease -related event, will alway s be reported promptly .
Lym phomas and invasive cervical carcinomas are excluded from this exemption; they  
must be reported as SAEs even if they  are considered t o be HIV -related.
8.4. Treatment of Overdose
For this open- label study , any  tablet intake exceeding the daily  tablet ofDTG + 3TC 
FDC will be considered an overdose [ TIVICAY Product I nsert, 2018 ; EPI[INVESTIGATOR_842458], 2018].  ViiV Healthcare does not recommend specific treatment for an 
overdose of DTG + 3TC FDC. As appropriate, the Investigator should use clinical 
judgment in the treatment of an overdose.
For the purposes of this study , an overdose is not an AE unless it is accompanied by  a 
clinical manifestation associated with the overdose.  If the clinical manifestation presents 
with serious criteria, the event is a SAE ( see Section 10.3).  If an overdose o ccurs and is 
associated with an adverse event requiring action, all study  medications should be 
temporaril y discontinued until the adverse event resolves.
In the event of an overdose, the investigator or treating ph ysician should:
1.Contact [CONTACT_842502] .
2.Closely  monitor the participant for AE/SAE and laboratory  abnormalities until 
DTG + 3TC FDC can no longer be detected s ystemically  (at least 2 day s).
3.Document the quantit y of the excess dose as well as the duration of the overdosing in 
the eCRF.
Decisions regarding dose interruptions or modifications will be made by  [CONTACT_43208]. 2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
638.5. Pharmacokinetics
PK parameters are not evaluated in this study .
8.6. Pharmacody namics
Pharmacod ynamic parameters are not evaluated in this study .
8.7. Genetics
Genetics are not evaluated in this study .
8.8. Biomarkers
Biomarkers are not being evaluated in this study .
8.9. Health Economics and Outcome Research
Health outcomes assessments will be conducted according to the SoA (Section 1.3).In 
the event of translations being unavailable, no such assessments will be conducted, and 
the responses will be considered as missing in the final anal yses.Assessments are 
recommended to be administered at the beginning of the visit prior to collection of blood 
for anal ysis and other scheduled assessments.  
Questionnaires will be administered on paper and should be completed b y participant 
without the assistance of others wher e possible.  If a subject is unable to read, it is 
acceptable for site personnel to read the questions and response options directly  as 
written with no further interpretation or assistance.  I n these situations, subject must 
clearl y indicate their response s which may  be recorded on paper form b y site personnel.
Sitesshould enter participant responses into eCRF and retain the paper forms in the 
participants chart.  
The following health outcomes assessment will be utilized in this study :
The Sy mptom Distre ss Module (also called the HIV Sy mptom Index or Sy mptoms 
Impact Questionnaire ) is a 20 -item self -reported measure that addresses the presence and 
perceived distress linked to sy mptoms commonly  associated with HIV or its treatment 
[Justice , 2001].
8.10. HIV-1 Poly merase Viral Genoty pi[INVESTIGATOR_842459] 1.3(for potential 
viral genoty pic and phenoty pic anal yses).  Participants meeting Confirmed V irologic 
Failure criteria or having HIV-[ADDRESS_1170849] plasma samples tested for HIV -1 PRO and RT genotype and phenoty pe and 
HIV-1 integrase genot ype and phenot ype from samples collected at the time of meeting 
Suspected Virologic Failure criteria; these results will be reported to the investigator as  2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
64soon as available to provide guidance for selection of an alternative regimen (see 
Section 7.3)
Details concerning the handling, labelling and shippi[INVESTIGATOR_339181] .  Genot ypic and phenotypic anal yses may  be carried out by  [CONTACT_339290], but not limited to, their Standard PhenoSense and GenoSure testing 
methods for PRO, RT, and integrase assay s.
A secondary  endpoint of the study  will be the incidence of observed genoty pic and 
phenoty pic resistance to DTG or 3TC in participants meeting Confirmed Virologic 
Failure criteria.  If participants meet a second Confirmed Virologic Failure after initiating
a new ART regimen during the stud y, susceptibility to any ART therap y received will 
also be assessed.  
8.10.1. HIV-1 Exploratory  Analysis
HIV-1 exploratory  analysis may  be carried out for participants meeting virologic failure 
criteria, and for all participants to more broadl y assess the contribution of Baseline 
genot ypic information on study  results.  These t ests may  be carried out on whole blood or 
stored plasma samples collected at Baseline and/or from other relevant time points as 
long as this is feasible per local country  and laboratory  practices.  These exploratory  tests 
and analyses may  include but are not limited to additional viral genot ypi[INVESTIGATOR_6926]/or 
phenoty pi[INVESTIGATOR_007], as well as other virologic evaluations such as linkage and minority  species 
analyses, low level HIV -1RNA quantitation, viral DNA quantitation, and measurement 
of viral replicative capacity .  
9. STATISTICA L CONSIDER ATIONS
9.1. Statistical Hy pothese s
This is a single arm study ;no formal statistical hypothesis will be tested.
9.2. Sample Size 
The study  will recruit approximately  [ADDRESS_1170850] been screened, screening will 
continue until enrolment of approximately  120 individuals is met. 
9.2.1. Sample Size Considerations
This is a single -arm study  with no statistical testing being performed therefore the sample 
size is not statistically  powered.  The study  will enrol approximately (±5%) 120 HIV -1 
treatment naïve individuals.  The sample size of 120 participants allows estimation of the
response rate at Week s 24 and 48 (i.e. HIV -1 RNA <50 c/m l), with precision shown in 
Table 2, assuming a high number of participants (i.e. ≥80% of participants) will be 
responders.  Table 2shows the estimated response rate, 95% Confidence Interval (CI) 
based on 
the Clopper- Pearson method and precision measured b y 95% CI width,
assuming various numbers of responders for the given sample size of 120 participants .  2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
65Table 2 Estimated Response Rate, 95% Confidence Interval and precision 
assuming various number of responders
Sample 
SizeNumber of 
RespondersResponse 
Rate95% Confidence 
IntervalPrecision
(95% CI Width)
120 96 80% 71.7% - 86.7% 15.0%
120 102 85% 77.3% - 90.9% 13.5%
120 108 90% 83.2% - 94.7% 11.5%
120 114 95% 89.4% - 98.1% 8.7%
9.2.2. Sample Size Sensitivity
Figure 2shows sensitivity  of expected response rate precision (measured by  [CONTACT_842503] 95% CI ) versus sample size, assuming four population response rates (i.e. 80%, 85%, 
90% and 95%).  Note that a much larger sample size than 120 participants is required to 
achieve higher precision in the estimated response rate for all four assumed observed 
rates.  For example, to get a ~ 40% more precise response rate estimate (for any  of the 
four assumed response rates) a sample size of ~300 p articipants is needed.
Figure 2 Sample Size Sensitivity
Figure 2: Expected precision (measured by 95% CI width) of estimated proportion of 
participants with HIV -1 RNA < 50 c/mL assuming fou r population response rates (i.e. 80%, 
85%, 90%, 95%) versus sample size.  Clopper -Pearson 95% CI widths have been calculated.  
The vertical grey dash line corresponds to a sample size of [ADDRESS_1170851]-line DTG + 3TC FDC Regimen Modification
Participants meeting an y of the safet y criteria described in Section 7.2.1 (i.e. Creatinine 
clearance of 
<30 mL/min/1.73m2, evidence of active HBV infection, Grade 3 or 4 
laboratory  abnormality ) will be evaluated for potentia l modification in their current first 
line DTG + 3TC FDC treatment and participants with Screening/Day  1genoty pic data 
that confer resistance to 3TC (e.g. M184V/I, K65R etc.) or with DTG primary resistance 
associated mutation will discontinue study  treatment.  Assuming that the probability  a 
participant to have a modification from first line DTG +3TC FDC regimen because of 
any of the above reasons ranges from 1% to 5%, the probability at least o ne participant to 
modify ing ART because of the above reasons ranges from 70% to 100%, assuming a 
sample size of 120 participants.
9.4. Data Analysis Considerations 
9.4.1. Analysis Populations
For purposes of analy sis, the following populations are defined:
Table 3 Analysis Populations
Population Description
Enrolled All participants who sign the ICF
Intent to Treat Exposed 
(ITT-E)All participants who receive at least one dose of study drug. This 
population will be used in all efficacy analys es.
Safety This population will be the same as the ITT -E population and will be 
used in all Safety analyses
The anal ysis populations for genot ypic and phenotypic anal yses and other populations 
potentially  needed for other anal yses will be fully describe d in the reporting and anal ysis 
plan (RAP).
9.5. Key Elements of the A nalysis Plan
9.5.1. Efficacy Analysis
Primary  anal ysis will be conducted when all Week [ADDRESS_1170852], if needed.
The prima ry anal ysis will be the proportion of participants with plasma HIV -1 RNA 
<50c/mL at Week 24 Visit, regardless of the ART regimen (Observed Analy sis). 2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
67The primary  Week 24 Observed Analy sis will classify  participants into Virologic Success 
or Virologic Fail ure categories as follows: 
Virologic Success
Participants with HIV -1 RNA < 50 c/mL at Week 24 will be classified as Virologic 
Successes irrespective of the ART regimen they  take at Week 24 (switch from DTG 
+ 3TC FDC to another ART is not penalised); re- test at Week 24 will be considered. 
Virologic Failure
The following cases will be classified as Virologic Failure:
Participants with plasma HIV -1 RNA ≥ 50 c/mL at Week 24 (re -test 
considered)
Participants with missing plasma HIV -1 RNA assessment at Week 24, but 
still on study
Participants who withdrew from study  for any  reason before Week 24 visit
Further details of th e primary  anal ysiswill be provided in the RAP.
9.5.2. Secondary  Analyses
Analy sis of proportion of participants with HIV -1 RNA <50 c/mL at Week 48Visit, 
regardless of the ART Regimen ( Observed Analysis, similar to the primary  anal ysis at 
Week 24).
Analy sis of p roportion of participants with plasma HIV -1 RNA <50 c/mL at Week 24 
and Week 48, using the FDA’s Snapshot algorithm.
FDA’s Snapshot algorithm will classify  all participants without plasma HIV- [ADDRESS_1170853], i.e. Week 24/48, either due to missing plasma HIV -[ADDRESS_1170854] line 
regimen of DTG + 3TC FDC for an y reason prior to the visit of interest will also be 
classified as Virologic non -Successes.  Participants still on DTG + 3TC FDC at the time 
of last HIV -[ADDRESS_1170855] will be classified as Virologic 
Successes if plasma HIV -1 RNA < 50 c/mL, or as Virologic Failures if plasma HIV -1 
RNA ≥50 c/mL .
Full details of the FDA’s Snapshot algorithm will be provided in the RAP. 
Other key efficacy secondary analyses :
Proportion of participants with ART modifications from the first line regimen due 
to abnormal Baseli ne lab oratory or Baseline genoty pic resistance data.  Proportion 
of participants with a modification from the first line regimen due to an y reason. 2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
68The incidence of HIV -1 disease progression (AIDS and death). 
Subgroup anal yses of proportion of participant s with plasma HIV -1 RNA 
<50c/mL  using the Observed Anal ysisand changes from Baseline in CD4+ cell 
count will be summarised by  [CONTACT_654], gender, race, Baseline CD4 counts and Baseline 
HIV-1 RNA levels.
A time to event anal ysisfor the time to first HIV -1 RNA < 50c/ml. 
Full details of all secondary  efficacy  endpoints will be provided in the RAP.
Given that participants are allowed to remain in the study  after ART modification (e.g.
due to Baseline laboratory or HIV-1 resistance mutation results, meet Suspected or 
Confirmed Virologic Failure criteria, toxicity  etc.) or protocol deviations (e.g. 
administration of prohibited medication, first trimester pregnancy  etc.) a very  small 
number of earl y study  withdrawals is expected (mainly  due to lost to follow -up or 
withdraw consent).  Data will be allocated to visit windows using actual visit dates rather 
than nominal visit dates.  Data collected from extra visits within a visit window will be 
listed and will be included in the derivation of the Observed and Snapshot r esponse at 
analysis visits of interest, but summary  tables (e.g. change in CD4+) using observed case
datasets will only  use the data captured closest to the target visit date.  Detailed 
explanations of the definition of visit windows will be included in th e RAP.  Any  
deviations from planned anal yses will be detailed in the clinical study  report (CSR).
9.5.3. Safety  Analyses
The observed case dataset will be the primary  dataset used for anal ysis of safet y 
endpoints.  All safety  analy ses will be based on the Safet y analy sis population.
All Safety  anal yses will be based on period under treatment with DTG + 3TC FDC .  In 
addition, selected safet y endpoints will also be analysed including data after participants 
have ART modifications from DTG + 3TC FDC . 
Exposure to fir st line regimen of DTG +3TC FDC , measured b y the number of weeks on 
study  drug, will be summarized. 
The proportion of participants reporting AEs will be tabulated.  The following summaries 
of AEs will be provided for AEs with onset under treatment with D TG + 3TC FDC (i.e. 
AEs occurred after DTG + 3TC FDC modification will be excluded) at the anal ysis time 
period:
oIncidence and severit y of all AEs;
oIncidence and severit y of treatment related AEs;
oIncidence and severit y of AEs leading to withdrawal; and
oIncidence of SAEs. 2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
69In addition, t he following summaries of AEs will be provided including those occurring 
after treatment modification from DTG + 3TC FDC :
oIncidence and severit y of all AES;
oIncidence and severit y of treatment related AEs;
oIncidence and severi ty of AEs leading to withdrawal; and
oIncidence of SAEs
Laboratory  and vital signs data will be summarised by  [CONTACT_842504] + 3TC FDC (i.e. data after ART modification to be excluded) only .  
In addition, the number and percen tage of participants with graded laboratory  toxicities 
(based on DAIDS categories; Section 10.8) will be summarised for those occurring when 
under treatment with DTG + 3TC FDC and for the overall period under st udy treatment 
(i.e. data after DTG + 3TC FDC modification to be considered).  Further details of safet y 
analyses will be included in the RAP.
[IP_ADDRESS]. Viral Genoty pi[INVESTIGATOR_007]/Phenoty pi[INVESTIGATOR_007] A nalyses 
The incidence of treatment -emergent genoty pic and phenoty pic resistance to DTG and 
3TC will be summarised for participants meeting C onfirmed Virologic F ailure criteria 
(Section 7.3).  Details of genot ypic/phenotypic analyses to be performed will be specified 
in the RAP.
9.5.4. Other A nalyses
The Sy mptom Bother analy sis will be described in the reporting and anal ysis plan.  
9.6. Interim Analyses
One anal ysis will be conducted to evaluate the primary objective of the protocol when all 
subjects have completed their Week [ADDRESS_1170856] had their Week 52 V isit 
and follow -up visit (if required) .  This includes any  visits for viral loa d re-test following 
the Week [ADDRESS_1170857] (End of Study ) analy sis and the 
only planned anal ysis after the primary  Week 24 analy sis.  Results from Week 24 and 48 
analyses will be p ublicl y presented. 2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
70As the potential Week 12 analysisand theWeek 48 analysis are secondary  and the study  
is single arm with no statistical hy pothesis testing performed, no adjustment for 
multiplicity  is needed.
The Reporting and Anal ysisPlan will descri be the planned anal yses in greater detail. 2020N440514_00
2019N398432 _01 CONFIDENTIA L
[PHONE_17528]. SUPPORTING DOCUMENTA TION AND OPERA TIONAL
CONSIDERA TIONS 
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight 
Considerations
10.1.1. Regulatory  and Ethical Considerations
This study  will be conducted in accordance with th e protocol and with:
Consensus ethical principles derived from international guidelines including 
the Declaration of Helsinki and Council for International Organizations of 
Medical Sciences (CIOMS) I nternational Ethical Guidelines
Applicable ICH Good Clini cal Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, I CF, Investigator Brochure, and other relevant 
documents ( e.g., advertisements) must be submitted to an IRB by [CONTACT_842505] a nd approved by  [CONTACT_842506]. 
Any amendments t o the protocol will require IRB approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an 
immediate hazard to study participants. 
The investigator will be responsible for the following:
Providing written summaries of the sta tus of the study  to the IRB annuall y or 
more frequently in accordance with the requirements, policies, and proc edures 
established by  [CONTACT_1201].
Notif ying the IRB of SAE or other si gnificant safety  finding s as required by  
[CONTACT_842507]
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB, European regulation 
536/2014 for clinical studies (if applicable), and all other applicable local 
regulations
10.1.2. Financial Disclosure
Investigators and sub-investigators will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests during the 
course of the stud y and for 1 y ear after completion of the study . 2020N440514_00
2019N398432 _01 CONFIDENTIA L
[PHONE_17529].1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally  authorized representative and answer all questions 
regarding the stud y. 
Participants must be informed that their participation is voluntary . Participants or 
their legally  authorized representative will be required to sign a statement of 
informed consent that meets the requirements of [ADDRESS_1170858] (HI PAA) 
requirem ents, where applicable, and the I RB or study  center. 
The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study  and the date the written 
consent was obtained. The authorized per son obtaining the informed consent must 
also sign the ICF.
Participants must be re -consented to the most current version of the ICF(s) during 
their participation in the study . 
A cop y of the ICF(s) must be provided to the participant or the participant’s l egall y 
authorized representative. 
10.1.4. Data Protection
Participants will be assigned a unique identifier by  [CONTACT_456]. Any participant 
records or datasets that are transferred to the sponsor will contain the identifier only; 
participant names or an y informa tion which would make the participant identifiable 
will not be transferred. 
The participant must be informed that his/her personal study -related data will be 
used by  [CONTACT_10999]. The level of 
disclosure must a lso be explained to the participant. 
The participant must be informed that his/her medical records may  be examined by  
[CONTACT_171138], by  [CONTACT_42506], and by  [CONTACT_90742].
10.1.5. Publication Policy
The results of this study  may  be published or presented at scientific meetings. If this 
is foreseen, the investigator agrees to submit all manuscripts or abstracts to the 
sponsor before submission. This al lows the sponsor to protect proprietary  
information and to provide comments.
The sponsor will comply  with the requirements for publication of study  results. In 
accordance with standard editorial and ethical practice, the sponsor will generall y 
support pu blication of multicenter studies only in their entiret y and not as individual 
site data. In this case, a coordinating investigator [INVESTIGATOR_159828] b y mutual 
agreement. 2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
73Authorship will be determined by  [CONTACT_11403] I nternational 
Committee of Medical Journal Editors authorship requirements.
10.1.6. Dissemination of Clinical Study  Data
Where required b y applicable regulatory  requirements, an investigator signatory  will 
be identified for the approval of the clinical stud y report.  The investiga tor will be 
provided reasonable access to statistical tables, figures, and relevant reports and will 
have the opportunity to review the complete study results at a ViiV/ [COMPANY_004] site or other 
mutually -agreeable location.
ViiV/ [COMPANY_004] will also provide the investiga tor with the full summary  of the study  
results.  The investigator is encouraged to share the summary  results with the study  
participant s, as appropriate.
The procedures and timing for public disclosure of the protocol and results summary  
and for development of a manuscript for publication for this study  will be in 
accordance with ViiV/ [COMPANY_004] Policy .
A manuscript will be progressed for publication in the scientific literature if the 
results provide important scientific or medical knowledge.
10.1.7. Data Quality  Assuran ce
All participant data relating to the study will be recorded on printed or electronic CRF 
unless transmitted to the sponsor or designee electronically  (e.g., laboratory data).
The investigator is responsible for verify ing that data entries are accurate and correct 
by [CONTACT_227569]. 
The investigator must maintain accurate documentation (source data) that supports 
the information entered in the CRF. 
The investigator must permit study -related monitoring , audits, IRB review, and 
regulatory  agency  inspections and provide direct access to source data documents. 
Monitoring details describing strategy  (e.g., risk -based initiatives in operations and 
quality  such as Risk Management and Mitigation Strategies and Anal ytical Risk -
Base d Monitoring), methods, responsibilities and requirements, including handling of 
noncompliance issues and monitoring techniques (central, remote, or on -site 
monitoring) are provided in the Monitoring Plan.
The sponsor or designee is responsible for the dat a management of this study  
including qualit y checking of the data. 
Study  monitors will perform ongoing source data verification to confirm that data 
entered into the CRF b y authorized site personnel are accurate, complete, and 
verifiable from source docum ents; that the safet y and rights of participants are being 
protected; and that the study  is being conducted in accordance with the currentl y 
approved protocol and any other stud y agreements, I CH GCP, and all applicable 
regulatory  requirements. 
Records and documents, including signed ICF, pertaining to the conduct of this study  
must be retained b y the investigator for 25 years from the issue of the final Clinical  2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
74Study  Report (CSR)/ equivalent summary unless local regulations or institutional 
policies requi re a longer retention period. No records may  be destroy ed during the 
retention period without the written approval of the sponsor. No records may  be 
transferred to another location or party without written notification to the sponsor. 
The sponsor assume s accountability  for actions delegated to other individuals ( e.g., 
Contract Research Organizations).
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant and 
substantiate the integrity  of the data collected. Source docum ents are filed at the 
investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies must 
be explained. The investigator may  need to request previous medical records or 
transfer records, depending on the stud y. Also, current medical records must be 
available.
Definition of what constitutes source data can be found in the SRM.
10.1.9. Study and Site Closure
ViiV/ [COMPANY_004] or its designee reserves the right to close the study  site or terminate the study  
at an y time for an y reason at the sole discretion of ViiV/ [COMPANY_004]. Study  sites will be closed 
upon study  completion. A study  site is considered closed when all required documents 
and study  supplies have been col lected and a study -site closure visit has been performed.
The investigator may  initiate study -site closure at any  time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.
Reasons for the earl y closure of a stud y site b y the sponsor or investigator may include 
but are not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the I RB
or local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recr uitment of participants by  [CONTACT_093]
Discontinuation of further study  intervention development 2020N440514_00
2019N398432 _01 CONFIDENTIA L
[PHONE_17530].2. Appendix 2: Clinical Laboratory  Tests
The tests detailed in Table 4will be performed b y the central laboratory .
Local laboratory results are only  required in the event that the central laboratory  
results are not available in time for response evaluation. If a local sample is 
required, it is important that the sample for central anal ysis is obtained at the same 
time.
Additional tes ts may  be performed at an y time during the stud y as determined 
necessary  by [CONTACT_43215].
Pregnancy  Testing 
 Refer to Section 5.1Inclusion Criteria for S creenin g/Day  1 pregnancy  criteria.
 Pregnancy  testing (urine and/or serum) should be conducted at all study  visits. 
Additional serum or urine pregnancy  tests may  be performed, as determined 
necessary  by [CONTACT_093], to establish the absence of pr egnancy  at an y time 
during the participant 'sparticipation in the study .
 Study  intervention should be discontinued if apregnancy  is detected in the first 
trimester, and the participant can remain in the study on a modified (new, non-
DTG based) ART regimen.   Pregnancies detected after the first t rimester can 
continue DTG + 3TC FDC . 2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
76Table 4 Protocol -Required Safety  Laboratory  Assessments
Hematology:
Platelet count Automated WBC differential:
RBC count Neutrophils
WBC count (absolute) Lymphocytes
Hemoglobin Monocytes
Hem atocrit Eosinophils
MCV Basophils
MCH
Clinical Chemistry:
BUN Potassium ASTTotal bilirubin
Direct bilirubina
Creatinine Chloride ALTa Albumin
Glucose Total CO2 Alkaline phosphatase GFR/Creatinine clearanceb
Sodium Phosphate Cystatin -C (Day 1 only )
Calcium Protein
Lipid Panel
Total cholesterol
HDL cholesterol
LDL cholesterol
Triglycerides
Urinalysis
specific gravity, pH, glucose, protein, blood and ketones by [CONTACT_5230] (with microscopic examination if blood 
or protein is abnormal), urine albumin/creatinine ratio, urine protein/creatinine ratio
Other Tests
Plasma HIV -1 RNAc
CD4+ and CD8+ lymphocyte counts, CD4+/CD8+ cell count ratio
Hepatitis B (HBsAg, anti -HBc, anti -HBs, HBV DNA) ; HBV 3TC Resistancee, HBV DNAe
Hepatitis C (anti -HCV)
Pregnancy test for participants of childbearing potentiald
HLA B5701 testf
1. MCV = mean corpuscular volume, MCH = mean corpuscular haemoglobin, RBC = red blood cells, WBC = white 
blood cells, BUN = Blood urea nitrogen, AST=aspartate aminotransferase, ALT = a lanine aminotransferase, CO 2= 
carbon dioxide, HDL = high density lipoprotein, LDL = low density lipoprotein, HbsAg= hepatitis B virus surface antigen , 
anti-HBc = Hepatitis B Core Antibody, HBV = Hepatitis B virus .
a) Details of liver chemistry stoppi[INVESTIGATOR_125401] -up assessments after liver stoppi[INVESTIGATOR_43191] 7.5and Section 10.6.  Direct bilirubin will be reflexiv ely performed for all 
total bilirubin values >1.5 ×ULN.
b) Glomerular filtration rate (GFR) will be estimated by [CONTACT_842508][INVESTIGATOR_10444] (CKD -EPI-creatinine) [Levey , 2009]. In addition, GFR will be estimated by [CONTACT_842509] -EPI-cystatin C [ Inker , 2012] at Screening/ Day 1 and when indicated by [CONTACT_842510].
c) For participants meeting virologic fail ure criteria, plasma samples and whole blood may be analyzed in attempt to 
obtain genotype/phenotype data.
d) Urine pregnancy test/ serum pregnancy test will be performed according to the Schedule of Activities. 
e) For participants with chronic HBV infection, t esting for HBV 3TC resistance will be performed using samples from 
Week 1 and Week 4 (depending on when ART modification occurs) as well as Screening/Day 1 samples.  HBV 
DNA will also be obtained at the Week 1 or Week 4 visit .
f) Please consult with the Medical Monitor. 2020N440514_00
2019N398432 _01 CONFIDENTIA L
[PHONE_17531].3. Appendix 3: A dverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
10.3.1. Definition of A E
AE Definition
An AE is an y untoward medical occurrence in a clinical study participant, temporally 
associated with th e use of a study  intervention, whether or not considered related to 
the study  intervention.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments ( e.g., ECG, radiological scans, vital signs 
measurements), in cluding those that worsen from baseline, considered clinically  
significant in the medical and scientific judgment of the investigator ( i.e., not related 
to progression of underl ying disease).
Exacerbation of a chronic or intermittent pre- existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug- drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdos e taken with possible suicidal/self -
harming intent. Such overdoses should be reported regardless of sequelae.
"Lack of efficacy " or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE. Such instances will be captured i n the efficacy 
assessments. However, the signs, s ymptoms, and/or clinical sequelae resulting from 
lack of efficacy  will be reported as AE or SAE if they  fulfill the definition of an AE 
or SAE. 
Events NOT Meeting the AE Definition 
Any clinically  signi ficant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_941]  2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
78investigator to be more severe than expected for the participant’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure ( e.g., endoscopy , appendectom y): the condition that 
leads to the procedure i s the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study  that do not worsen.
10.3.2. Definition of SA E
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospi[INVESTIGATOR_1080]/sy mptoms of the disease under study , 
death due to progression of disease).
A SA E is defined as any untoward medical occurrence that, at any dose:
Results in death
Is life -threatening
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, 
which hy potheticall y might have caused death, if it were more severe.
Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_492742] d (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_42244] . If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the 
AE should be considered serious.
Hospi[INVESTIGATOR_550902] t of a pre -existing condition that did not worsen from 
baseline is not considered an AE.
Results in persistent disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical  2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
79significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (e .g., sprained ankle) which may  interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
Is a congenital anomaly/birth defect
Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical even ts that may  
not be immediately  life-threatening or result in death or hospi[INVESTIGATOR_268678]. These events shoul d usually  
be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or develop ment of drug dependency  
or drug abuse.
10.3.3. Definition of Cardiovascular Events
Cardiovascular Events (CV) Definition:
Investigators will be required to fill out the specific CV event page of the CRF for the 
following AEs and SAEs:
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension
Cerebrovascular events/stroke and transient ischemic attack
Peripheral arterial thromboembolism
Deep venous thrombosis/pulmonary  embolism
Revascularization
10.3.4. Recording and Follow -Up of A E and S AE
AE and SAE Recording
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation ( e.g., hospi[INVESTIGATOR_1088], laboratory , and diagnostics reports)  2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
80related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_004] in lieu of completion of the [COMPANY_004] /AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_842460] b y [COMPANY_004]. In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copi[INVESTIGATOR_31785].
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an as sessment of intensity  for each AE and SAE reported 
during the stud y and assign it to 1 of the categories in the Division of AI DS Table for 
Grading the Severity  of Adult and Pediatric Adverse Events (“DAIDS AE Grading 
Table”) in Section 10.8:
Grade 1 / Mild:
Grade 2 / Moderate
Grade 3 / Severe
Grade 4 / Potentially  life threatening
Grade 5 / Death
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE.
A "reasonable possibility " of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration will be considered and investigated.
The investigator will also consult the I nvestigator’s Brochure (IB) and/or Product 
Information, for m arketed products, in his/her assessment [TIVICAY Package Insert,  2020N440514_00
2019N398432 _01 CONFIDENTIA L
212355
812018 ; EPI[INVESTIGATOR_842444], 2018; DOVATO Package Insert, 2019] .
For each AE/SAE, the investigator must document in t he medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred, and the investigator has 
minimal information to include in the initial report to ViiV/[COMPANY_004]. However, it is very 
important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to ViiV/[COMPANY_004]/[COMPANY_003].
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and se nd an SAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
Follow -up of AE and SAE
The investigator is obligated to perform or arrange for th e conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  
[CONTACT_350800]/[COMPANY_004]/[COMPANY_003] to elucidate the nature and/or causality  of the AE or SAE as fully  as 
possible. This may  include additional laboratory  tests or investigations , 
histopathological examinations, or consultation with other health care professionals .
If a participant dies during participation in the study or during a recognized follow -
up period, the investigator will provide ViiV/[COMPANY_004] with a cop y of an y post -mortem 
findings including histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to [COMPANY_004] within 24 hours of 
receipt of the information.
10.3.5. Reporting of SA E and other events to Vi iV/[COMPANY_004]/[COMPANY_003]
Reporting of SAEs and other events to ViiV/[COMPANY_004]/[COMPANY_003]
The primary  mechanism for reporting SAE to ViiV/[COMPANY_004]/[COMPANY_003] will be the electronic 
data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collectio n tool (see next section) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
The investigator or medically -qualified sub -investigator must show evidence within 
the eCRF (e.g., check review box, signature, etc.) of review and verification of the 
relationship of each SAE to study  intervention /study  participation (causality ) within  2020N440514_00
2019N398432 _01 CONFIDENTIA L
[PHONE_17532] hours of SAE entry  into the eCRF.
After the stud y is completed at a given site, the electr onic data collection tool will be 
taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to the medical monitor by [CONTACT_756] .
Contacts for SAE reporting can be found in the SRM.
SAE Reporting to ViiV/[COMPANY_004]/[COMPANY_003] via Paper CRF
If the electronic s ystem is unavailable for greater than 24 hours, the site will use the 
paper SAE data collection tool and scan and email it to the Medical Monitor
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE reporting can be found in the SRM. 2020N440514_00
2019N398432_01 CONFIDENTIA L
[PHONE_17533].4. Appendix 4: Toxicity  Management
Adverse events that occur during the trial should be evaluated b y the investigator and 
graded according to the DAIDS toxicity  scales ( see Section 10.8).  Additional 
information regarding detecting, documenting and reporting AEs and SAEs are available 
in Section 10.3.
Study intervention may  be interrupted at the discretion of the investigator and according 
to the severit y of the AE. If DTG + 3TC FDC is held due to toxicity  or AEs, all 
additional ART medications that were added per protocol, should be held to reduce the 
risk of development of HIV-1 resistance taking into account the length of the planned 
interruptions and the PK half -life of each ART of the regimen, in order to minimize the 
risk of development of resistance.
No toxicity -related dose reductions of study  inter ventions will be allowed.  Study  
intervention should be restarted as soon as medically appropriate; in general, this should 
be no longer than 4 weeks after interruption (unless Grade [ADDRESS_1170859]).  
Decisions regarding sequential reintroductio n of study  intervention or temporary  
interruption of one but not all drugs within the ART regimen must be discussed with the 
Medical Monitor and should be made with the understanding that these changes may  
result in incomplete viral suppression and selecti on of resistant virus.   Guidance is 
provided below on participant management and study intervention interruptions based on 
the severit y of the AE for specific toxicities.  All modifications in study  intervention must 
be accuratel y recorded in the participa nt’s eCRF.
Grade 1 or Grade 2 Toxicity/Adverse Event
Participants who develop a Grade 1 or Grade 2 AE or toxicity  may  continue study  
intervention at the discretion of the investigator.  The investigator may  also choose to 
discontinue DTG + 3TC FDC and chan ge to an alternate ART and participant can remain 
in the study .  Participants who choose to withdraw from the study  due to a Grade [ADDRESS_1170860] the study  Withdrawal and F ollow -up evaluations completed.
Grade 3 Toxicity/Adverse Event
Participants w ho develop a Grade 3 AE or toxicity should be managed as follows: 
If the investigator has compelling evidence that the Grade [ADDRESS_1170861] study  intervention withheld and be 
rechecked each week until the AE returns to Grade 2.  Once the AE is Grade ≤2, study  
intervention may  be restarted. 
Should the same Grade [ADDRESS_1170862] dose of study  interventions.
Participants with asymptomatic Grade 3 laboratory abnormalities should be investigated 
for all potential non -drug related causes, and, following discussion with the medical 
monitor, may  continue study  intervention if the investigator has compelling evidence that 
the toxicity  is not related to study  intervention.
Exceptions are noted for rash in Section [IP_ADDRESS] and lipid abnormalities in 
Section [IP_ADDRESS] .
Grade 4 Toxicity/Adverse Event
Participants who develop a Grade [ADDRESS_1170863] a new ART regimen initiated and can remain in the study .  
These participants should be followed weekl y until resolution of the AE .  Participants 
who choose to withdraw from the study  are encouraged to complete the W ithdrawal and 
Follow -up evaluation s.
Participants with asymptomatic Grade 4 laboratory abnormalities should be investigated 
for all potential non -drug related causes, and, following discussion with the medical 
monitor, may  continue therap y if the investigator has compelling evidence that t he 
toxicity  is not related to study  intervention.  Exceptions are noted for lipid abnormalities 
in Section [IP_ADDRESS] .  
An in -clinic Follow -Up V isit will be conducted approximately  4weeks after the last dose 
of study  medication for participants with ongoing AEs, serious adverse events (SAEs) 
regardless of attributability , and any  laboratory  abnormalities that are considered to be 
AEs or potentially  harmful to the participant (as defined in Section 2.3.1 ), at the last on -
study  visit.   The investigator, in consultation with the medical monitor, should follow-up 
with the participant until the event is resolved, stabilized, otherwise explained, or the 
participant is lost to follow -up.
10.4.1. Specif ic Toxicities/Adverse Event Management
General guidelines for the management of specific toxicities that are considered to be 
related or possibl y related to study  intervention are provided below. 
Participants who permanently  discontinue study  intervention for reasons of toxicity  may 
remain in the study  and have a new ART regimen initiated.  The participant shou ld be 
followed weekly  until resolution of the AE.  Participants who choose to withdraw from 
the study  are encouraged to complete the W ithdrawal and Follow -up evaluations. 2020N440514_00
2019N398432_01 CONFIDENTIA L
[PHONE_17534].4.1.1. Liver Chemistry  Stoppi[INVESTIGATOR_842461] w-up Criteria
Liver chemistry  threshold stoppi[INVESTIGATOR_842462] y and to evaluate liver event aetiology during administration of study  intervention 
and the fol low-up period. For a complete listing of stoppi[INVESTIGATOR_53101]- up criteria refer 
to Section 10.6.1 .
[IP_ADDRESS]. Restarting Study  Intervention
Refer to Section 10.6.2 for details on drug restart follo wing transient resolving liver 
events not related to study  intervention.
[IP_ADDRESS]. Decline in Renal Function
Participants who experience an increase in serum creatinine from Baseline of 
45 micromoles/liter ( Mol/L ) (or 0.5 milligrams/deciliter [mg/dL ]) should return for a 
confirmatory  assessment within 2 to 4 weeks.  A urinaly sis, urine albumin/creatinine and 
urine total protein/ creatinine ratios, serum cy statin C and an estimated GFR using the 
CKD -EPI (cystatin C) [ Inker , 2012] should also be done at this confirmatory  visit.  If the 
creatinine increase is confirmed, the investigator should contact [CONTACT_842511]-up and medical management.
Participants who experience progression to an estimated GFR (using the CKD -EPI-
creatinine) of <30 mL/min/1.73m2must return for a confirmatory assessment within 
2weeks [ Leve y, 2009].  A urinaly sis, urine albumin/creatinine and urine 
protein/creatinine ratios, serum cy statin C and an estimated GFR using the CKD -EPI 
(cystatin C) [ Inker, 2012] should be done at this confirmatory  visit.  If an estimated GFR 
of <30 mL /min/1.73m2is confirm ed using the CKD -EPI (cy statin C) , then study  
intervention should be discontinued, and new ART initiated.  
[IP_ADDRESS]. Proteinuria
Participants with an abnormal urine albumin/creatinine ratio (>0.3 mg/mg, >300 mg/g, or 
>34 mg/mmol) that represents a change from Baseline and no associated increase in 
creatinine, should have a repeat spot urine albumin /creatinine ratio performed within 2 -4 
weeks.  If confirmed, then consideration should be given to additional evaluation after 
consultation with the study  medical monitor. Additional evaluation may include a 24-
hour urine protein and creatinine measuremen t and nephrology  referral.
Participants with an abnormal urine albumin/creatinine ratio (>0.3 mg/mg, 300 mg/g, or 
>34 mg/mmol and representing a change from Baseline) and a serum creatinine increase 
>45 μmol/L  (or 0.5 mg/dL) should have confirmation of bot h results within 2 weeks. If 
confirmed, the stud y medical monitor should be contact[CONTACT_88815] y.  Agreement on 
further management should be agreed between the investigator and medical monitor.
Refer to the SPM for details on the collection and processin g of these urine samples. 2020N440514_00
2019N398432_01 CONFIDENTIA L
[PHONE_17535].4.1.5. Allergic reaction
Participants may  continue study  intervention for Grade [ADDRESS_1170864] the 
Investigator immediatel y if there is an y worsening of sy mptoms or if further sy stemic 
signs or s ymptoms develop.  Antihistamines, topi[INVESTIGATOR_11930], or antipruritic agents 
may be prescribed. 
Participants with Grade ≥3 allergic reactions that are considered to be possibly  or 
probably  related to the study  intervention should permanentl y discontinue study  
intervention , and a new ART regimen initiated. Participants should be treated as 
clinically  appropriate and followed until resolution of the AE.   Participants who choose to 
withdraw from the study  are encouraged to complete the W ithdrawal and Follow -up 
evaluations.
[IP_ADDRESS]. Rash
Mild to moderate rash is an expected adverse reaction for DTG- containing ART.  
Epi[INVESTIGATOR_842463], rarel y require 
interruptions or discontinuations of therapy and tend to resolve within two to three weeks.  
No instances of serious skin reaction, including SJS, TEN and ery thema multiforme, have 
been reported for DTG in clinical trials.  For further characterisation of HSR and rash 
observed with DTG -containing ART, please see the current version of the IB and any  IB 
supplements [ DTG IB , 2018 ; TIVICAY Product Insert, 2018 ].
Participants with an isolated Grade 1 rash may  continue study  intervention at the 
Investigator’s discretion.  The participant should be advised to contact [CONTACT_339287], if any  systemic signs or sy mptoms 
appear, or if mucosal involvement develops.
Participants may  continue study  intervention for an isolated Grade 2 rash.  However, 
study  intervention (and all other concurrent medication(s) suspected in the Investigators 
causality  assessment) should be permanentl y discontinued for an y Grade ≥[ADDRESS_1170865] the 
physician immediatel y if rash fails to resolve (after more than two weeks), if there is an y 
worsening of the rash, if any  systemic signs or allergic s ymptoms develop, or if mucosal 
involvement develops.
Participants should permanently  discontinue study intervention [and all other concurrent 
medication(s) suspected in the I nvestigators causality  assessment] for an isolated Grade 3 
or 4 rash, except where the aetiology  of the rash has been definitive ly diagnosed as NOT 
attributable to study  intervention (see below) .  Participants should be treated as clinically  
appropriate and followed until resolution of the AE.  Every  effort should be made to 
collect as much information as possible about the evoluti on of the event and any  
relationship with potentially  related medical events (e.g., viral infection) or start of 
concomitant medication.    2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
87The rash and an y associated sy mptoms should be reported as adverse events and 
appropriate toxicity  ratings should be used to grade the events (based on DAIDS toxicity  
gradings, Section 10.8.
However, if the aetiology of the rash has been definitively  diagnosed as being unrelated 
to study  intervention and due to a specific medi cal event or a concomitant infection or a 
concomitant non -study  medication, routine management should be performed, and 
documentation of the diagnosis provided. In this situation, the study  intervention should 
be continued. 
[IP_ADDRESS]. Hypertrigly ceridemia/Hyperchol esterolemia
Samples for lipid measurements must be obtained in a fasted state according to the 
Schedule of Activities ( Section 1.3).  Participants who experience as ymptomatic 
triglyceride or cholesterol elevations may continue to receive stud y intervention.
REFERENCE :
Inker LA, Schmid CH, Tighiouart H, Eckfeldt J.H, Feldman H.I, Greene T, et al; 
Estimating Glomerular Filtration Rate from Serum Creatinine and Cy statin C. N Engl J 
Med. 2012;367:20-9.
Levey  AS, Stevens LA, Schmid CH , Zhang Y, Castro III A.F, Feldman H.I, et.al. A new 
equation to estimate glomerular filtration rate.  Ann Int Med. 2009;150:604-12. 2020N440514_00
2019N398432_01 CONFIDENTIA L
[PHONE_17536].5. Appendix 5: Contraceptive Guidance and Collection of 
Pregnancy  Information
10.5.1. Definitions:
Participants of Childbearing Poten tial ( POCBP )
A female at birth is considered fertile following menarche and until becoming post-
menopausal unless permanently  sterile (see below).
Participants who are f emale at birth in the following categories are not considered 
POCBP
1.Premenarchal
2.Premenopausal with 1 of the following:
Documented h ysterectomy
Documented bilateral salpi[INVESTIGATOR_1656]
Documented bilateral oophorectom y
For individuals with permanent infertility  due to an alternate medical cause other 
than the above, ( e.g., mullerian agenesis, andr ogen insensitivity ), investigator 
discretion should be applied to determining stud y entry .
Note: Documentation can come from the site personnel’s: review of the 
participant’s medical records, medical examination, or medical history  interview.
3.Postmenopausa l 
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. 
A high follicle stimulating hormone (FSH) level in the postmenopausal 
range may  be used to confirm a postmenopausal state in participants who 
were female s at birth and not using hormonal contraception or hormonal 
replacement therap y (HRT). 
Females at birth on HRT and whose menopausal status is in doubt will be 
required to use one of the non- estrogen hormonal highl y effective 
contraception methods if they  wish to continue their HRT during the stud y. 
10.5.2. Contraception Guidance:
Participants of childbearing potential are eligible to participate if they  agree to use a 
highl y effective method of contraception consistently and correctly as described in Table 
5.
The list does not apply  to participants of child bearing potential who are and will 
continue to be abstinent from penile-vaginal intercourse on a long term and persistent 
basis, when this is their preferred and usual lifest yle. Periodic abstinence (e.g. calendar,  2020N440514_00
2019N398432_01 CONFIDENTIA L
[ADDRESS_1170866] -ovulation methods) and withdrawal are not acceptable 
methods of contraception.
Table [ADDRESS_1170867] of Highly  Effective Contraceptive Methods
 CONTRACEPTIVESaALLOWED DURING THE STUDY INCLUDE:
 Highly Effective MethodsbThat Have Low User Dependency 
 Failure rate of <1%  per year when used consistently and correctly.
 Implantable progestogen -only hormone contraception associated with inhibition of ovulationc
 Intrauterine device (I UD)
 Intrauterine hormone -releasing system (IUS)c
 Bilateral tubal occlusion
 Vasectomized partner
Note: Vasectomized partner is a highly effective contraceptive method provided that the 
partner is the sole sexual partner of the participant of childbearing potential and the 
absence of sperm has been confirmed. If not, an additional highly effective method of 
contraception should be used. Spermatogenesis cycle is approximately 90 days.
 Highly Effective MethodsbThat Are User Dependent
Failure rate of <1% pe r year when used consistently and correctly .
 Combined (estrogen -and progestogen -containing) hormonal contraception associated with 
inhibition of ovulation
oral
intravaginal
transdermal
injectable
 Progestogen -only hormone contraception associated with in hibition of ovulation
oral
injectable
 Sexual abstinence
Note :Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated with 
the study intervention. Th e reliability of sexual abstinence needs to be evaluated in 
relation to the duration of the study and the preferred and usual lifestyle of the participan t
a. Contraceptive use by [CONTACT_842512] c ontraceptive 
methods for those participating in clinical studies.
b. Failure rate of <1%  per year when used consistently and correctly. Typi[INVESTIGATOR_159831].
1. Note: Periodic abstinence (calendar, sympto -thermal, post -ovulation methods), withdrawal (coitus interruptus), 
spermicides only, and lactational amenorrhoea method (LAM) are not acceptable methods of contraception for this 
study. Male condom and female condom should not be used together (due to r isk of failure with friction) 2020N440514_00
2019N398432_01 CONFIDENTIA L
[ADDRESS_1170868] label. The investigator is responsible for 
ensuring that participants understand how to properly use these methods of contraception.
10.5.3. Collection of Pregnancy  Information:
Participants who become pregnant and are in the first trimester shoul d immediately 
discontinue DTG +3TC FDC and an alternate ART regimen that does not contain 
DTG should be started, unless no suitable alternative is available ,in consultation 
with the Medical Monitor .  If the pregnancy is after the first trimester, the 
participant can continue study treatment.   Any participant who becomes pregnant 
during the study can remain in the s tudy, including those who needed to modify the 
ART Regimen.   
Investigator will collect pregnancy  information on any  female participant at birth, 
who becomes pregnant while participating in this study . 
Information will be recorded on the appropriate form and submitted to 
ViiV/[COMPANY_004]/[COMPANY_003] within 24 hours of learning of a participant's pregnancy . 
Participants will be followed to determine the outcome of the pregnancy . The 
investigator will collect follow up information on participant and neonate, which will 
beforwarded to ViiV/[COMPANY_004]/[COMPANY_003].   Generall y, follow -up will not be required for 
longer than 6 to 8 weeks bey ond the estimated delivery  date.  [COMPANY_004]’s central safet y 
department will forward this information to the Antiretroviral Pregnancy  Registry .  
The internatio nal registry is jointly  sponsored b y manufacturers and licensees of 
antiretroviral products.  Additional information and a list of participating
manufacturers/licensees are available from http://www.apregistry .com/.  
Any termination of pregnancy  will be r eported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure. 
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy for medical reasons will be 
reported as an AE or SAE. 
A spontaneous abortion (occurring at < 22 weeks gestational age) or still birth 
(occurring at > 22 weeks gestational age) , congenital anomalies, or ectopic 
pregnancy are considered SAE sand must be reported. 
Any SAE occurring as a result of a post -study  pregnancy which is considered 
reasonabl y related to the study  intervention b y the investigator, will be reported to 
[COMPANY_004] as described in Section 10.3. While the investigator is not obligat ed to activel y 
seek this information in former stud y participants, he or she may learn of an SAE 
through spontaneous reporting.  2020N440514_00
2019N398432_01 CONFIDENTIA L
[PHONE_17537].6. Appendix 6: Liver Safety  Required A ctions and Follow -up 
Assessments and Study  Intervention Rechallenge 
Guidelines
Study  treatme nt refers to all drugs evaluated in the study  and therefore includes ViiV 
study  intervention and non -ViiV ART therapi[INVESTIGATOR_842464].
A liver stoppi[INVESTIGATOR_842465] (ALT, 
bilirubin and or INR) that trigger discontinuation of study treatment and requirement of 
additional actions and follow up assessments to be performed.
A liver monitoring event is as an occurrence of predefined liver chemistry  changes (ALT, 
bilirubin and or INR) that triggers increased monitoring of the participant’s liver 
chemistries, but no action is taken with study  treatment unless liver chemistry stoppi[INVESTIGATOR_118048].
10.6.1. Liver Chemistry Stoppi[INVESTIGATOR_2121]:  Required A ctions a nd Follow 
up A ssessments
Liver Chemistry Stoppi[INVESTIGATOR_2121] - Liver Stoppi[INVESTIGATOR_842466] ≤1.5x ULN
ALT- absolute ALT  8xULN
ALT Increase ALT  5xULN but <8xULN persists for 2 weeks (with bilirubin <2xULN and no 
signs or symptoms of acute hepatitis or hypersensitivity)
Bilirubin1, 2ALT  3xULN andbilirubin 2xULN (>35% direct bilirubin) 
Cannot 
MonitorALT  5xULN but <8xULN and cannot be monitored every 1 - 2 weeks
Symptomatic3ALT  3xULN with symptoms (new or worsening) believed to be related to liver 
injury or hypersensitivity
If baseline ALT >1.5x ULN
ALT- absolute ALT ≥ 5x baseline OR >500 U/L (whichever occurs first)
ALT Increase ALT ≥3x baseline but <5x baseline persists for ≥2 weeks (with bilirubin <2xULN 
and no signs or symptoms of acute hepatitis or hypersensitivity)
Bilirubin1, 2 ALT ≥3x baseline OR >300 U/L (whichever occurs first) andbilirubin ≥2xULN
Cannot 
MonitorALT ≥3x baseline but <5x baseline and cannot be monitored every 1 -2 weeks 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
92Symptomatic3ALT ≥3x baseline and symptoms (new or worsening) believed to be related to 
liver injury or hypersensitivity.
Required Actions and Follow up Assessments following ANY Liver Stoppi[INVESTIGATOR_90567]
Immediately discontinue study intervention.
Report the event to the Medical Monitor
within 24 hours .
Complete the liver event eCRF and complete 
an SAE data collection tool if the event also 
meets the criteria for an SAE2.
Complete the liver imaging and/or liver biopsy 
eCRFs if these tests are performed.
Perform liver event follow up assessments. 
Monitor the participant until liver chemistries 
resolve, stabilise, or return to within baseline 
(see MONITORING below).
Do not restart participant with study 
intervention unless allowed per protocol and 
VSLC approval is granted (refer to 
Section 10.6.2 ).
If restart is not allowed or not granted , 
permanently discontinue study intervention 
and may continue participant in the study for 
any protocol specified follow up assessments.
MONITORING:
Make every reasonable attempt to have 
participants return to clinic within 24 hours
for re peat liver chemistries (include ALT, 
AST, alkaline phosphatase, bilirubin) and 
perform liver event follow up assessments. 
Monitor participants twice weekly until liver 
chemistries resolve, stabilise or return to 
within baseline.
A specialist or hepatology consultation is 
recommended.Make every attempt to carry out liver event 
follow -up assessments at the central 
laboratory as described below:
Viral hepatitis serology, including:
 Hepatitis A immunoglobulin M (IgM) 
antibody;
 HBsAg and hepatitis B core 
antib ody;
 Hepatitis C RNA;
 Hepatitis E IgM antibody.
Cytomegalovirus IgM antibody.
Epstein -Barr viral capsid antigen IgM 
antibody (or if unavailable, obtain 
heterophile antibody or monospot testing).
Syphilis screening.
Drugs of abuse screen, including alcohol.
Serum acetaminophen adduct HPLC 
assay (quantifies potential acetaminophen 
contribution to liver injury in participants 
with definite or likely acetaminophen use 
in the preceding week [ James , 2009]).  
The site must contact [CONTACT_171041] l Monitor 
when this test is required.
Serum CPK and lactate dehydrogenase 
(LDH).
Fractionate bilirubin, if total bilirubin 
1.5xULN.
Obtain complete blood count with 
differential to assess eosinophilia.
Anti-nuclear antibody, anti -smooth muscle 
antibody, T ype 1 anti -liver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG or gamma  2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
93globulins).
Liver imaging (ultrasound, magnetic 
resonance, or computerised tomography) 
and /or liver biopsy to evaluate liver 
disease; complete Liver Imagi ng and/or 
Liver Biopsy eCRF forms.
Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, fatigue, decreased 
appetite, nausea, vomiting, abdominal 
pain, jaundice, fever, or rash as relevant 
on the AE report form.
Reco rd use of concomitant medications 
on the concomitant medications report 
form including acetaminophen, herbal 
remedies, other over the counter 
medications.
Record alcohol use on the liver event 
alcohol intake eCRF.
1. CPK -creatine phosphokinase
1. Serum biliru bin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study intervention for that participant if ALT 3xULN andbilirubin  2xULN. 
Additionally, if serum bilirubin fractiona tion testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations and suggesting liver injury. 
2. All events of ALT 3xULN andbilirubin  2xULN (>35% direct bilirubin) must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) ; INR measurement is not required, and the threshold value stated 
will not apply to participants receiving anticoagulants
3. New or worsening symptoms believed to be related to liver injury (such as fatigu e, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia)   2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
94Liver Chemistry Increased Monitoring Criteria with Continued Therapy
Liver Chemistry Increased Monitoring Criteria –Liver Monitoring Event
Criteria Actions
If baseline ALT ≤1.5x ULN, 
ALT ≥5x ULN and <8xULN and 
bilirubin <2xULN without symptoms 
believed to be related to liver injury 
or hypersensitivity, monitor 
participant every 2 weeks until 
resolution to ALT <5x ULN.Notify the Medical Monitor within 24 hours of 
learning of the abnormality to discuss participant 
safety. 
Participant can continue study intervention  
Participant must return every 1 – 2 week sfor 
repeat liver chemistries (ALT, AS T, alkaline 
phosphatase, bilirubin) until resolution or 
stabilisation (ALT <5×ULN on 2 consecutive 
evaluations) 
If at any time participant meets the liver chemistry 
stoppi[INVESTIGATOR_3418], proceed as described aboveIf baseline ALT >1.5x ULN, 
ALT ≥3x baseline and <5x baseline 
and bilirubin <2xULN without 
symptoms believed to be related to 
liver injury or hypersensitivity, 
monitor participant every 2 weeks 
until resolution to ALT <3x baseline
Reference s
James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, et.al...
Pharmacokinetics of Acetaminophen -Adduct in Adults with Acetaminophen Overdose 
and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.
10.6.2. Study Intervention Restart after Stoppi[INVESTIGATOR_842467] a participant meets liver chemistry  stoppi[INVESTIGATOR_90549]/rechallenge 
participant with study  treatment unless:
ViiV Healthcare Safet y and L abelling Committee (VSL C)approval is granted
Ethics and/or I RB approval is obtained, if required, and
Separate consent for treatment restart/rechallenge is signed b y the participant
If VSL Capproval to restart/rechallenge subject with study  treatment is not granted , then 
subject must permanently  discontinue study  treatment and may  continue in the study for 
protocol -specifi ed foll ow up assessments .
Drug restart may be considered for liver events with a clear underl ying cause (e.g., 
biliary , pancreatic events, hy potension, acute viral hepatitis), if not associated with drug - 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
95induced liver injury , alcoholic hepatitis or hy perse nsitivity , and drug not associated with 
human leukocy te antigen (HLA) marker of liver injury , when liver chemistries improve 
to within 1.5x Screening/Day  1and ALT<3xUL N)(Table 6, Figure 3) .
Drug Restart
Phase III “drug restart” can be approved b y the VSL C for transient, defined non -drug -
induced liver injury if no evidence of:
•immunoallergic injury  /HLA association with injury
•drug-induced liver injury  (DILI)
•alcoholic hepatitis
Study  intervention is held while labs and evaluation are completed to assess diagnosis.
VSLC Decision Process for Drug Restart Approval or Disapproval ( Figure 3): 
Investigator requests consideration of drug re -initiation for a participant stable or 
improving on study  intervention, who exhibits liver chemistry  elevation meeting 
participant stoppi[INVESTIGATOR_3418], which is transient, non- drug-related, and liver 
chemistries improve to within 1.5x baseline and ALT< 3xUL N. 
In setting of a definitive non -study -drug-related diagnosis (e.g., acute viral or 
syphilitic hepatitis), restart will be consider ed once ALT <3x ULN (for 
participant s with baseline AL T <1.5x UL N) or < 3x baseline AL T value (for 
participan ts with baseline AL T >1.5x UL N).
Medical monitor and Clinical Safety Physician to review the participant’s diagnosis, 
restart risk factors and complete checklist ( Table 6).
The LOC medical director (ViiV Healthcare and [COMPANY_004] where applicable) should 
be informed that stud y intervention restart is under consideration and of the final 
decision, whether or not to proceed. 2020N440514_00
2019N398432_01 CONFIDENTIA L
[ADDRESS_1170869] for Phase III drug restart after well -explained liver injury  
(e.g., biliary , pancreatic, hypotensive events, congestive heart 
failure, acute viral hepatitis), improving to liver chem. 1.5x baseline 
& ALT<3xULN
Yes No
Was participant stable or improving on study intervention?
Do not restart if the following risk factors at initial liver i njury :
fever, rash, eosinophilia, or hypersensitivity 
drug-induced liver injury 
alcoholic hepatitis (AST>ALT, typi[INVESTIGATOR_897] <10xULN)
study intervention has an HLA genetic marker associated with liver injury 
(e.g., lapatinib, abacavir, amoxicillin /clavulanate)
Previous drug history
Relevant phy sicians must review and agree on request for drug restart:  
Safety  Team Leader, VP, or Senior Safet y Physician
Medicines Development Leader and Project Ph ysician Leader.
Hepatotoxicity  Panel consultat ion is available.
Justification for drug restart outlining the benefit and risk for this participant must be 
recorded b y [COMPANY_004]’s Global Clinical Safety and Pharmacovigilance (GCSP) Phy sician 
and sent to the VSL C Secretary .
VSL C must approve drug re -initiatio n and dosing regimen 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
97Figure 3 VSLC process for drug restart approval or disapproval
1.Andrade , 2009; 2. Papay 2009; 3. Hunt , 2010
Medical Monitor, GCSP Physician and PI [INVESTIGATOR_842468] (Global Clinical Safety and Pharmacovigilance) GCSP 
Physician A ctions
Medical Monitor must notify  PI [INVESTIGATOR_339201]’s restart decision and recommended 
dosing regimen in writing and Medical Monitor must record note in stud y files.
The Safet y Review Team must record restart outcomes and the GCSP Phy sician 
must send these to the VSL C
All severe reactions (restart associated with bilirubin>2xULN or jaundice, or 
INR1.5), SAEs or fatalities with drug re start must be immediately reported to 
Line Management, VSLC Chair, VP Global Medical Strategy  and EU Qualified 
Person for Pharmacovigilance. 
Principal Investigator A ctions:
The PI  [INVESTIGATOR_699877] I nstitutional Review Board approval of drug
restart, as required.  2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
98If drug re -initiation VSLC -approved, the participant must provide informed consent 
with a clear description of possible benefits and risks of drug administration 
including recurrent, more severe liver injury  or possible death.
The p articipant’s informed consent must be recorded in the study  chart, and the drug 
administered at agreed dose, as communicated b y Medical Monitor.
Liver chemistries must be followed once weekly for ‘restart’ cases for one month or 
for as long as clinically  indicated following drug re- initiation.  I f participant exhibits 
protocol -defined liver chemistry  elevations, study  intervention should be 
discontinued as protocol specified.
VSLC and the IRB must be informed of the participant’s outcome following drug 
restart.
Restart safety  outcomes :
0 = no liver chemistry  elevation
1 = recurrent liver chemistry  elevation not meeting participant stoppi[INVESTIGATOR_3418]
2 = recurrent liver chemistry  elevation meeting participant stoppi[INVESTIGATOR_3418]
3 = serious adverse event
4 = fat ality
References
Andrade RJ, Robles M, Lucena MI.  Rechallenge in drug -induced liver injury : the 
attractive hazard.  Expert Opin Drug Saf. 2009; 8:709-714.
Hunt, CM.  Mitochondrial and immunoallergic injury  increase risk of positive drug 
rechallenge after drug-induced liver injury : A s ystematic review.  Hepatol. 2010; 
52:2216-2222. 
Papay  JI, Clines D, Rafi R, Yuen N., Britt S.D., Walsh J.S., Hunt C.M.   Drug -induced 
liver injury  following positive drug rechallenge.  Regul Tox Pharm. 2009; 54:84 -90.  2020N440514_00
2019N398432_01 CONFIDENTIA L
[PHONE_17538].7. Append ix 7: Prohibited Medications
The following concomitant medications or therapi[INVESTIGATOR_842469] :
HIV immunotherapeutic vaccines are not permitted at an y time during the study . 
Other experimental agents, cy totoxic chemotherap y, or radiation therapy  may  not 
be administered. 
Systemicall y administered immunomodulators (such as interleukin and interferon 
agents) are prohibited (a list of examples is provided in the SRM).  This includes 
topi[INVESTIGATOR_842470].  Use of 
topi[INVESTIGATOR_449424]. 
For participants with an unanticipated requirement for HCV therap y during 
study , interferon or any other medications that have a potential for adverse drug -
drug interactions with study  intervention are prohibited during the conduct of the 
study .  
Acetaminophen (paracetamol) cannot be used in participants with acute viral 
hepatitis [ James, 2009].
The following medications or their equivalents may  cause decreased concentrations of 
DTG. Therefore, the following medications must not be administered concurrentl y with 
DTG.
Carbamazepi[INVESTIGATOR_050]
Oxcarbamazepi[INVESTIGATOR_050]
Phenobarbital
Pheny toin
Rifampin
St. John’s wort (Hypericum perforatum )
Dofetilide is prohibited as DTG may inhibit their renal tubular secretion resulting in 
increased dofetilide concentrations and potential for toxicity .
Note:   Any prohibited medication should be discontinued for a minimum of two weeks or 
a minimum of three half -lives (whichever is longer) prior to the first dose.  
For information on concurrent therapi[INVESTIGATOR_842471] , please consult the local prescribing 
information. 2020N440514_00
2019N398432_01 CONFIDENTIA L
[ADDRESS_1170870] in Adults with Acetaminophen Overdose 
and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784. 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
[ZIP_CODE].8. Appendix 8:  Division of A IDS Table for Grading the Severity  
of Adult and Pediatric A dverse Events Version 2.1, March 
2017
VERSION 2.1, March 2017
The Division of AIDS Table for Grading the Severity  of Adult and Pediatric Adverse 
Events (“DAIDS AE Grading Table”) is a descriptive terminology  which can be utilised 
for Adv erse Event (AE) reporting.  A grading (severity ) scale is provided for each AE 
term [DAIDS , 2017].
Estima ting Severity Grade for Pa rameters Not Identified in the Gra ding Table
Thefunctional tablebelow should be used to g radetheseverity of a n AE t hat is not 
specifically identified in the grading table. In addition, all deaths re lated to an AE areto 
be cla ssified as grade5.
PARAMETERGRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Clini caladverse
event NOT
identified 
elsewhe re in the
grading tab leMildsymptoms
causing no or 
minima l 
interference w ith
usual social & 
functional
activ ities with
intervention not
indicatedMod erate symptoms
causing gr eater th an 
minimal interferen ce 
withusual social &
functionalactiv ities 
withintervention 
indicatedSevere symptoms
causing inab ilityto 
perform usual
social & functional
activ ities with
intervention o r 
hospi[INVESTIGATOR_714779] n 
indicatedPotentiallylife-
threatening symptom s 
causing inab ility to
perfo rmbasic self-care 
functions with
intervention i ndicated to
prevent permanent
impair ment, persistent
disability, or d eath
Major Clinical Conditions Cardiovascular
PARAMETERGRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Arrhythm ia
(by [CONTACT_842513])
Specify t ype, i f 
applicableNosymptoms
AND No
intervention 
indicatedNosymptoms
ANDNon-urgent 
intervention 
indicatedNon-life-
threatenin g 
symptom s AND
Non-urgent
intervention
indicatedLife-thr eatenin g 
arrhythm ia OR
Urgent inter vention
indicated 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
102PARAMETERGRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Blood Pressu re
Abnorma lities1
Hypertension(with 
the lowestreading 
taken afte r repea t 
testingduring a
visit)
≥ 18yearsof
age140to< 160
mmHg sy stolic
OR
90 to < 100
mmH g 
diastolic≥ 160to
< 180 mmHg
systolic OR
≥ 100to< 110 
mmHg
diastolic≥ 180 mmHg
systolic
OR ≥ 110 mmH g 
diastolicLife-thr eatenin g 
consequences ina 
participant no t 
previouslydiagnosed 
withhype rtension (e.g ., 
malignant
hype rtension) OR
Hosp italizatio n 
indicated
< 18 years of
age> 120/80
mmHg≥ 95thto< 99th 
percentile + 5
mmHg adju sted for
age, heigh t,and
gend er (systolic 
and/or diastolic)≥99thpercentile
+5mmHg adju sted 
for age, heigh t, 
and gend er
(systolicand/or
diastolic)Life-thr eatenin g 
consequences ina 
participant no t 
previouslydiagnosed 
withhype rtension (e.g ., 
malignant
hype rtension) OR
Hosp italizatio n 
indicated
Hypotension Nosympto ms Symptom s 
corrected withoral
fluid replacementSymptoms A NDIV
fluid s indi catedShock requ iring use of 
vasopressors or 
mechanical assistance 
to ma intainblood
pressure
Cardia c Ischemia
orInfarction
ReportonlyoneNA NA New symptoms
with is chemi a 
(stable angina)
ORNew testing
consistent with
ischem iaUnstable angin a OR
Acutemyocardi al 
infarc tion
Hear t Failure Nosymptoms
AND
Laboratoryor 
cardia c 
imaging 
abnorma litiesSymptoms w ith
mild to moderate 
activit y orexertionSymptom s at rest
or withminimal
activit y or
exertion (e.g. , 
hypoxemia ) OR
Inter vention
indicated (e.g. , 
oxygen)Life-thr eatenin g 
consequences OR
Urgent inter vention 
indicated (e.g. , 
vasoactive
medi cation s,
ventricular a ssist
device, heart
transpl ant)
1Blood pressure norms for children < 18 years of age can be found in: Expert Panel on Integrated 
Guidelines for Cardiovascular Health and Risk Reduction in Children and A dolescents. Pediatrics 
2011;128;S213; originally published online November 14, 2011; DOI: 10.1542/peds.2009 -2107C 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
103Cardiovascular
PARAMETERGRADE 1 
MILDGRADE 2 
MODERATEGRADE 3 
SEVEREGRADE 4 
POTENTIALLY LIFE -
THREATENING
Hemorrhage
(withsignifi cant
acute blood lo ss)NA Symptoms A ND
No tr ansfu sion
indicatedSymptoms
AND
Transfu sion of
≤2 units
packedRBCs 
indicatedLife-thr eatenin g 
hypotensionOR
Transfu sion of > 2units 
packedRBCs ( for 
children, packedRBCs
> 10 cc/kg) indicated
Prolonged PR 
Inter val or AV
Block
Reportonlyone
> 16 years of agePR inter val 0.21
to< 0.25
secon dsPR inter val
≥ 0.25 seconds 
ORType I2nd
degree AV blo ckType II2nd
degree AV
block OR
Ventricular
pause ≥3.0
secondsComple teAV block
≤ 16yearsofage 1stdegree AV
block
(PR inter val> 
normal for ag e 
and rat e)Type I2nddegree
AV blockType II2nd
degree AV
block OR
Ventricular
pause ≥3.0
secondsComple teAV block
Prolonged Q Tc
Inter val20.45 to 0.47
secon ds> 0.47 to
0.50 
seconds> 0.50 seconds OR
≥ 0.06 seconds 
above baselineLife-thr eatenin g 
consequences (e.g., 
Torsade de pointes, 
other a ssociated se rious 
ventricular
dysrhythmia)
Thrombo sisor
Embo lism
ReportonlyoneNA Symptoms A ND
No intervention 
indicatedSymptoms
AND
Inter vention 
indicatedLife-thr eatenin g 
embolic event (e.g. , 
pulmonaryembolism, 
throm bus)
2As per B azett’s formula 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
104Derma tologic
PARAMETER GRADE 1 MILDGRADE 2 
MODERATEGRADE 3 
SEVEREGRADE 4 
POTENTIALLY LIFE -
THREATENING
Alopecia (scalponly)Detectab le by
[CONTACT_8712] , 
caregiver,or 
physician AND
Causing no or 
minimal
interference
with usual
social & 
functional
activ itiesObvi ous on v isual 
inspection A ND
Causing gr eater
than minimal
interferen ce with
usual social & 
functional
activ itiesNA NA
Bruising Localized to
one areaLocalized to
more thanone 
areaGenera lized NA
Cellulitis NA Non-parenter al 
treatment
indicated (e.g.,
oral antibio tics, 
antifungals, 
antivirals)IVtreatmen t 
indicated
(e.g., IV 
antibiotics, 
antifungals, 
antivirals)Life-thr eatenin g 
consequences 
(e.g., sepsis,tissue 
necrosis)
Hyperpi[INVESTIGATOR_842472] l 
interference
with usual
social &
functional
activ itiesMarked or 
generalized
causing gr eater
than minim al 
interference w ith 
usual social & 
functional
activ itiesNA NA
Hypopi[INVESTIGATOR_842472] l 
interference
with usual
social &
functional
activ itiesMarked or 
generalized
causing gr eater
than minim al 
interference w ith 
usual social & 
functional
activ itiesNA NA
Petechiae Localized to
one areaLocalized to
more thanone 
areaGenera lized NA 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
105PARAMETER GRADE 1 MILDGRADE 2 
MODERATEGRADE 3 
SEVEREGRADE 4 
POTENTIALLY LIFE -
THREATENING
Pruritus3
(without skinlesions)Itching causing
no or minima l 
interference
with usual
social & 
functional
activ itiesItching causing 
greater than
minim al 
interference w ith 
usual social & 
functional
activ itiesItching causing 
inabilityto
perfo rm usual
social & 
functional
activ itiesNA
Rash
Specify 
type, i f 
applicableLocalized ra sh Diffu se rash
ORTarget
lesionsDiffu se rash
ANDVesicles 
orlimited 
number of
bullae or 
superfici al 
ulcerations of 
mucous 
membra ne 
limitedtoone 
siteExten sive or
generalized bullous
lesions ORUlceration
of muc ous membran e 
involvi ng
two or mo re 
distinct mucosal
sites OR
Stevens-Johnson
syndrome OR
Toxic epi[INVESTIGATOR_842473]
3For prur itus associated w ithinjections or infu sions,see the Site Reactions toInjections and Infu sions
section (p age 23 in source DAIDS Tab le).
Endocrine and Metabolic
PARAMETER GRADE 1MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY 
LIFE -
THREATENING
Diabete s Mellitus Controlled
without 
medicationControlled w ith 
medication OR
Mod ification o f 
current
medi catio n 
regimenUncontrolled
despi[INVESTIGATOR_549064] t 
modificationOR
Hosp italization
for imme diate 
gluco se control
indicatedLife-thr eatenin g 
consequences (e.g., 
ketoacidosis, 
hyperosmolar non-
ketotic coma, end
organ failure)
Gynecomastia Detectab le by
[CONTACT_8712] , 
caregiver,or 
physician AND
Causing no or 
minimal
interference w ith 
usual social & 
functional
activ itiesObvi ous on v isual 
inspection A ND
Causing pa inwith 
greater than
minim al 
interference w ith 
usual social & 
functional
activ itiesDisfigu ring
chan ges AND
Sympto ms 
requiring
intervention or
causing inab ilityto 
perform usual
social
& 
functional 
activ itiesNA 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
106PARAMETER GRADE 1MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY 
LIFE -
THREATENING
Hyperthy roidism Nosymptoms
ANDAbnormal 
laboratoryvalueSymptom s 
causing greater
than minim al 
interference w ith 
usual social & 
functional
activ ities OR
Thyro id 
suppre ssion
thera py indicatedSymptom s 
causing inab ility
toperfo rm usual
social & 
functional
activ ities OR
Uncontrolled 
despi[INVESTIGATOR_549064] t 
modificationLife-thr eatenin g 
consequences 
(e.g., thyroid
storm)
Hypothy roidism Nosymptoms
ANDAbnormal 
laboratoryvalueSymptom s 
causing greater
than minim al 
interference w ith 
usual social & 
functional
activ ities OR
Thyro id 
replacement
therap y indicatedSymptom s 
causing inab ility
toperfo rm usual
social & 
functional
activ ities OR
Uncontrolled 
despi[INVESTIGATOR_549064] t 
modificationLife-thr eatenin g 
consequences 
(e.g., myxedem a 
coma)
Lipoatr ophy4 Detectab le by
[CONTACT_8712] , 
caregiver,or 
physician AND
Causing no or 
minimal
interference
with usual
social &
functional
activ itiesObvi ous on v isual 
inspection A ND
Causing gr eater
than minimal
interferen ce with
usual social & 
functional
activ itiesDisfigu ring
chan gesNA
Lipohypertr ophy5Detectab le by
[CONTACT_8712] , 
caregiver,or 
physician AND
Causing no or 
minimal
interference w ith 
usual social & 
functional
activ itiesObvi ous on v isual 
inspection A ND
Causing gr eater
than minimal
interferen ce with
usual social & 
functional
activ itiesDisfigu ring
chan gesNA
4Defin ition: A d isorder char acterized by [CONTACT_842514],extremities,andbuttocks.
5Defin ition: A d isorder char acterized by [CONTACT_842515] b ack of th e neck, breasts, and
abdomen 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
107Gastrointestinal
PARAMETER GRADE 1 MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4 
POTENTIALLY 
LIFE -
THREATENING
Anorexia Loss of appetite 
without
decreased oral
intakeLoss of appetite 
associated w ith 
decreased oral
intake without
signifi cant weight
lossLoss of
appetite 
associated w ith 
signifi cant
weigh t lossLife-thr eatenin g 
consequences OR
Aggressive 
intervention 
indicated (e.g., tub e 
feeding, total
parenter al nutrition)
Ascites Nosympto ms Symptoms
AND
Inter vention 
indicated (e.g.,
diure tics,
therapeu tic 
paracentesis)Symptom s recur
or persist
despi[INVESTIGATOR_10811]-
threatenin g 
consequences
Bloating or 
Distension
ReportonlyoneSymptom s 
causing no or
minima l 
interference w ith 
usual social & 
functional
activ itiesSymptom s causing 
greater than
minim al 
interference w ith 
usual social & 
functionalactiv itiesSymptom s 
causing inab ility
toperfo rm usual
social & 
functional
activ itiesNA
Chol ecystitis NA Symptoms A ND
Medi cal
intervention 
indicatedRadiologic , 
endos copic,
or op erative
intervention
indicatedLife-thr eatenin g 
consequences 
(e.g., sepsis,
perfora tion)
Constipation NA Persisten t 
constipation 
requiring regular
use of dieta ry 
modifications, 
laxatives,or
enem asObstipation
with manual
evacuation 
indicatedLife-thr eatenin g 
consequences 
(e.g., 
obstructio n)
Diarrhea
≥ 1year of age Tran sient or 
interm ittent 
epi[INVESTIGATOR_842474]≤ 
3 stoolsover
baseline
per24-hour pe riodPersistent ep isodes 
ofunformed to 
watery stools OR
Increase of 4to 6 
stoolsover
baseline p er24-
hour pe riodIncrease of ≥ 7 
stoolsper 24-
hour p eriodOR
IV flu id 
replacemen t 
indicatedLife-thr eatenin g 
consequences (e.g., 
hypotensive shock) 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
108PARAMETER GRADE 1 MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4 
POTENTIALLY 
LIFE -
THREATENING
< 1year of age Liquidstools 
(more unformed
than usual)but
usual number of
stoolsLiquidstools with 
increased number
of stools ORMild 
dehydra tionLiquidstools with 
moderate 
dehydra tionLife-thr eatenin g 
consequences (e.g., 
liquid st ools 
resulting in severe 
dehydra tion, 
hypotensive shock)
Dysphag iaor
Odynophagia
Reportonlyone
and specify 
locationSymptom s but
able to eat usual
dietSymptom s causing 
altered dieta ry
intake withno
intervention 
indicatedSymptom s causing 
severely a ltered 
dieta ryintake with 
intervention
indicatedLife-thr eatenin g 
reduction in oral
intake
Gastrointe stinal
BleedingNot requ iring 
intervention
other than ir on 
suppleme ntEndosc opic 
intervention 
indicatedTransfu sion  
indicatedLife-thr eatenin g 
consequences 
(e.g., 
hypotensive 
shock)
Mucositis or 
Stoma titis
Reportonly
one and 
specify 
locationMucosal erythema Patch y 
pseudomembrane s 
or ulcerationsConfluent 
pseudomembrane s 
or ulcerations OR
Mucosal bl eedin g 
withminortraumaLife-thr eatenin g 
consequences (e.g., 
aspi[INVESTIGATOR_1516], choking)
ORTissue necrosis 
ORDiffuse 
spontaneous 
mucosal bl eeding
Nausea Tran sient(< 24 
hours)or 
interm ittent
AND No or
minima l 
interference
with oral int akePersistent
nausea resulting
in
decreased oral
intake for 24 to 48
hoursPersistent naus ea 
resultingin
minima l oral
intake for> 48 
hours OR
Rehydra tion 
indicated (e.g.,
IV fluid s)Life-thr eatenin g 
consequences 
(e.g., 
hypotensive 
shock)
Panc reatitis NA Symptoms w ith 
hospi[INVESTIGATOR_842475]-thr eatenin g 
consequences 
(e.g., circulato ry
failure, 
hemo rrhage,
sepsis)
Perfora tion
(colon or r ectum)NA NA Intervention 
indicatedLife-
threatenin g 
consequen ces  2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
109PARAMETER GRADE 1 MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4 
POTENTIALLY 
LIFE -
THREATENING
Proctitis Rectal d iscomfo rt 
withno
intervention 
indicatedSymptom s causing 
greater than
minim al 
interference w ith 
usual social & 
functionalactiv ities 
ORMedi cal 
intervention 
indicatedSymptom s causing 
inabilityto
perfo rm usual
social & 
functional
activ ities OR
Opera tive 
intervention
indicatedLife-thr eatenin g 
consequences 
(e.g., 
perfora tion)
Rectal Disch arge Visible discharge Discharg e 
requiring the use 
of pa dsNA NA
Vom iting Tran sientor 
interm ittent
AND No or
minima l 
interference
with oral int akeFrequent
epi[INVESTIGATOR_842476] (e.g., IV
fluid s)Life-thr eatenin g 
consequences 
(e.g., 
hypotensive 
shock)
Musculoskeletal
PARAMET ER GRADE 1 MILDGRADE 2 
MODERATEGRADE 3 
SEVEREGRADE 4 
POTENTIALLY LIFE -
THREATENING
Arthralg ia Joint pa incausi ng 
no or minima l 
interference w ith 
usual social & 
functional
activ itiesJoint pa in
causing gr eater
than minim al 
interference w ith 
usual social & 
functional
activ itiesJoint pa in
causing 
inabilityto
perfo rm usual
social & 
functional
activ itiesDisab ling joint pa in 
causing inab ilityto 
perform ba sic self-
care f unctions
Arthr itis Stiffness or joint 
swelling causing 
no or minimal 
interference wit h 
usual social & 
functional 
activitiesStiffness or joint 
swelling causing 
greater than 
minimal 
interference 
with usual social 
& functional 
activitiesStiffness or 
joint sw elling 
causing 
inability to 
perform usual 
social & 
functional 
activitiesDisabling joint 
stiffness or sw elling 
causing inability to 
perform basic self -
care functions 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
110PARAMET ER GRADE 1 MILDGRADE 2 
MODERATEGRADE 3 
SEVEREGRADE 4 
POTENTIALLY LIFE -
THREATENING
Myalg ia
(generalized)Muscle pain 
causing no o r 
minima l 
interference
with usual
social &
functional
activ itiesMuscle pain
causing greater
than minim al 
interference w ith 
usual social & 
functional
activ itiesMuscle pain
causing inability
toperfo rm usual
social & 
functional
activ itiesDisab ling musc le 
pain causing inab ility
to perform ba sic self-
care f unctions
Osteone crosis NA Nosymptom s 
but with
radiogra phic 
findings AND
No opera tive 
intervention 
indicatedBone pain w ith 
radiogra phic 
finding s OR
Opera tive 
intervention
indicatedDisab ling bone
pain with
radiogra phic 
findings causing 
inabilityto
perfo rm
basic self-ca re
functions
Osteopen ia6
≥ 30yearsofageBMD t-score
-2.5to-1NA NA NA
< 30 years ofage BMD z-sco re
-2to-1NA NA NA
Osteopor osis6
≥ 30yearsofageNA BMD t-score < -
2.5Pathologic 
fracture (e.g.,
compre ssion 
fractu re cau sing
loss ofvertebral
heigh t)Pathologic fractu re 
causinglife-
threatenin g 
consequences
< 30 years of
ageNA BMD z-sco re < -2 Pathologic 
fracture (e.g.,
compre ssion 
fractu re cau sing
loss ofvertebral
heigh t)Pathologic fracture 
causinglife-
threatenin g 
consequences
6BMD tandz scores can b e found in: K anisJAon beha lfof the WorldHealthOrganization Scientif ic 
Group (2007 ).Assessme nt of osteoporosis at the primary hea lth-care l evel.Techni cal Re port.World
Health Organization Co llaborating Cen tre for Meta bolic Bone Dis eases,University ofSheffield, [LOCATION_006].
2007: Printed by [CONTACT_3433] e University ofSheffield 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
111Neurologic
PARAMETERGRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Acute CNSIschem iaNA NA Tran sient
ischemi c attackCerebral vascular 
accident (e.g.,
stroke with
neurologi cal defic it)
Altered Mental
Statu s (for
Demen tia, see 
Cognitive,
Behaviora l,or 
Attentional
Disturbanc e below)Chan ges 
causingno or
minima l 
interference
with usual
social & 
functional
activ itiesMildlethargy o r 
somnolence 
causing gr eater
than minim al 
interference w ith 
usual social & 
functional
activ itiesConfusion,
memor y 
impairmen t,
lethargy , or 
somnolence 
causing inab ility
to perform usual
socia l & 
functional 
activ itiesDeliriumOR
Obtundation OR
Coma
Ataxia Symptom s 
causing no or
minima l 
interference
with usual
social & 
functional
activ ities OR
Nosymptom s 
withataxia 
detected on
examina tionSymptom s 
causing gr eater
than minim al 
interference w ith 
usual social & 
functional
activ itiesSymptom s 
causing inab ility
toperfo rm usual
social & 
functional
activ itiesDisab ling sympto ms 
causing inab ilityto 
perform ba sic self-
care f unctions
Cogn itive,
Behavio ral, or 
Attentional 
Disturbanc e 
(includes demen tia 
and a ttention 
defic itdisorder)
Specify t ype, if
applicab leDisab ility
causing no or
minimal
interference
with usual
social & 
functional
activ ities OR
Specialized 
resources not 
indicatedDisab ility
causing greater
than minim al 
interference w ith 
usual social & 
functional
activ ities OR
Specialized 
resources on pa rt-
time basis 
indicatedDisab ility
causing inability
toperfo rm usual
social & 
functional
activ ities OR
Specialized 
resources ona 
full-time basis 
indicatedDisab ilitycausing 
inabilitytoperfo rm
basic self-ca re
functions OR
Institutiona lizatio n 
indicated 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
112PARAMETERGRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Developmental
Delay
< 18 years of
age
Specify t ype,
if applicab leMild
developmenta l 
delay, e ither
moto r or
cogn itive,as 
determined by 
[CONTACT_842516] t ool 
appropriate 
for the settingMod erate 
developmental
delay , either
motor or 
cogn itive,as 
determined by 
[CONTACT_833694] w itha 
development al 
screening t ool 
appropriate for
the settingSevere
developmental
delay , either motor
orcogn itive,as 
determined by 
[CONTACT_833694] w itha 
development al
screening t ool 
appropriate for the 
settingDevelopmental 
regression, either
motor or cogn itive,as 
determined b y 
compa rison w itha 
development al 
screening t ool 
appropriate for the 
setting
Headache Symptom s 
causing no or
minima l 
interference
with usual
social & 
functional
activ itiesSymptom s 
causing gr eater
than minim al 
interference w ith 
usual social & 
functional
activ itiesSymptom s 
causing inab ility
toperfo rm usual
social & 
functional
activ itiesSymptom s causing 
inabilitytoperfo rm
basic self-ca re
functions OR
Hosp italizatio n 
indicated OR
Headache with
signifi cant 
impairment of
alertness or other
neurolog ic 
function
Neuromuscula r 
Weakne ss 
(includes 
myopathy and 
neuropathy)
Specify t ype, if
applicab leMinimal
muscl e 
weakness 
causing no or
minima l 
interference
with usual
social & 
functional
activ ities OR
Nosymptom s 
with
decreased 
strengthon 
examina tionMuscle weakne ss 
causing gr eater
than minimal
interferen ce with
usual social & 
functional
activ itiesMuscle 
weakne ss 
causing inab ility
to perform usual
social & 
functional 
activ itiesDisab ling musc le 
weakness causing 
inabilitytoperfo rm
basic self-ca re
functions OR
Resp iratorymusc le 
weakness 
impa iring
ventilation 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
113PARAMETERGRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Neurosens ory 
Alteration
(includes 
paresthesia and
painf ul 
neuropathy)
Specify t ype, if
applicab leMinimal
paresthesia 
causing no or 
minimal
interference
with usual
social & 
functional
activ itiesOR
Nosymptom s 
withsenso ry 
alteration o n 
examina tionSenso ry
alterationor 
paresthesia 
causing greater
than minim al 
interference w ith 
usual social & 
functional
activ itiesSenso ry
alterationor 
paresthesia 
causing inability
toperfo rm usual
social & 
functional
activ itiesDisab ling senso ry 
alteration or
paresthesia causing
inabilityto perform
basic self-care 
functions
Seizures
New Onset Se izure
≥ 18yearsofageNA NA 1to 3seizur es Prolon gedand
repetitive seizure s (e.g.,
status epi[INVESTIGATOR_7397])OR
Difficu lt tocontrol
(e.g., refractory
epi[INVESTIGATOR_002])< 18 years of
age (includes 
new or pre-
existing feb rile 
seizures)Seizu re 
lasting< 5 
minutes with
< 24 ho urs 
postictalstateSeizu re lasting 5 to
<
20 mi nutes with
< 24 hou rs 
postictal stateSeizu re lasting≥ 
20 minutes OR
> 24 ho urs 
postictalstateProlon gedand
repetitive seizure s (e.g.,
status epi[INVESTIGATOR_7397])OR
Difficu lt tocontrol
(e.g., refractory
epi[INVESTIGATOR_002])
Pre-existing Se izure NA Increased
frequency from
previous level of
control without 
chang e inseizu re 
characterChang e in
seizu re 
character e ither
in duration or
quality ( e.g.,
severity or 
focality)Prolon gedand
repetitive seizure s (e.g.,
status epi[INVESTIGATOR_7397])OR
Difficu lt tocontrol
(e.g., refractory
epi[INVESTIGATOR_002])
Syncope Near sync ope 
without loss 
of 
consciousness 
(e.g., pre-
syncope)Loss of 
consciousness 
with no
intervention 
indicatedLoss of 
consciousness 
AND
Hosp italization o r 
intervention
requiredNA 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
114Pregnancy, Puerperium, and Perinatal
PARA METERGRADE 1
MILDGRADE 2
MODE RATEGRADE 3
SEVE REGRADE 4 
POTENTIALLY LIFE -
THREATENING
Stillbirth
(reportusing 
mothe r’s 
participant ID)
ReportonlyoneNA NA Fetal d eath 
occurring at ≥ 20
weeks gestationNA
Preterm
Birth(report 
using
mothe r’s 
participant
ID)Live birthat 34 to
< 37 w eeks 
gestationalageLive birthat 28 to
< 34 w eeks 
gestationalageLive birthat 24 to
< 28 w eeks 
gestationalageLive birthat< 24 week s 
gestationalage
Spontaneou s 
Abortion or 
Miscarriage7
(report using
mothe r’s 
participant ID)
Reportonly
oneChemic al 
pregnancyUncomp licated 
spontaneous 
abortion or
miscarriageComp licated 
spontaneous 
abortion or
miscarriageNA
7Defin ition: A pr egnancy lo ss occurring at < 20 w eeksgestationalage 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
115Psychiatric
PARAMETERGRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVERERADE 4
POTENTIALLY LIFE -
THREATENING
Insomn ia Milddifficulty 
falling asleep, 
staying a sleep,
or waking up
early causing
noor minima l 
interference
with usual
social &
functional
activ itiesMod erate 
difficulty falling
asleep, staying
asleep, o r 
waking up early 
causing mo re 
than
minimal
interferen ce with
usual social & 
functional
activ itiesSevere difficult y 
falling asleep,
staying asleep, or
wakingup early
causing
inabilityto
perfo rm usual
social &
functional
activ ities
requiring
intervention or
hosp italizationNA
Psychiatr ic 
Disorders 
(include s 
anxiety , 
depre ssion,
mania, an d 
psychosis)
Specify 
disorderSymptoms w ith 
intervention no t 
indicated OR
Behavior
causing no or
minima l 
interference
with usual
social & 
functional
activ itiesSymptoms w ith 
intervention 
indicated OR
Behaviorcausing 
greater than
minim al 
interference w ith 
usual social & 
functional
activ itiesSymptoms w ith 
hospi[INVESTIGATOR_714779] n 
indicated OR
Behavior
causing inabili ty
toperfo rm usual
social & 
functional
activ itiesThreaten s harm toself 
or othe rs ORAcute 
psychosis OR
Behavior causing
inabilityto perform
basic self-care 
functions
Suicidal
Idea tion or
Attempt
ReportonlyonePreoccupi[INVESTIGATOR_842477] d eath AND
Nowishto kill
oneselfPreoccupi[INVESTIGATOR_842478] o r 
intentThough ts of
killing on eself
withpartial or
comple te plans
but n o attempt
todoso OR
Hosp italization
indicatedSuicide attempt ed 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
116Respi[INVESTIGATOR_842479] 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Acute 
BronchospasmForced
expi[INVESTIGATOR_833574] e in1
secon d or peak
flow reduced to
≥ 70 to < 80%
ORMild
symptoms
withintervention
not indi catedForcedexpi[INVESTIGATOR_833574] e in1 secon d 
or peak flow 50 to
< 70%OR
Sympto ms w ith
intervention
indicated OR
Symptom s causing 
greater than
minim al 
interference w ith
usual social &
functionalactiv itiesForced
expi[INVESTIGATOR_833574] e in1
secon d or
peak flow 25
to
< 50%OR
Symptom s 
causing
inabilityto
perfo rm usual
social & 
functional
activ itiesForcedexpi[INVESTIGATOR_833574] e in1 second or 
peak flow < 25%OR
Life-thr eatenin g 
respi[INVESTIGATOR_842480] e OR
Intuba tion
Dyspnea o r 
Respi [INVESTIGATOR_842481] w ith
noor minima l 
interference
with usual
social &
functional
activ ities OR
Wheezing OR
Minimal
increase in
respi[INVESTIGATOR_842482] & 
functionalactiv ities 
ORNasal fla ringOR
Interco stal retraction s 
ORPulse oximetry
90 to < 95%Dyspnea at
rest causing
inabilityto 
perform usual
social
& functional
activ ities OR
Pulse oximetry
< 90%Resp iratoryfailure with 
ventilator suppo rt 
indicated (e.g., CPAP , 
BPAP, intuba tion)
Sensory
PARA METERGRADE 1
MILDGRADE 2
MODE RATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Hear ing Lo ss
≥ 12yearsofageNA Hearing aidor 
intervention
not indicatedHearing aidor 
intervention
indicatedProfound bilatera l 
hearing lo ss (> 80 dB at
2 kHz andabove)OR
Non-servi ceable hearing
(i.e.,>50 dB a udiogra m 
and<50% sp eech 
discrimina tion)
< 12 years of
age
(based on a 1,
2, 3, 4,6 and 8
kHz > 20 dB 
hearing loss 
at ≤ 4kHz> 20 dB hearing
loss at> 4kHz> 20 dB hearing
loss at ≥ 3kHz in
one ear with
additional speech
langu age related
services i ndicatedAudiolog ic indication for
cochl ear implant a nd 
additional speech-
langu age relatedservice s 
indicated(whe re 
available) 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
117PARA METERGRADE 1
MILDGRADE 2
MODE RATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
audiogra m) (where available)
ORHearing lo ss 
sufficient to
indicate 
therapeu tic 
intervention, 
including h earing 
aids
Tinnitus Symptom s 
causing no or
minima l 
interference
with usual social
& functional
activ ities with
intervention not
indicatedSymptom s 
causing greater
than minim al 
interference w ith 
usual social & 
functional
activ ities with
intervention 
indicatedSymptom s 
causing inab ility
toperfo rm usual
social & 
functional
activ itiesNA
Uveitis Nosymptoms
ANDDetectab le 
on examina tionAnte rior uveitis 
with symptom s 
ORMedi cal
intervention 
indicatedPosterior or pan-
uveitis OR
Opera tive 
intervention
indicatedDisab ling visual lo ss in 
affected eye (s)
Vertigo Vertigocausing
no or minima l 
interference
with usual social
& functional
activ itiesVertigocausing 
greater than
minim al 
interference w ith 
usual social & 
functional
activ itiesVertigocausing 
inabilityto
perfo rm usual
social & 
functional
activ itiesDisab lingvertigo 
causing inab ilityto 
perform ba sic self-care 
functions
Visual Changes
(assessed from
baseline)Visual
chan ges 
causing no or 
minima l 
interference
with usual
social &
functional
activ itiesVisual chan ges 
causing gr eater
than minimal
interferen ce with
usual social & 
functional
activ itiesVisual chan ges 
causing inab ility
to perform usual
social
& functional
activ itiesDisab ling visual lo ss in 
affected eye (s) 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
118Systemic
PARAMETERGRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Acute All ergic
ReactionLocalized
urticaria ( wheals)
withno medical
intervention 
indicatedLocalized
urticaria with
intervention 
indicated OR
Mild 
angioedema
with no
intervention 
indicatedGenera lized
urticaria OR
Angioedema
with intervention
indicated OR
Symptom s of
mild
bronchospasmAcute anaphylaxis 
ORLife-thr eatenin g 
bronc hospasmOR
Laryn geal edema
Chills Symptom s causing
no or minima l 
interference w ith
usual social &
functional
activ itiesSymptom s 
causing gr eater
than minima l 
interference
with usual
social &
functional
activ itiesSymptom s 
causing 
inabilityto
perfo rm usual
social & 
functional
activ itiesNA
Cytokin e Release
Synd rome8Mildsigns and 
symptoms
AND Therapy
(i.e., antibody
infusion) 
interruptionnot 
indicatedTherapy (i.e., 
antibody
infusion) 
interruption 
indicated A ND
Respond s
promp tly to
sympto matic 
treatment OR
Prophyl actic 
medication s 
indicated for ≤
24 ho ursProlon ged
severe signs and
symptom s OR
Recurrenc e of 
symptoms
followi ng initial
impro vementLife-thr eatenin g 
consequences 
(e.g., requiring
pressoror 
ventilator suppo rt)
Fatigue or 
Mala ise
ReportonlyoneSymptom s causing
no or minima l 
interference w ith
usual social &
functionalactiv itiesSymptom s 
causing gr eater
than minima l 
interference
with usual
social &
functional
activ itiesSymptom s 
causing 
inabilityto
perfo rm usual
social & 
functional
activ itiesIncapacita ting
symptom s of fatigue or
malais e cau sing
inabilityto perform
basic self-care 
functions
Fever (non-
axillary 
temperature s 
only)38.0 to < 38.6° C or
100.4to< 101.5°F≥ 38.6 to
<39.3°C or
≥ 101.5 to
<102.7°F≥ 39.3 to < 40.0°C
or≥ 102.7to
< 104.0°F≥ 40.0°C or ≥ 104.0°F 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
119PARAMETERGRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Pain9(not
associat ed with
studyagent 
injection s and
not specified
elsewher e)
Specify l ocationPain causing no
or minimal
interferen ce with
usual social & 
functional
activ itiesPain causing 
greater th an 
minima l 
interference
with usual
social &
functional
activ itiesPain causing
inability to
perfo rmusual 
social & 
functional 
activ itiesDisab ling pa incausing 
inabilitytoperfo rm
basic self-care
functions OR
Hosp italization
indicated
Serum Sickne ss10Mildsigns 
and 
sympto msMod erate signs 
and symptoms
AND
Inter vention 
indicated (e.g. , 
antihistamine s)Severe signs and 
symptoms AND
Higher l evel 
intervention
indicated (e.g.,
steroids or I V 
fluid s)Life-thr eatenin g 
consequences 
(e.g., requiring
pressoror 
ventilator suppo rt)
Underweight11
> 5to19years of
ageWHO B MI z-sco re
< -1to-2WHOBMI z-sco re
< -2to -3WHO B MI z-sco re
< -3WHO B MI z-sco re< -3
withlife-thr eatenin g 
consequences
2to5yearsof
ageWHO B MI z-sco re
< -1to-2WHOWeight-
for- height z-
score< -2to-3WHOWeight-
for- height z-
score < -3WHOWeight-for-
heigh t z-scor e < -3 w ith
life- thr eatening
consequences
< 2yearsofage WHO B MI z-sco re
< -1to-2WHOWeight-
for- leng thz-
score< -2to -3WHOWeight-
for- leng thz-
score < -3WHOWeight-for-
length z-sco re < -3 w ith
life- thr eatening
consequences
Unintentiona l 
Weight Lo ss 
(excludes 
postpartum 
weight lo ss)NA 5to< 9% lo ss 
in body weight
from baseline≥ 9to< 20%
loss in body
weight fr om 
baseline≥ 20% loss in body 
weight from base line 
ORAggressive 
intervention indicated
(e.g., tub e feeding,
total parenter al 
nutrition)
8Defin ition: A d isorder char acterized by [CONTACT_842517], h eadache, t achycardia, hy potensi on, rash, and/or sho rtness 
of br eath.9For painassociated w ithinjection s or infu sions, see the Site Reacti ons to Inj ections and Infu sionssection
(page 23 in source DAIDS Table).
10Defin ition: A d isorder char acterized by [CONTACT_842518] r,arthralgia, myalgia, skin er uptions,lymphadenopathy,
marked discomfo rt,and/or dyspnea11WHO r eferenc e tables may b e accessed by c licking th e desiredage range or by [CONTACT_842519] e following
URLs:
http://ww w.who.int/growthref/wh o2007_bmi_for_ age/en/ for pa rticipan ts >5
to19 yea rs ofage and 
http://ww w.who.int/childgrowth /standards/chart_ catalogue/en/ for t hose ≤ [ADDRESS_1170871] 
obstruction
with 
hydronephrosis 
or renal
dysfunctionObstructioncausing 
life-thr eatenin g 
consequences
Site Reactions to Injections and Infusions
PARAMETER GRADE 1MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY 
LIFE -
THREATENING
Injection S ite P ain
or Tenderne ss
ReportonlyonePain or
tenderne ss 
causing no or 
minimal
limitation of
use oflimbPain or t enderne ss 
causing gr eater th an 
minimal lim itation
of use oflimbPain or
tenderne ss 
causing
inabilityto 
perform usual
social
& functional
activ itiesPain or t enderne ss 
causing inab ilityto 
perform ba sic self-
care f unctionOR
Hosp italizatio n 
indicated
Injection S ite 
Erythem a or 
Redne ss12
Reportonlyone
> 15 years of age2.5to< 5 cm in 
diameter OR
6.25 to< 25 cm2
surfac e area
ANDSymptom s 
causing no or
minimal
interference w ith 
usual social & 
functional
activ ities≥ 5to< 10 cm in 
diameter OR≥ 25
to< 100 cm2
surface a rea OR
Sympto ms causing
greater th an 
minimal
interferen cewith
usual social &
functionalactiv ities≥ 10 cm in
diamet er OR ≥ 
[ADDRESS_1170872] ainage 
ORSymptom s 
causing 
inabilityto
perfo rm usual
social & 
functional
activitiesPotentiallylife-
threatenin g 
consequences 
(e.g., abscess,
exfoliative 
derma titis,
necrosis 
involving derm is 
or deeper tissue) 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
121PARAMETER GRADE 1MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY 
LIFE -
THREATENING
≤ 15yearsofage ≤ 2.5 cm
in 
diamet er> 2.5 cm in
diamet er with< 
50% surf ace are a 
of the extremity 
segment invol ved 
(e.g., upper a rmor 
thigh)≥ 50% surf ace 
area of the 
extremity 
segment
invol ved (e.g.,
upper a rmor 
thigh) OR
Ulceration OR
Seconda ry 
infection OR
Phlebitis OR
Sterile
abscess OR
DrainagePotentiallylife-
threatenin g 
consequences 
(e.g., abscess,
exfoliative 
derma titis,
necrosis 
involving derm is 
or deeper tissue)
Injection S ite
Indu ration or 
Swelling
Reportonlyone
> 15 years of
ageSame as fo r 
Injection
Site 
Erythema
or Rednes s,
>15 ye ars 
of ageSame as fo r 
Injection S ite 
Erythema o r 
Rednes s,> 15
years of ageSame as fo r 
Injection S ite 
Erythema o r 
Rednes s,> 15
years of ageSame as for
Injectio n Site 
Erythema or 
Rednes s,> 15 years 
of age
≤15yearsofage Same as fo r 
Injection S ite 
Erythema o r 
Rednes s,≤ 15
years of ageSame as fo r 
Injection S ite 
Erythema o r 
Rednes s,≤ 15
years of ageSame as fo r 
Injection S ite 
Erythema o r 
Rednes s,≤ 15
years of ageSame as for
Injectio n Site 
Erythema or 
Rednes s,≤ 15years
of age
Injection S ite 
Prur itusItching lo calized
to the injection
site thatis 
relieve d 
spontaneouslyor
in< 48 hou rs of 
treatmentItching bey ond the 
injection site that
is notgeneralized
ORItching
localized to the 
injection si te 
requiring ≥ 48
hours treatmentGenera lized 
itchin g causing
inabilityto 
perform usual
social & 
functional 
activ itiesNA
12Injection Site Ery themaor Redne ssshoul d be eval uated andgraded using thegreatestsinglediamete r or 
measured su rface area. 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
122Laborat ory Values*
Chemistries
PARAMETER GRADE 1 MILDGRADE 2 
MODERATEGRADE 3 
SEVEREGRADE 4 
POTENTIALLY LIFE -
THREATENING
Acido sis NA pH ≥ 7.3 to < 
LLNpH < 7.3 w ithout
life- thr eatenin g 
consequencespH < 7.3 w ithlife-
threatenin g 
consequences
Albumin,
Low
(g/dL; g/L)3.0to< LLN
30to< LLN≥ 2.0to< 3.0
≥ 20to<30< 2.0
<20NA
Alkalin e 
Phosphatase , 
High1.25 to <
2.5 xULN2.5to< 5.0 x
ULN5.0to< 10.[ADDRESS_1170873]≥ 10.[ADDRESS_1170874]
Alkalo sis NA pH > U LN to ≤ 
7.5pH > 7.5 w ithout
life- thr eatenin g 
consequencespH > 7.5 w ithlife-
threatenin g 
consequences
ALT or SGPT,
High
Reportonlyone1.25 to <
2.5 xULN2.5to< 5.0 x
ULN5.0to< 10.[ADDRESS_1170875]≥ 10.[ADDRESS_1170876]
Amyla se 
(Pancr eatic) or
Amyla se (T otal),
High
Reportonlyone1.1 to< 1.5 x
ULN1.5 to< 3.0 x
ULN3.0to< 5.[ADDRESS_1170877] ≥ 5.[ADDRESS_1170878] or SGOT,
High
Reportonlyone1.25 to
<2.5 x
ULN2.5 to< 5.0 x
ULN5.0 to< 10.[ADDRESS_1170879]≥ 10.[ADDRESS_1170880]
Bicarbonate, L ow
(mEq/L; mmo l/L)16.0 to < LLN
16.0 to < LLN11.0 to <16.0
11.0 to < 16.08.0 to< 11.0
8.0 to< 11.0< 8.0
< 8.0
Bilirubin
DirectBilir ubin13, 
High
> 28 day s of ageNA NA > ULNwith
other signs and
symptom s of
hepatotoxic ity.> ULN w ithlife-
threatenin g 
consequences (e.g., 
signs and symptom s of 
liver failure)
≤ 28days of a geULN to ≤ 1mg/d L> 1to≤ 1.5
mg/dL> 1.5to≤ 2 mg/ dL > 2mg/dL
Total Bilir ubin,
High
> 28 day s of
age1.1to< 1.6 x
ULN1.6to< 2.6 x
ULN2.6to< 5.[ADDRESS_1170881] withother
signs and 
symptom s of 
hepatotoxic ity.≥ 5.[ADDRESS_1170882] w ithlife-
threatenin g 
consequences (e.g., 
signs and symptom s of 
liver failure). 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
123PARAMETER GRADE 1 MILDGRADE 2 
MODERATEGRADE 3 
SEVEREGRADE 4 
POTENTIALLY LIFE -
THREATENING
≤ 28days of a geSee
Appendix Ain 
Source DAIDS 
Table . Total
Bilirubinfor 
Term and
Prete rm 
NeonatesSee
Appendix A
in Source 
DAIDS Table . 
Total
Bilirubinfor 
Term and
Prete rm 
NeonatesSee 
Appendix A in 
Source DAIDS 
Table . Total
Bilirubinfor 
Term and
Prete rm 
NeonatesSeeAppendix A in 
Source DAIDS Ta ble.
Total Bilir ubinfor
Termand Prete rm
Neonates
Calcium, High
(mg/dL; mmol/L)
≥ 7days ofage10.6to< 11.5
2.65to <2.8811.5 to <12.5
2.88to <3.1312.5 to< 13.5
3.13to <3.38≥ 13.5
≥ 3.38
< 7days of age 11.5 to <12.4
2.88to <3.1012.4 to <12.9
3.10to <3.2312.9 to < 13.5
3.23 to <3.38≥ 13.5
≥ 3.38
Calcium (Ionized ),
High
(mg/dL; mmol/L)> ULN to < 6.0
> UL N to < 1.56.0to< 6.4
1.5to<1.66.4to< 7.2
1.6to<1.8≥ 7.2
≥ 1.8
Calcium, L ow
(mg/dL; mmol/L)
≥ 7days ofage7.8 to< 8.4
1.95 to <2.107.0 to< 7.8
1.75to <1.956.1to< 7.0
1.53to <1.75< 6.
< 1.53
< 7days of age 6.5to< 7.5
1.63 to <1.886.0to< 6.5
1.50to <1.635.50 to < 6.0
1.38to <1.50< 5.50
< 1.38
Calcium (Ionized ),
Low
(mg/dL; mmol/L)< LLN to 4.0
<LLN to1.03.6to< 4.0
0.9to<1.03.2to< 3.6
0.8to<0.9< 3.2
< 0.8
Cardia c 
Tropon inI, 
HighNA NA NA Levels consistent w ith 
myocardial infarc tion 
or un stable angin a as 
defined by [CONTACT_3433] e local 
laboratory
Creatine Kinase,
High3to< 6x ULN 6to< 10x U LN 10 to < [ADDRESS_1170883] ≥ [ADDRESS_1170884]
Creatinine, High
*Reportonly one1.1to1.[ADDRESS_1170885] > 1.3to1.[ADDRESS_1170886] OR
Increase to 1.3
to< 1.5 x
participant’s 
baseline> 1.8 to< 3.[ADDRESS_1170887] ORIncrea se 
to1.5to<2.0x 
participan t’s
baseline≥ 3.[ADDRESS_1170888] OR Increase 
of ≥ 2.0 x participant ’s 
baseline 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
124PARAMETER GRADE 1 MILDGRADE 2 
MODERATEGRADE 3 
SEVEREGRADE 4 
POTENTIALLY LIFE -
THREATENING
Creatinin e 
Clearance14or 
eGFR,Low
*Reportonly oneNA < 90 to 60
ml/minor 
ml/min/ 1.73 m2
OR10 to < 30%
decrease from
participant’s 
baseline< 60 to 30 m l/min
or ml/min/ 1.73
m2OR30to
<50% d ecrease
from participan t’s
baseline< 30 m l/minor 
ml/min/ 1.73 m2
OR≥ 50%
decrease from 
participan t’s
baseline or 
dialy sis needed
Gluco se
(mg/dL; mmol/L)
Fasting, High110to125
6.11 to < 6. 95> 125to250
6.95 to < 1 3.89> 250 to 500
13.89to<27.75≥ 500
≥ 27.75
Nonfasting, High 116to160
6.44 to < 8. 89> 160to250
8.89 to < 1 3.89> 250 to 500
13.89 to< 27. 75≥ 500
≥ 27.75
Glucose, L ow
(mg/dL; mmol/L)
≥ 1monthofage55 to64
3.05 to <3. 5540to<55
2.22 to < 3.0530 to<40
1.67 to < 2. 22< 30
< 1.67
< 1 m onth of age 50 to 54
2.78 to < 3. 0040 to < 50
2.22 to < 2. 7830 to < 40
1.67 to < 2. 22< 30
< 1.[ADDRESS_1170889] to < 2.0x
ULN w ithout 
acidosis≥ 2.[ADDRESS_1170890]
without acidosisIncreased l actate
with pH < 7.3
without life-
threatenin g 
consequencesIncreased l actatewith 
pH < 7.3 w ithlife-
threatenin g 
consequences
Lipase, High 1.1 to< 1.5 x
ULN1.5 to< 3.0 x
ULN3.0 to< 5.[ADDRESS_1170891] ≥ 5.[ADDRESS_1170892] ers
(mg/dL; mmol/L)
Cholesterol,
Fasting, High
≥ 18yearsofage200 to< 240
5.18 to < 6.[ZIP_CODE] to< 300
6.19 to < 7.77≥ 300
≥ 7.77NA
< 18 years of
age170 to< 200
4.40 to < 5.15200to< 300
5.15 to < 7.77≥ 300
≥ 7.77NA
LDL, Fasting,
High
≥ 18yearsof
age130 to< 160
3.37 to < 4.12160to< 190
4.12 to < 4.90≥ 190
≥4.90NA
> 2to< 18
years of age110 to< 130
2.85 to < 3.34130to< 190
3.34 to < 4.90≥ 190
≥ 4.90NA 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
125PARAMETER GRADE 1 MILDGRADE 2 
MODERATEGRADE 3 
SEVEREGRADE 4 
POTENTIALLY LIFE -
THREATENING
Trigl yceri des,
Fasting, High150to300
1.71 to 3.42>300 to500
>3.42 to5.7>500to< 1,000
>5.7 to 11.4> 1,000
> 11.4
Magne sium15,
Low
(mEq/L;
mmo l/L)1.2 to< 1.4
0.60 to < 0. 700.9to< 1.2
0.45 to < 0. 600.6 to< 0.9
0.30 to < 0. 45< 0.6
< 0.30
Phosphate, L ow
(mg/dL; mmol/L)
> 14 years of age2.0to< LLN
0.65 to < LLN1.4to< 2.0
0.45 to < 0. 651.0to< 1.4
0.32 to < 0.45< 1.0
< 0.32
1to14years of
age3.0 to< 3.5
0.97 to < 1.132.5to< 3.0
0.81 to < 0.971.5to< 2.5
0.48 to < 0.81< 1.5
< 0.48
< 1year of age 3.5to< 4.5
1.13 to < 1.452.5 to< 3.5
0.81 to < 1.131.5to< 2.5
0.48 to < 0.81< 1.5
< 0.48
Pota ssium, High
(mEq/L; mmo l/L)5.6to< 6.0
5.6 to< 6.06.0to< 6.5
6.0to< 6.56.5to< 7.0
6.5to< 7.0≥ 7.0
≥ 7.0
Pota ssium, L ow
(mEq/L; mmo l/L)3.0to< 3.4
3.0to< 3.42.5to< 3.0
2.5to< 3.02.0to< 2.5
2.0to< 2.5< 2.0
< 2.0
Sodium, High
(mEq/L; mmo l/L)146 to< 150
146 to < 1 [ZIP_CODE] to< 154
150 to < 1 [ZIP_CODE] to< 160
154 to < 1 60≥ 160
≥160
Sodium, L ow
(mEq/L; mmo l/L)130 to< 135
130 to < 1 [ZIP_CODE] to< 130
125 to < 130121 to< 125
121 to < 1 25≤ 120
≤ 120
Uric Acid, High
(mg/dL; mmol/L)7.5 to< 10.0
0.45 to < 0.5910.0 to < 12.0
0.59 to < 0.7112.0 to <15.0
0.71 to < 0.89≥ 15.0
≥ 0.89
eGFR -estimated glomerular filtration rate
*Reminder:An asymptoma tic abnormal la boratoryfinding w ithout anaccompanying A E shouldnot be 
reportedtoDAIDSinan expeditedtime frame unless itmeets protocol-sp ecific reporting requiremen ts.
13Direct b ilirubin> 1.5 mg/dL ina participant <28 day s of ag e should be graded a s grade 2,if< 10% of th e 
total b ilirubin
14Use t he applicab le formu la (i.e., Co ckcroft-Gau lt inmL/m inor Schwa rtz, MDRD, CKD -Epi [INVESTIGATOR_842483]/min/ 1.73m2).Sites shou ld choo se the method defined in their study and when not sp ecified, us e the 
method mo strelevanttothestudypopulation.
*Reminder:Choo se the method that sel ects for th e higher grade
15To converta magne sium valu e from mg/dL tommo l/L, laboratories shouldmultiplyby0.4114 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
126Hematology
PARAMETERGRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Absolu te CD 4+
Count, Low
(cell/mm3;
cells/L )
> 5yearsofage
(notHIV infected)300to< 400
300to< 400200to< 300
200to< 300100to< 200
100 to < 2 00< 100
< 100
Absolu te 
Lym phocyte
Coun t,Low
(cell/mm3;
cells/L )
> 5yearsofage 
(not HIV infected) 600 to< 650
< 0.600 x109to 
< 0.650 x 109500 to< 600
0.500 x 109 to 
< 0.600 x 109350to< 500
0350 x 109to 
< 0.500 x 109< 350
< 0.350 x109
Absolu te 
Neutr ophil
Coun t (ANC),
Low
(cells/mm3;
cells/L )
> 7days of
age800to1,000
0.800 x 109to
1.000 x 109600to799
0.600 x 109to
0.799 x 109400to599
0.400 x 109to
0.599 x 109< 400
< 0.400 x 109
2to7days of age 1,250to1,500
1.250 x 109to
1.500 x 1091,000to1,249
1.000 x 109to
1.249 x 109750to999
0.750 x 109to
0.999 x 109< 750
< 0.750 x 109
≤ 1day of age 4,000to5,000
4.000x 109to
5.000x 1093,000to3,999
3.000 x 109to
3.999 x 1091,500to2,999
1.500 x 109to
2.999 x 109< 1,500
< 1.500 x 109
Fibrinogen,
Decreased
(mg/dL; g/L)100 to< 200
1.00 to < 2.00
OR
0.75 to < 1.00 x
LLN75 to< 100
0.75 to < 1.00
OR
≥ 0.50 to < 0.75 x
LLN50 to<75
0.50 to < 0.75
OR
0.25 to < 0.[ADDRESS_1170893]< 50
< 0.50
OR
< 0.[ADDRESS_1170894]
ORAssociated w ith gross 
bleeding
Hemoglobin16,
Low
(g/dL;
mmo l/L)17
≥ 13yearsof
age(male only)10.0 to 10.9
6.19 to 6. 769.0to< 10.0
5.57 to < 6. 197.0to< 9.0
4.34 to < 5. 57< 7.0
< 4.34
≥ 13yearsofage
(fema le only)9.5to10.4
5.88 to 6. 488.5to< 9.5
5.25 to < 5. 886.5to< 8.5
4.03 to < 5. 25< 6.5
< 4.03 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
127PARAMETERGRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
57days of ag e to
<13 years of age
(male and female)9.5to10.4
5.88 to 6. 488.5to< 9.5
5.25 to < 5. 886.5to< 8.5
4.03 to < 5. 25< 6.5
< 4.03
36 to 56 days of
age
(maleand female)8.5to9.6
5.26 to 5. 997.0to< 8.5
4.32 to < 5. 266.0to <7.0
3.72to<4.32< 6.0
< 3.72
22 to 35 days of
age
(male and female)9.5to11.0
5.88 to 6. 868.0to< 9.5
4.94 to < 5. 886.7to< 8.0
4.15 to < 4. 94< 6.7
< 4.15
8to≤ 21 day s of
age
(male and female)11.0 to 13.0
6.81 to 8. 109.0to< 11.0
5.57 to < 6. 818.0to< 9.0
4.96 to < 5. 57< 8.0
< 4.96
≤ 7days ofage
(male and female)13.0 to 14.0
8.05 to 8. 7210.0 to < 13.0
6.19 to < 8. 059.0to< 10.0
5.59 to < 6. 19< 9.0
< 5.59
INR, High
(not on
anticoagulation
therapy)1.1to< 1.5 x
ULN1.5to< 2.[ADDRESS_1170895] 2.0 to< 3.0 x UL N≥ 3.[ADDRESS_1170896]
Methemoglob in
(%hemogl obin)5.0to< 10.0% 10.0 to <15.0% 15.0 to < 20.0% ≥ 20.0%
PTT, High
(not on
anticoagulation
therapy)1.1 to
< 1.66 x
ULN1.66 to
< 2.3 3 x
ULN2.33 to
< 3.[ADDRESS_1170897]≥ 3.[ADDRESS_1170898]
Platele ts,Decreased
(cells/mm3;
cells/L )100,000 to
<125,000
100.000 x 109to
< 125.000 x [ZIP_CODE],000 to
<100,000
50.000 x 109to
< 100.000 x [ZIP_CODE],000 to< 50,000
25.000 x 109 to
< 50.000x 109< 25,000
< 25.000x 109
PT,High
(not on
anticoagulation
therapy1.1 to
< 1.25 x
ULN1.25 to
<1.50 x
ULN1.50 to
<3.[ADDRESS_1170899]≥ 3.[ADDRESS_1170900]
WBC,
Decreased
(cells/mm3;
cells/L )
> 7days of
age2,000to2,499
2.000 x 109to
2.499 x 1091,500to 1,999
1.500 x 109to
1.999 x 1091,000to1,499
1.000 x 109to
1.499 x 109< 1,000
< 1.000 x 109
≤ 7days ofage 5,500to6,999
5.500 x 109to
6.999 x 1094,000to5,499
4.000 x 109to
5.499 x 1092,500to3,999
2.500 x 109to
3.999 x 109< 2,500
< 2.500 x 109 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
12816Male and female sex are defined as sex at birth. For transgender participants [ADDRESS_1170901] 
been on hormone therapy for more than 6 consecutive months grade hemoglobin based on the gender with 
which they identify (i.e., a transge nder female should be graded using the femaile sex at birth hemoglobin 
laboratory values).
17The mostcomm only used c onversion factor toconvertg/dL tommo l/Lis 0.6206. For grading
hemogl obinresults obtained by [CONTACT_842520] 0.6206, the resu lt
mustbe converted to g/dL u sing appropriate conversion factor for th e particular l aboratory
Urinalysis
PARAMETERGRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY LIFE -
THREATENING
Glycosuria
(random 
collection te sted
by [CONTACT_5230])Trace to1+ or
≤ 250 mg2+ or ˃ 250 to
≤ 500 mg> 2+ or > 500 mg NA
Hematur ia(notto
be reported based
on dipstick
findings or on 
blood be lieve dto
be of menstrual
origin)6 to< 10RBCs
per high power
field≥ 10RBCs per
high power fie ldGross,withor 
without clots OR
WithRBC casts 
ORInter vention 
indicatedLife-thr eatenin g 
consequences
Proteinuria
(random 
collection te sted
by [CONTACT_5230])1+ 2+ 3+ or higher NA 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
129Appendix A: Total Bilirubin Table for Term and Preterm Neonates
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY 
LIFE -
THREATENING
Total B ilirubin18,
High
(mg/d L; 
µmol/L)19
Term  
Neonate20
< 24 hours of 
age4to< 7
68.4 to < 1 19.77to< 10
119.7to < [ZIP_CODE] to<17
171to< 290.7≥ 17
≥ 290.7
24 to < 48
hours of age5to< 8
85.5 to < 1 36.88to< 12
136.8to< 20 5.212 to<19
205.2 to< 324.9≥ 19
≥ 324.9
48 to < 72
hours of age8.5to<13
145.35 to < 2 22.313 to < 15
222.3to< 25 6.515 to<22
256.5 to< 376.2≥ 22
≥ 376.2
72 hou rs to < 7
days of age11 to < 16
188.1to < 273.616 to < 18
273.6to < 307.818to<24
307.8to< 410.4≥ 24
≥ 410.4
7to28 day s of
age
(brea stfeeding)5to< 10
85.5 to < 1 7110 to < 20
171to< [ZIP_CODE] to < 25
342to< 427.5≥ 25
≥ 427.5
7to28 day s of
age
(not brea st
feeding)1.1to< 1.[ADDRESS_1170902] 1.6to< 2.[ADDRESS_1170903] 2.6to< 5.[ADDRESS_1170904]≥ 5.[ADDRESS_1170905]
Preterm
Neonate20
35 to < 37 w eeks 
gestational ageSame as for Total
Bilir ubin, High,
TermNeonate 
(basedon day s of
age).Same as for Total
Bilir ubin, High,
TermNeonate 
(basedon day s of
age).Same as for Total
Bilir ubin, High,
TermNeonate 
(basedon day s of
age).Same as for Total
Bilir ubin, High, Te rm
Neonate (basedon
days ofage).
32 to < 35
weeks 
gestational ag e 
and < 7 days
ofageNA NA 10 to < 14
171to< 239.4≥ 14
≥ 239.4
28 to < 32
weeks 
gestational ag e 
and < 7 days
ofageNA NA 6to< 10
102.6to< 171≥ 10
≥ 171
< 28 w eeks 
gestational ag e 
and
< 7days of ageNA NA 5 to< 8
85.5 to < 1 36.8≥ 8
≥ 136.8 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
130PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY 
LIFE -
THREATENING
7to 28 days of
age
(brea stfeeding)5to< 10
85.5 to < 1 7110 to < 20
171to< [ZIP_CODE] to < 25
342to< 427.5≥ 25
≥ 427.5
7to28 day s of
age
(not brea st
feeding)1.1to< 1.[ADDRESS_1170906] 1.6to< 2.[ADDRESS_1170907] 2.6to< 5.[ADDRESS_1170908]≥ 5.[ADDRESS_1170909] week of life . Severity grading inthis appendixcorrespo nds approximately tocut-o ffs for
indication s for phototherapy at grad e 3and for exchang e transfu sion at gra de 4.19A laboratoryvalue of 1 mg/dL isequivalent to 17.1 µmo l/L.
20Defin itions:Termis defined a s ≥ 37 w eeks gestationalage;near-term, as ≥ 35 weeks gestational age; 
preterm, as < 35 weeks gestational age; and neonate, as 0 to 28 days of age.
Reference
U.S. Department of Health and Human Services, National Institutes of Health, National 
Institute o f Allergy  and Infectious Diseases, Division of AIDS. Division of AIDS 
(DAIDS) Table for Grading the Severity  of Adult and Pediatric Adverse Events, Version 
2.1. Jul2017. Available from: https://rsc.tech -res.com/docs/default -source/safet y/daids -
ae-grading -table -mar2017.pdf (date accessed: 5 Mar 2019). 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
[ZIP_CODE].9. Appendix 9:  CDC Classification for HIV -1 Infection (2014)
Note that the CD4+ T -lymphocy te count takes precedence over the CD4+ T -lymphocy te 
percentage in HIV infection stages 1, 2, and 3.  The CD4+ T -lymphocy te percentage 
should only  be considered if the count is missing.
HIV infection, stage 0
Indicates earl y HIV infection, inferred from a negative or indeterminate HIV test 
result within 180 day s of a positive result.  The criteria for stage 0 supersede and 
are independent of criteria used for other stages.
HIV infection, stage 1
Laboratory  confirmation of HIV infection with no AIDS -defining condition, 
and
oCD4+ T -lymphocy te count of ≥500 cells/ L, or
oCD4+ T -lymphocy te percentage of total ly mphocy tes of ≥26%.
HIV infection, stage 2
Laboratory  confirmation of HIV infection with no AIDS -defining condition, and
oCD4+ T -lymphocy te count of 200 to 499 cells/ L, or
oCD4+ T -lymphocy te percentage of total ly mphocy tes of 14% to 25%.
HIV infection, stage 3 (AIDS)
Laboratory  confirmation of HIV infection, and
oCD4+ T -lymphocy te count of <200 cells/ L, or
oCD4+ T -lymphocy te percentage of total ly mphocy tes of <14%, or
oDocument ation of an AIDS -defining condition (see below).
Documentation of an AIDS- defining condition supersedes a CD4+ T -lymphocy te 
count of >200 cells/ L and a CD4+ T -lymphocy te percentage of total 
lymphocy tes of >14%. 
HIV infection, stage unknown
Laboratory  confirmation of HIV infection, and
oNo information on CD4+ T- lymphocy te count or percentage, and
oNo information on presence of AIDS -defining conditions.
Stage -3-defining opportunistic illnesses in HIV infection
Candidiasis of bronchi, trachea, or lungs 
Candid iasis of oesophagus 
Cervical cancer, invasive 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
132Coccidioidomy cosis, disseminated or extrapulmonary  
Cryptococcosis, extrapulmonary  
Cryptosporidiosis, chronic intestinal (>1 month's duration)
Cytomegalovirus disease (other than liver, spleen, or nodes), ons et at age >1 
month
Cytomegalovirus retinitis (with loss of vision)
Encephalopath y, HIV-related 
Herpes simplex: chronic ulcers (>1 month's duration) or bronchitis, pneumonitis, 
or oesophagitis (onset at age >1 month)
Histoplasmosis, disseminated or extrapu lmonary  
Isosporiasis, chronic intestinal (>1 month's duration) 
Kaposi's sarcoma 
Lym phoma, Burkitt's (or equivalent term) 
Lym phoma, immunoblastic (or equivalent term) 
Lym phoma, primary , of brain 
Mycobacterium avium complex or My cobacterium kansasii, d isseminated or 
extrapulmonary  
Mycobacterium tuberculosis of any  site, pulmonary , disseminated or 
extrapulmonary  
Mycobacterium, other species or unidentified species, disseminated or 
extrapulmonary
Pneumocy stis jirovecii pneumonia 
Pneumonia, recurrent
Progressive multifocal leukoencephalopath y 
Salmonella septicaemia, recurrent 
Toxoplasmosis of brain, onset at age >1 month 
Wasting sy ndrome attributed to HIV. 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
[ZIP_CODE].10. Appendix 10: A bbreviations and Trademarks
3TC Lamivudine, EPI[INVESTIGATOR_227302] R
ABC Abacavir, ZIAGEN
ABC/3TC Abacavir/lamivudine, EPZICOM, KIVEXA
ACTG International AIDS Society
AE Adverse event
AIDS Acquired immunodeficiency  syndrome
ALT Alanine aminotransferase
Anti- HBc Hepatitis B Core Antibody
ARV Antiretroviral
ART Antiretroviral therap y
AST Asparta te aminotransferase
BIC Bictegravir
BMI Body Mass Index
BUN Blood Urea Nitrogen
c/mL Copi[INVESTIGATOR_014]/milliliter
CDC Centers for Disease Control and Prevention
CIOMS Council for International Organizations of Medical Sciences
CKD -EPI [INVESTIGATOR_842484] A cquired Immunodeficiency  Syndrome
DDI Drug -Drug Interaction
dL Deciliter
DHHS Department of Health and Human Services
DILI Drug induced liver injury
DNA Deox yribonucleic acid
DTG Dolutegravir, TIVICAY
EACS European AIDS Clinical Society
ECG Electrocardiogram
eCRF Electronic case report form
EFV Efavirenz
eGFR Estimated glomerular filtration rate
FDA Food and Drug Administration
FDC Fixed -dose combination
FSH Follicle stimulating hormone
FTC Emtricitabine
GCP Good Clinical Practice
GCSP [COMPANY_004]’s Global Clinical Safet y and Pharmacovigilance
[COMPANY_004] GlaxoSmithKline 2020N440514_00
2019N398432_01 CONFIDENTIA L
[ADDRESS_1170910]
HIV Human immunodeficiency virus
HLA Human leukocy te antigen
HRT Hormonal replacement therap y
HSR Hypersensitivity  reaction
IAS International AIDS Society
IB Investigator’s Brochure
ICH International Conference on Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use
ICF Informed Consent Form 
IgG Immunoglobulin G
IgM Immunoglobulin M
IMP Investigational medicinal product
INI Integrase inhibitor
INST I Integrase strand transfe r inhibitor
INR International normalized ratio
IQR Interquartile range
IRB Institutional Review Board
ITT-E Intent -to-treat exposed
IUD Intrauterine device
IUS Intrauterine hormone -replacing s ystem
IWRS /IWRS Interactive Voice/Web Recognition Sy stem
LDL Low density  lipoprotein
MCH Mean corpuscular hemoglobin
MCV Mean corpuscular volume
MedDRA Medical dictionary  for regulatory  activities
Mol/L Micromole/L iter
Mg Milligram
Mg/dL Milligram per deciliter
Mg/min Milligram per minute
MSDS Materia l Safet y Data Sheet
NNRTI Non-nucleoside reverse transcriptase inhibitor
NRTI Nucleoside reverse transcriptase inhibitor
OC Observed Case
OCT -[ADDRESS_1170911] Development 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
135PrEP Pre-exposure proph ylaxis
PRO Protease
PSRAE Possible suicidality -related adverse event
QTc Corrected QT interval 
RAL Raltegravir
RAP Reporting and Anal ysis Plan
RBC Red blood cell
RNA Ribonucleic acid
RPR Rapid plasma reagin
RT Reverse transcriptase
SAE Serious adverse event
SDM Symptom Distress Module
SoA Schedule of Activites
SJS Stevens -Johnson sy ndrome
SRM Study  Reference Manual
S[LOCATION_003]R Suspected unexpecte d serious adverse reactions
TAF Tenofovir alafenamide 
TDF/FTC Tenofovir disoproxil fumarate/Emtricitabine, Truvada
TEN Toxic epi[INVESTIGATOR_842485], dolutegravir, and lamivudine
ULN Upper limit of normal
VSL C ViiV Safet y and Labelling Committee
WBC White blood cell
WHO World Health Organization
ZDV/3TC Zidovudine/lamivudine, COMBIVIR
Trademark Information
Trademarks of ViiV Healthcare Trademarks not owned by [CONTACT_842521] -1
DOVATO GenoSure
EPI[INVESTIGATOR_227302] R Monogram Biosciences
EPZICOM/ KIVEXA PhenoSense
TIVICAY Symptom Distress Module
TRIUMEQ Truvada
ZIAGEN 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
[ZIP_CODE].11. Appendix 11 : Protocol A mendment History
The Protocol Amendment Summary  of Changes Table for the current amendment is 
located directly  before th e Table of Contents (TOC). 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
[ZIP_CODE]. REFERENCES
Bacon O, Chin JC, Hsu L, Cohen SE, Sachdev D, Jones D, et al. The Rapid ART 
Program for HIV Diagnoses in San Francisco. CROI 2018. Presented at the Conference 
of Retroviruses and Opportunistic I nfections; [LOCATION_011], MA; March [ADDRESS_1170912].
Cahn P, Madero JS, Arribas J, Antinori, Ortiz R, Clarke A, et al. Non -inferior efficacy  of
dolutegravir (DTG) plus lamivudine (3TC) versus DTG plus tenofovir/emtricitabine 
(TDF/FTC) fixed -dose combination in antiretroviral t reatment -naïve adults with HIV -[ADDRESS_1170913] TUAB0106LB.
Cahn P, Madero JS, Arribas J, Antinori, Ortiz R, Clarke A, et al. Dolutegravir plus 
lamivudi ne versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in 
antiretroviral -naïve adults with HI V-1 infection (GEMINI -1 and GEMINI -2): week 48 
results from two multicentre, double -blind, randomised, non -inferiorit y, phase 3 trials. 
Lancet 2019; 393: 143- 155.
Cahn, P, Rol ón, MJ, Figueroa, MI, Gun, A, Patterson P, Sued O. Dolutegravir -
lamivudine as initial therapy  in HIV -1 infected, ARV -naïve patients, 48 week results for 
the PADDLE (Pi[INVESTIGATOR_439404]) study . Journal 
of the International AIDS Society , 2017; 20: [ZIP_CODE].
CDC. Revised Surveillance Case Definition for HIV Infection – [LOCATION_002], 2014. 
MMWR 2014; 63 (RR -03);1-10.
Department of Health and Human Services (DHHS).  Guidelines for the use of 
antiretroviral agents in HIV -1 infected adults and adolescents Living with HIV .  May 
2018 .  Available at: https://aidsinfo.nih.gov/guidelines/html/1/adult -and-adolesc ent-
treatment -guidelines/0.  Accessed 18 February  2019.
Dolutegravir (TIVICAY) Product I nsert.  Available at:  
http://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Inf
ormation/Tivicay /pdf/TIVI CAY -PI-PIL.PDF.  October 2018.  Accessed February  28, 
2019.
DOVATO (Dolutegravir/Lamivudine FDC) Product I nsert.  Available at 
https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_In
formation/Dovato/pdf/DOVATO -PI-PIL.PDF .  April 2019.  Accessed May  9, 2019.
EPI[INVESTIGATOR_122498]/Lamivudine Product Insert.  Avail able at: 
https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_In
formation/Epi[INVESTIGATOR_54736]/pdf/EPI[INVESTIGATOR_227302] R-PI-PIL.PDF.  April 2018.  Accessed March 5, 201 9.
European AIDS Clinical Society  (EACS) Guidelines for the clinical management and 
treatm ent of HIV Infe cted Adults in Europe. Version 9.0, October 2017.  Available at:  
http://www.eacsociet y.org/files/guidelines_9.0- english.pdf .  Accessed March 5, 2019 . 2020N440514_00
2019N398432_01 CONFIDENTIA L
212355
138GlaxoSmithKline Document Number RM2007/[ZIP_CODE]/12 : [COMPANY_004]1349572 Clinical 
Investigator's Brochure [DTG IB], 15 November 2018.
Inker LA, Schmid CH, Tighiouart H, et al; Estimating Glomerular Filtration Rate from
Serum Creatinine and C ystatin C. N Engl J Med. 2012;367:20-9.
Justice. Development and validation of a self completed HIV s ymptom index. Jo urnal of 
Clinical Epi[INVESTIGATOR_623] . 2001; 54:S77 -S90. Journal of Clinical Epi[INVESTIGATOR_623]. 
2001;54:S77- S90. 
Koenig SP, Dorvil N, Devieus JG, Hedt -Gauthier B.L, Riviere C, Faustin M, et al. Same-
day HIV testing with initiation of antiretroviral therapy  versus sta ndard care for persons 
living with HIV: a randomized unblinded trial. PLos Medicine. 2017;14:31002357.
Levey  AS, Stevens LA, Schmid CH, Zhang Y, Castro III AF, Feldman HI, et.al. A new 
equation to estimate glomerular filtration rate.  Ann Int Med. 2009;150:604 -12.
Paterson D, Swindells S, Mohr J, Brester M, Vergis E, Squier C, et. al. Adherence to 
Protease Inhibitor Therapy  and Outcomes in Patients with HI V Infection. Ann Int Med. 
2000;133:21 -30.
Rosen S, Maskew M, Fox MP, Ny oni C, Mongweny ana C, Malete G, et al. I nitiating 
antiretroviral therap y for HIV at a patient’s first clinic visit: the RapI T randomized 
controlled trial. PL OS Medicine. 2016;13 (5):e1002015.
Saag M, Benson CA, Gandhi RT, Hoy  JF, Landovitz, RJ, Mugavero, MJ, et al.  
Antiretroviral drugs for treatment and prevention of HIV infection in adults:  2019 
recommendations of the International Antiviral Society  –[LOCATION_003] Panel.  JAMA. 2018; 320 
(4): 379-392.
Taiwo, BO, Zheng, L, Stefanescu, A, Ny aku,A, Benzins, B, Wallis, C, et al. ACTG 
A5353: A Pi[INVESTIGATOR_48085] t Study  of Dolutegravir Plus Lamivudine for Initial Treatment of Human 
Immunodeficiency  Virus -1 (HIV -1)-infected Participants With HI V-1 RNA <500,000 
Copi[INVESTIGATOR_014]/mL . 2018;66(11): 1689 -1697.
Walmsley  S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong -Josses M- A, 
et al. Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV -1 Infection in 
Antiretroviral Therap y-Naive Patients: Week [ADDRESS_1170914] . 2015;70:515–519.
Walmsley  SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutieŕrez F, et. al.  
Dolutegravir plus abacavir-lamivudine for the treatment of HIV- 1 infection. N Engl J 
Med. 2013;369(19):1807 -18.
World Health Organization (WHO). Guidelines for managing advance d HIV disease and 
rapid initiation of antiretroviral therap y. July  2017, Available at: 
https://apps.who.int/iris/bitstream/handle/[ZIP_CODE]/255884/9789241550062 -
eng.pdf;jsessionid=1C3FD77CAE3B167FBEA2A8E4211F7818?sequence=1 .Accessed 
March 5, 2019. 2020N440514_00